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1. Introduction  
In 2011, the World Health Organisation announced antimicrobial resistance as the third 
greatest threat to human health [1]. Acquired antimicrobial resistance is defined as 
resistance of a microorganism (including bacteria, fungi, parasites and viruses) to an 
antimicrobial agent that was originally effective in treating the infection caused by the 
microorganism. As a consequence, standard treatments become ineffective and patients 
remain infected for a prolonged period, increasing the risk of spreading the microorganisms 
to others, and elevating health care expenses. Furthermore, there is a greater risk of death, 
particularly in immunocompromised patients or patients suffering from severe underlying 
diseases, when infected with multidrug resistant (MDR) organisms, as only limited treatment 
options are available [2]. 
Bacteria that are increasingly prevalent in our hospitals and are increasingly resistant to 
many of the applied antimicrobial agents have been termed “ESKAPE” organisms and include 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter species [3]. Of these pathogens, A. 
baumannii was considered susceptible to most of the antimicrobials in the 1970s, however 
resistance to all first-line antibiotics has now been described [4, 5]. Within this thesis, the 
role of A. baumannii as a successful pathogen in the health care environment will be 
illustrated. As a main emphasis, bacterial efflux pumps, which promote the resistance to 
multiple drugs in A. baumannii, will be explained and discussed.  
1.1 The genus Acinetobacter 
The genus Acinetobacter is a member of the family Moraxellaceae within the class of                
γ-Proteobacteria and is defined as Gram-negative, strictly aerobic, oxidase-negative, glucose 
non-fermenting, catalase-positive, indole- and nitrate negative, non-fastidious bacteria with 
a G + C content of 40-48% [6, 7]. On blood agar plates these organisms form smooth, 
sometimes mucoid, pale yellow to greyish white colonies (Fig. 1.1A). Depending on the 
growth phase, the cells’ shape can vary from coccoid to coccobacillary (Fig. 1.1B, C).  
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Figure 1.1 Morphology of A. baumannii. (A) Appearance of A. baumannnii on blood agar plate. 
Taken from Jakubů [8]. Scanning electron micrograph of A. baumannnii strains (B) AYE and (C) ACICU. 
Adapted from Visca et al. [9]. 
It took 60 years from its first isolation until the genus designation Acinetobacter was 
officially acknowledged. Although the Dutch microbiologist Bijernick was the first one who 
detected an Acinetobacter strain from a soil sample in 1911, originally named Micrococcus 
calcoaceticus, it was not until 1954 when Brisou and Prevot proposed the current genus 
name [10]. Detailed phenotypical analysis of Baumann et al. finally lead to the official 
acknowledgement of the genus Acinetobacter in 1971 [11, 12]. 
The name Acinetbacter derives from the Greek ακινετοσ (akinetos), meaning non-motile rod. 
However, recent studies have shown that Acinetobacter, in particular the species A. 
baumannii, indeed shows motile activity (Fig. 1.2), moving along wet surfaces in a ‘twitching’ 
manner by retraction of type IV pili. Furthermore, A. baumannii responds to light; driven by 
blue-light-sensing photoreceptors, it is motile in the absence of light [13-15]. 
 
Figure 1.2 A colony of A. baumannii spreading over the surface of an agar plate. 
      Taken from Wilharm [16].  
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1.1.1 Acinetobacter species and identification techniques 
In 1986, studies based on DNA-DNA hybridisation by Bouvet and Grimont enabled the 
identification of species within the Acinetobacter genus [17]. To date, the genus comprises 
62 species, with 57 published names (e.g. A. baumannii, A. baylyi, A. calcoaceticus, A. lwoffii, 
A. nosocomialis, A. seifertii and A. pittii) and 5 provisional designations such as Acinetobacter 
DNA group 6 (http://apps.szu.cz/anemec/Classification.pdf). Due to their close genetic 
relatedness and similar phenotypic properties, it is often challenging to discriminate 
between these species using phenotypic or taxonomic methods. As the best-known 
example, A. baumannii, A. calcoaceticus, A. nosocomialis, A. pittii and A. seifertii are often 
grouped together in the so-called “A. calcoaceticus - A. baumannii (Acb) complex” [18, 19]. 
However, from the clinical perspective this grouping is unsatisfactory as antibiotic 
susceptibilities and clinical significance of these five species differ from each other [20-22]. 
To facilitate a better identification of the species, molecular techniques such as amplified 
ribosomal DNA restriction analysis (ARDRA) [23] and high-resolution amplified fragment 
length polymorphism (AFLP) [24] have been used. Allowing the identification of genetic 
fingerprints typical of each species, these methods are able to properly discriminate 
between them. However, these techniques are almost exclusively applied in reference 
laboratories. In diagnostic microbiological laboratories, most often the semi-automated 
matrix-assisted laser desorption-ionization-time-of-flight mass spectrometry (MALDI-TOF 
MS) or automated Vitek2 system is used for species identification. Whereas MALDI-TOF MS 
generates mass spectra specific for each species, which can subsequently be matched to 
spectra in an online database [25], Vitek2 measures metabolic activities (e.g. acidification, 
alkalinisation, enzyme hydrolysis) to distinguish species [26]. Furthermore, PCR-based 
approaches based on species-specific DNA regions, such as the blaOXA-51 carbapenemase 
gene intrinsic to A. baumannnii or sequencing of the DNA gyrase subunit B encoding gene 
gyrB, are used [27, 28]. However, so far a gold standard to discriminate between 
Acinetobacter species (Acinetobacter spp.) has not been established. Therefore, due to 
varying specificity and sensitivity of the applicable methods, data sets from different 
laboratories should be compared with caution if different methods where used for species 
identification.  
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1.1.2 Natural habitat of Acinetobacter spp. 
In 1968, Baumann reported that he isolated Acinetobacter spp. from 28 of 30 soil samples 
and 29 of 30 water samples taken in California (USA) [29]. Since then, this genus has been 
considered as ubiquitous in nature. More recent studies confirmed these findings by 
isolating A. nosocomialis and A. baylyi from soil [30, 31]. Similarly, A.baylyi, A. bouvettii and 
A. towneri, among others, were cultivated from activated sludge [32]. Even in the extreme 
environment of Andean lakes, five different Acinetobacter spp. could be isolated [33]. 
However, human carriage has also been reported. In 1997, Seifert et al. reported 
colonization of skin and mucous membranes in 43% of healthy individuals, where A. lwoffii 
and A. johnsonii were found to be the most prevalent [34]. In a similar study conducted in 
the UK, Acinetobacter skin carriage was found in 44% of 192 healthy humans, with A. lwoffii 
again accounting for most of the isolates (61%) [35]. Investigating the faecal carriage, 
isolates could be cultivated among 25% of healthy people with A. johnsonii being the 
predominant species [36]. Among hospitalised patients, 75% were found positive for 
Acinetobacter spp. [34].  
Based on the early dogma of Acinetobacter being an environmental organism, A. baumannii 
has also been described as such, although no appropriate reference supports this 
assumption [37]. Instead, A. baumannii is almost exclusively found in the hospital 
environment, emerging as an opportunistic nosocomial pathogen. Occasional reports of A. 
baumannii occurring in the environment (vegetables, soil, aquacultures) are available [38-
40], but it is not clear whether these infrequent findings are due to contamination or contact 
with humans, or if the environment indeed serves as natural reservoir. A. baumannii isolates 
recovered from human lice [41], vegetables collected in supermarkets, greengrocers and 
private gardens [38] as well as from surfaces like tables in parks and game consoles, which 
themselves are inanimate but in contact with humans, [42] rather speak for a human-
associated natural reservoir. Furthermore, pets like dogs, cats and horses, were found to be 
colonized by A. baumannii [43, 44]. Causing clinical outbreaks worldwide (meaning that 
multiple patients within a hospital are infected with the same strain), this organism has 
developed to the clinically most relevant species among the genus Acinetobacter.  
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1.1.3 Clinical relevance of Acinetobacter spp. 
The first case of a community-acquired Acinetobacter infection was reported in two patients 
with excessive alcohol consumption in the US in 1977 [45]. However, incidences of 
community-acquired Acinetobacter infections have increasingly been reported during the 
last 15 years. Due to the prolonged lack of reference methods for species identification, care 
should be taken when reviewing reports interpreting which Acinetobacter spp. are involved 
in infections. Nevertheless, A. baumannii, A. nosocomialis and A. pittii have been implicated 
in community-acquired infections, with A. baumannii being the most predominant [46]. 
Infections include primarily pneumonia, skin infections, secondary meningitis, and 
endocarditis, which mostly occur in elderly people and are often associated with (chronic) 
underlying diseases, such as diabetes mellitus [47-49]. Interestingly, A. baumannnii 
infections have mainly been reported during summer in tropical and subtropical areas like 
Southeast Asia and tropical Australia [50, 51]. Possible reasons for this phenomenon have 
yet to be elucidated. More recently, A. baumannii was isolated from wounds of survivors of 
natural disasters, such as earthquakes [52, 53] and a tsunami [54]. Overall, community-
acquired infections caused by A. baumannii are rare and rather based on single events. 
Nevertheless, a mortality rate between 40-60% has been correlated especially with 
community-acquired pneumonia caused by this species, underlining its clinical impact [55].  
Within hospitals, the situation is different. An increasing number of health-care associated 
outbreaks of multidrug resistant A. baumannii, ranging from a hospital-specific to inter-
hospital as well as inter-continental dissemination, have been described around the world. 
Similar to community-acquired infections, hospital-acquired infections are mainly due to A. 
baumannii, A. nosocomialis and A. pittii, with A. baumannii being the most frequent. 
Whereas, A. nosocomialis and A. pittii isolates are relatively susceptible to antimicrobials and 
cause sporadic infections with mortality rates between 7-18% [56, 57], A. baumannii 
outbreaks are often clonal and spread nationally as well as internationally [6, 9]. 
Furthermore, infections are associated with prolonged hospital stay and considerable 
morbidity and mortality in up to 58% of cases [58-60]. The situation in intensive care units 
(ICUs) and surgical units is of particular severity. As these wards host critically ill patients 
with impaired host defences, the units including its patients create an optimal niche for 
opportunistic bacteria such as A. baumannii. Due to the high incidence of antimicrobial 
usage in these environments, opportunistic pathogens develop antibiotic resistance and 
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spread among patients. Indeed, during the past three decades A. baumannii has been 
increasingly reported to cause a large variety of nosocomial infections among 
immunocompromised patients, such as ventilator-associated-pneumonia (VAP), 
bloodstream infection following invasive procedures, as well as wound and urinary tract 
infections, meningitis and soft-tissue infections [61]. Due to its appearance in infections 
subsequent to injuries sustained in conflict areas such as Afghanistan and Iraq, A. baumannii 
was colloquially referred to as “Iraqibacter” by American military personal [62]. 
Analysing clinical A. baumannii outbreaks worldwide, three clones have been characterized 
to predominantly emerge and spread epidemically across hospitals, which therefore have 
been called international clones (IC) 1-3 (formerly called EUI-III) [63, 64]. Within a large 
survey using imipenem-resistant A. baumannii isolates, five further epidemic lineages (IC4-8) 
were identified [65]. The spread of clonal lineages is proposed to be triggered by transfer of 
colonized patients between wards and hospitals [66-68], and ultimately airline travel 
facilitates intercontinental dissemination [69, 70]. It is of particular concern that isolates 
within these clones display increasing resistance against multiple antimicrobial agents. 
Whereas in the 1970s A. baumannii was associated with susceptibility to most 
antimicrobials, today this organism is displaying resistance against all first-line antibiotics 
[37]. Outbreaks of multidrug [71-73], extensively drug [74-76] and even pandrug resistant [4, 
5] strains have been described (see Table 1.1 for definitions). 
Table 1.1 Standardized international terminology to describe acquired resistance profiles. 
   Adapted from Magiorakos et al. [77] with permission from Elsevier. 
Type of resistance Definition 
Multidrug resistance (MDR) 
Non-susceptibility to ≥1 agent in ≥ 3 
antimicrobial classes* 
Extensively drug resistance (XDR) 
Non-susceptibility to ≥1 agent in all but ≤ 2 
antimicrobial classes* 
Pandrug resistance (PDR) non-susceptibility to all antimicrobial agents* 
*for a list of approved antimicrobials against Acinetobacter spp. see Suppl. Table I  
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1.1.4 A. baumannii – a persisting hospital pathogen 
Special traits of A. baumannii that contribute to its predominant appearance in hospital 
settings include its resistance to desiccation, biofilm formation and its genomic plasticity, 
which allows the easy acquisition of resistance determinants. 
Investigating the desiccation tolerance of A. baumannii isolates on dry surfaces, Jawad at el. 
reported a mean survival time of 27 days on glass coverslips [78]. This survival time was 
considerably longer in comparison to other Acinetobacter spp. [79, 80] as well as to E. coli 
and other Enterobacteriaceae [6]. Even a long-term survival of more than 4 months has been 
reported [81]. With this unique trait, A. baumannii dissemination is facilitated in the hospital 
environment. If a patient with a silent A. baumannii colonization is hospitalized, in particular 
if transferred from another hospital, the organism may spread to the surrounding 
environment by air droplets and scales of skin [82]. Isolates have indeed been recovered 
from pillows, bed curtains, and furniture during outbreaks [67, 83]. The A. baumannii 
colonies on these surfaces can in turn be picked up on the hands of medical personal, 
further spreading the isolate within the ward or the hospital.  
Additionally, the ability to form biofilm facilitates the adherence of A. baumannii isolates to 
biotic as well as abiotic surfaces [84]. Comparing the biofilm formation of species of the Acb-
complex to species which are not part of the complex, members of the Acb-complex were 
threefold more likely to form a biofilm on a liquid-solid interface [85, 86]. This creates a 
particular problem with medical devices including mechanical ventilators and catheters, 
serving as additional reservoirs (humans being the primary reservoir) [87]. After invasive 
procedures, patients that are already in a critical health state may easily have contact with 
persisting A. baumannii clones, which in the worst case exhibit MDR. Indeed, invasive 
procedures have been described as a risk factor of getting A. baumannii infections in the 
hospital setting [6, 68, 88].  
The upregulation of innate resistance mechanisms [89] and its ability to easily acquire 
antimicrobial resistance determinants are key features which help A. baumannii to 
withstand the antibiotic pressure it is facing in hospital settings. Its genomic plasticity can be 
exemplified by the acquisition of variable genomic regions called resistance islands. These 
islands are inserted into the chromosome and encode multiple genes conferring resistance 
to distinct antimicrobials. In the MDR A. baumannii isolate AYE, Fournier et al. identified a 
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resistance island of 86 kb in size named AbaR1 [37]. Of the 88 encoded genes, 45 were 
predicted to be resistance genes, conferring resistance against aminoglycosides, β-lactams, 
chloramphenicol, and tetracycline, amongst others. Furthermore, this resistance island was 
composed of mobile genetic elements and also contained genes derived from other 
pathogenic Gram-negative organisms such as Pseudomonas, Salmonella and E. coli, 
illustrating inter-species genomic exchange. To date, 26 further resistance islands have been 
described (AbaR2-AbaR27) in various A. baumannii isolates originating from all over the 
world [90-96]. They are all slightly different in their composition [which, and how many 
(resistance) genes are encoded] but were always inserted into the same chromosomal 
region, disrupting a putative ATPase open reading frame. In addition to resistance islands, 
further often broad-host-range mobile genetic elements have been characterized in A. 
baumannii (transposons, insertion sequences, integrons) which either introduce new 
resistance genes or upregulate the expression of innate resistance mechanisms thereby 
contributing to antimicrobial resistance in this organism [97-99]. Altogether, the outlined 
genome plasticity of A. baumannii facilitates its ability to acquire resistance determinants, 
ultimately leaving limited treatment options against infections and impairing the control of 
hospital outbreaks. 
1.1.5 Antimicrobial resistance mechanisms in A. baumannii 
Different antibiotic classes have been discovered or developed to inhibit bacterial cell 
growth (bacteriostatic mode of action) or kill bacteria by causing cell death (bactericidal 
mode of action). Cellular processes targeted by antimicrobials approved against 
Acinetobacter spp. (Suppl. Table I) include cell wall, DNA, RNA and protein synthesis as well 
as folate synthesis. To date, resistance mechanisms against all of the currently available 
antimicrobial agents have been described in A. baumannii, which include decreased 
permeability, enzymatic inactivation and modification of antimicrobials, target-site 
modification, and active efflux. Below, the activity of relevant antimicrobial classes is 
described followed by the description of specific resistance mechanisms displayed by A. 
baumannii. Resistance mechanisms and the antimicrobial site of action are illustrated in Fig. 
1.3.  
Ribosomes, which drive protein synthesis from mRNA templates, are divided into two 
subunits – the 30S and the 50S subunit. Aminoglycosides (e.g. amikacin and gentamicin) 
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inhibit protein synthesis by binding to the 16S ribosomal RNA of the 30S subunit of the 
ribosome. As a consequence, the incoming mRNA is misread and non-functional proteins are 
generated. In bacteria, drug-modifying enzymes have been described, which prevent 
aminoglycosides from binding to the ribosome. In A. baumannii three types of 
aminoglycoside-modifying enzymes, including aminoglycoside acetlytransferases (e.g. 
AacC1-4), nucleotidyltransferases (e.g. AntA1-4), and phosphotransferases (e.g. AphA1-6), 
have been discovered [100-102]. In addition, methylation of residues in the aminoglycoside-
binding site of the 16S ribosomal RNA (e.g. by ArmA), which impairs aminoglycoside binding, 
is another resistance mechanisms leading to high-level aminoglycoside resistance [103, 104].  
Similar to aminoglycosides, tetracyclines (e.g. tetracycline and minocycline) and 
glycylcyclines (tigecycline) interfere with RNA synthesis by targeting the 30S ribosomal 
subunit. However, in contrast, the transfer RNA binding site is blocked so that the aminoacyl-
transfer RNA cannot attach to the mRNA, and thus peptide chain elongation is inhibited. 
Active efflux mediated through the tetracycline-specific efflux pumps TetA and TetB are the 
primary cause of resistance to tetracyclines in A. baumannii [105, 106]. Furthermore, the 
ribosomal protection protein Tet(M) protects the ribosome from tetracyclines via a shielding 
mechanism [107]. Initially designed to not be a substrate of tetracycline-specific efflux 
pumps [108], the synthetic antimicrobial tigecycline showed promising in vitro activity 
against most A. baumannii isolates and was hoped to be affective against MDR isolates [109, 
110]. However, it was later revealed that tigecycline is a substrate of polyspecific efflux 
pumps [111, 112]. Furthermore, mutations in the gene encoding an S-adenosyl-L-
methionine-dependent methyltransferase (trm) [113] as well as a 1-acyl-sn-glycerol-3-
phosphate acyltransferase (plsC) [114] have been shown to decrease tigecycline 
susceptibility in A. baumannii strains that were serially passaged in tigecycline.  
Targeting the 50S ribosomal subunit and thereby preventing the translocation of the 
aminoacyl-transfer RNA within the ribosome, chloramphenicol and macrolides (e.g. 
azithromycin and erythromycin) induce translational termination. For both antimicrobial 
classes, specific drug modifying enzymes (the acetyltransferase Cat for chloramphenicol and 
Mph for macrolides [115, 116]) as well as specific efflux pumps (CmlA in the case of 
chloramphenicol [37] and Mel2 in macrolides [117]) have been associated with resistance in 
A. baumannii. 
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Quinolones (e.g. nalidixic acid) inhibit DNA synthesis by targeting the bacterial DNA gyrase 
(topoisomerase II) and topoisomerase IV which are needed to relieve topological stress and 
decatenate DNA during DNA replication. By modifying quinolones with the addition of a 
fluorine at the C6 carbon (generating fluoroquinolones, e.g. ciprofloxacin, levofloxacin), the 
affinity to topoisomerases was increased. However, amino acid substitutions in the 
chromosomal DNA gyrase (due to mutations in the DNA gyrase encoding genes gyrA and 
gyrB) or topoisomerase IV (mutations in encoding genes parC and parE), respectively, 
interfere with target site binding and subsequently lead to resistance in A. baumannii [118-
120]. In particular ciprofloxacin resistance has most often been associated with two specific 
mutations, resulting in the Ser83→Leu substitution in GyrA and Ser80→Leu change in ParC. 
.  
Figure 1.3 Antibiotic modes of action and bacterial strategies to resist. Antibiotics target different 
cellular processes (e.g. DNA, RNA, protein or cell wall synthesis) leading to bacterial cell death or 
reduced cell growth. Bacteria however, developed different strategies to combat the antibiotic 
action, including modification of the antibiotic target, inactivation of the drug, decreased influx and 
increased efflux of the agents. Adapted from Mulvey et al. [121] with permission. 
RNA synthesis is inhibited by rifampicin. Binding to the active centre of the bacterial RNA 
polymerase, transcription initiation is inhibited. Resistance to rifampicin is conferred by 
mutations in rpoB encoding the β-subunit of the RNA polymerase. Furthermore, rifampicin 
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can be inactivated by enzymatic ribosylation mediated by ADP-ribosyltransferases, such as 
Arr-2 [122]. 
In Gram-negative bacteria, the cell wall consists of cross-linked peptidoglycan layers which 
are linked to the outer membrane (containing lipopolysaccharides, phospholipids and 
channel forming porins) by lipoproteins. Each peptidoglycan layer consists of an alternating 
order of the sugar derivates N-acetylglucosamine and N-acetylmuramic acid (MurNAc). 
MurNAc is further linked to peptide side chains (e.g. D-alanine). The crosslinking of 
peptidoglycan layers during cell wall synthesis is catalysed by transpeptidases, which link the 
D-alanine peptide side chains strengthening the peptidoglycan layers. Structurally mimicking 
the naturally occurring D-alanine-D-alanine structure, β-lactam antibiotics inhibit the 
crosslinking of peptidoglycan. The transpeptidases tightly bind to the antibiotic forming long-
lived complexes. As a consequence, poorly crosslinked peptidoglycan is produced and the 
cell wall is unable to resist turgor pressure which subsequently leads to cell lysis. With 
regards to A. baumannii infections, it is carbapenems (e.g. meropenem and imipenem), a 
subclass of β-lactams, that are the drugs of choice. The most clinically significant mechanism 
to inactivate carbapenems is through the production of carbapenem-hydrolysing β-
lactmases. Carbapenemases (e.g. OXA-23, OXA-58, NDM-1, NMD-2, IMP-1, VIM-1), have 
been reported worldwide in A. baumannii, leading to a vast limitation of treatment options 
for combatting A. baumannii infections [123, 124].  
Cell death as described for β-lactams is also induced by polymyxins, such as colistin, which 
bind to lipid A of lipopolysaccharides at the bacterial membrane. By binding to the cell 
membrane, polymyxins alter the membrane structure, leaving it more permeable. Target 
modification by adding a phosphoethanolamine moiety to lipid A, driven by increased 
expression of the two-component regulatory genes pmrAB, has been identified in colistin-
resistant isolates [125].  
In bacteria, folate is essential for cell growth and replication as it is used for purine 
biosynthesis (thus DNA synthesis) and the synthesis of amino acids (glycine, methionine, 
serine). Sulphonamides (e.g. sulfamethoxazole) and trimethoprim inhibit the bacterial folate 
metabolism targeting the enzymes necessary for the generation of the folate intermediate 
dihydropteroic acid (sulphonamides) or inhibiting the last step in folate synthesis which 
generates tetrahydrofolic acid (trimethoprim). A bactericidal effect is achieved when both 
antimicrobials are administered in combination (as co-trimoxazole). In A. baumannii the 
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generation of usually plasmid-encoded isoenzymes (sul or dfr genes) has been reported, 
which show reduced affinity to both antimicrobials [124]. Furthermore, efflux has been 
associated with decreased susceptibility to trimethoprim or co-trimoxazole, respectively [89, 
126, 127].  
All the above mentioned resistance mechanisms are specific to one antimicrobial class or 
even single drugs. However, decreased membrane permeability as well as increased drug 
efflux contributes to multidrug resistance by affecting multiple antimicrobial classes.  
Porins, or porin channels are water-filled outer membrane pores that allow the passive 
diffusion of substances, including antimicrobials, across the outer membrane. Due to the 
small number and size of these porins in Acinetobacter, its outer membrane permeability is 
less than 5% compared to other Gram-negative bacteria, preventing drug influx and thus 
promoting resistance [128, 129]. In particular, loss of the outer membrane porins CarO, 
OprD or the 33-36kDa protein have been associated with carbapenem resistance [130-132].  
Increased expression of efflux pumps that actively expel multiple, structurally different 
classes of antimicrobials out of the cell, has been shown to confer multidrug resistance in A. 
baumannii. Exported antimicrobials include aminoglycosides, β-lactams, carbapenems 
cephalosporins, chloramphenicol, fluoroquinolones, erythromycin, tetracyclines and 
tigecycline [112, 126, 133]. 
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 1.2 Bacterial efflux pumps 
Bacterial efflux pumps are chromosomally or plasmid encoded components of the bacterial 
membrane that capture and excrete metabolic end products and deleterious substances 
from within the cell to the extracellular environment [134, 135]. Lowering the intracellular 
concentration of toxic compounds, the ancient function of efflux pumps is thought to aid 
bacterial survival in a harmful environment [136]. Bacterial tolerance to structurally diverse 
compounds like bile salts, detergents, solvents, dyes and antibiotics was reported to be 
conferred by efflux pumps [134, 137, 138]. In particular, the efflux of antibiotics is allowing 
bacteria to survive despite high concentrations of antimicrobial agents, leading to a 
resistance phenotype. Since the first discovery of chromosomally encoded efflux pumps in 
Gram-negative bacteria in 1993 [139, 140], the ever-increasing identification and 
characterization of overexpressed transporters that confer multidrug resistance, particularly 
in the ESKAPE pathogens, underlines the grave threat they cause to health care 
environments.  
Based on their primary structure and energy source, bacterial efflux pumps are classified 
into five distinct families, including the ATP (adenosine triphosphate)-binding cassette (ABC) 
superfamily, the multidrug and toxic compound extrusion (MATE) family, the major 
facilitator superfamily (MFS), the small multidrug resistance (SMR) family and the resistance-
nodulation-cell division (RND) family (Fig. 1.4). These individual efflux families are described 
in the following section, mostly referring to studies performed in E.coli, with the main focus 
on RND-type transporters. 
1.2.1 Transporter of the ABC superfamily 
Efflux pumps belonging to the ABC superfamily are uniporters which use the binding and 
hydrolysis of ATP as an energy source to pump out their substrates [141]. Organised as 
dimers, ABC transporters consist of four domains, two cytoplasmic nucleotide-binding 
domains (NBD) and two trans-membrane domains (TMDs) embedded in the intracellular 
membrane (Fig. 1.5) [142]. Each of the two NBDs harbour an ATP binding site and the TMDs, 
consisting of 12-20 transmembrane segments (TMS), form a transmembrane pore which 
serves as a path across the intracellular membrane [143]. 
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Figure 1.4 Composition of efflux pump families in Gram-negative bacteria. Transporters of the ABC-, 
MFS-, MATE- and SMR-type transporters are antiporters which span the inner membrane. They 
extrude ligands from the cytoplasm to the periplasm. The RND-type pumps are tripartite spanning 
the inner and the outer membrane. As a consequence, substrates are exported from the periplasm 
to the extracellular environment. OM: outer membrane; IM: inner membrane; modified from Du et 
al. [136]. 
Substrate extrusion is accomplished by ATP-dependent conformational changes of the 
transporter [144-146]. Although the chronological order of events has not yet been 
elucidated, it is proposed that in the absence of bound substrates and ATP, ABC efflux 
pumps are in an inward-facing ‘open’ confirmation (Fig. 1.5) [147]. Thereby, the assumed 
substrate-binding chamber formed by the two TMDs within the membrane is facing the cell 
interior. Upon direct substrate binding to the TMDs and binding of two ATP molecules within 
the NBD dimer interface (looking like a ‘cassette’), the NBDs dimerize. This conformational 
change involves the closure of the inward-facing and the opening of the outward-facing 
confirmation of the TMDs. In this stage the two TMDs diverge into two discrete 'wings' that 
point away from each other towards the periplasm (in the case of Gram-negative bacteria). 
ATP hydrolysis, the release of ADP and transport of the substrate, leads to the dissociation of 
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the NBD dimers and sets the ABC pump back to its initial inward facing configuration ready 
for the next cycle.  
 
Figure 1.5 Export mechanism of ABC transporters. Being in the inward-facing conformation, ABC 
pumps bind their substrates “D” (drug) in the cytoplasm or the inner leaflet of the membrane. 
Following, two molecules of ATP are bound, resulting in a dimerization of the nucleotide binding 
domains (NBDs) and a conformational change of the transmembrane domains (TMDs) to the 
outward-facing configuration, results in the export of the substrate to the periplasm. Adapted from 
Wilkens [147]. 
In Gram-negative bacteria there are only a small number of examples of this exporter family. 
The best studied bacterial ABC pump is MacB in E.coli, which particularly raises macrolide 
MIC values when overexpressed [148]. In contrast to typical primary ABC pumps, the MacB 
dimer interacts with the periplasmic adaptor protein MacA, which is assumed to connect 
MacB to the outer membrane pore TolC, without a direct connection between the pump and 
the pore [149, 150]. As the outer membrane pore spans the extracellular membrane, this 
trimeric complex facilitates the efflux of MacB substrates from the cytoplasm directly to the 
extracellular space.  
1.2.2 Pumps of the MF superfamily 
With more than 1000 identified members to date, the MFS superfamily comprises the 
largest protein transporter group [151]. Usually composed of 400-600 amino acid residues, 
MFS pumps are antiporters using the electrochemical gradient across the inner membrane 
as an energy source for the export of substrates from the cytosol to the periplasm [151, 
152]. MFS transporters generally function as monomers and comprise two domains, each of 
which is composed of six to seven distorted α-helices making a total of 12-14 TMS spanning 
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the inner membrane (Fig. 1.4). Thereby, both helical bundles are connected by a long, 
flexible central loop and the N- as well as the C-terminus are located in the cytoplasm. Four 
membrane helices face away from the interior, whereas the remaining helices form an 
internal cavity. The composition of this central pore, lying between both the N- and the C-
domains, has been reported to determine the substrate specificity of the MFS pump. 
Whereas a cavity comprised of many hydrophilic residues is associated with the transport of 
specific substrates (e.g. tetracyclines in the case of TetA pump [153]), MFS pumps with a 
hydrophobic core, like EmrD in E. coli, have been reported to have a broad substrate 
specificity transporting a multitude of lipophilic compounds, including proton uncouplers, 
quaternary ammonium compounds and SDS [154, 155]. Cationic dyes, chloramphenicol and 
fluoroquinolones have also been reported as substrates of MdfA, another MFS efflux pump 
in E.coli [155].  
MFS pumps are proposed to transport their substrate via an alternating-access mechanism, 
involving two major conformations, the inward-facing and the outward facing configuration 
[152]. Crystal structures have revealed the protonated inward-facing composition of the E. 
coli MFS pumps EmrD and MdfA [154, 156]. Thereby, an inverse V- or heart-shape of the 
monomer was reported with the internal cavity open to the cytoplasm (Fig. 1.6 A). The 
substrate binding site within the hydrophobic cavity was found right in the middle of the 
membrane. Substrates are suggested to reach the binding site via the inner membrane 
leaflet or the cytoplasm. Upon binding, rotation between the N-and the C-terminal domains 
around the axis parallel to the membrane lead to an outward-facing form of the monomer 
(Fig. 1.6 C). In this conformation the internal cavity is open to the periplasm and substrate 
translocation can occur via an H+-antiport.  
Similar to the MacAB ABC-type exporter, the presence of tripartite MFS pumps was 
proposed. As an example, the E. coli MFS efflux pump EmrB has been reported to form 
dimers and a complex with the accessor protein EmrA, encoded upstream of EmrB [157]. It 
was hypothesised that binding to an outer membrane pore would facilitate the substrate 
transport from the cytoplasmic site directly to the extracellular space.  
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Figure 1.6 Transport mechanism of MFS efflux pumps. A. In its protonated state, MFS transporter 
show an inward-facing conformation and can bind ligands from the inner leaflet of the bilayer (1) or 
the cytoplasm (2). B. Binding of the substrates leads to an occluded and further to C. an outward 
facing conformation. The pump is deprotonated and the ligand is released to the periplasm. Taken 
from Yin et al. [154]. Reprinted with permission from AAAS.  
1.2.3 Transporters of the MATE family 
In Gram-negative bacteria, efflux transporters of the MATE family have been associated with 
fluoroquinolone resistance and reduced susceptibility to aminoglycosides [158, 159]. These 
pumps are antiporters ranging from 400 to 700 amino acid residues, which use the proton or 
cation gradient (Na+) across the inner membrane to extrude their substrates from the 
cytoplasm to the periplasm. Regarding the structure of MATE exporters, two lobes, a C-
terminal and an N-terminal lobe, each of which consists of six transmembrane helices, form 
a cleft within the inner membrane (Fig. 1.4) [160]. In its outward-facing conformation, the 
Na+-driven MATE pump NorM of Vibrio cholerae was reported to form a V-shape structure, 
similar to pumps of the MFS family (Fig. 1.6). Thereby, the two lobes which are connected by 
a cytoplasmic loop, form an internal cavity between them displaying an opening to the 
extracellular space. Within the internal cavity, which is divided into the larger N-lobe and a 
C-lobe cavity, a drug binding pocket (N-lobe cavity) as well as the cation-binding site (C-lobe 
cavity) have been identified. Analysis of the archeal H+-gradient driven pump PfMATE 
suggests that the bound substrate is released into the extracellular environment (periplasm 
in the case of Gram-negative bacteria) upon a protonation-dependent bending of the first 
transmembrane helix which results in the collapse of the N-lobe [161]. Until today MATE 
transporters could only be captured in their outward-open configuration. However, 
proton/cation binding or release has been shown to induce essential rearrangements of the 
seventh and eighth transmembrane helix which might play a role in the conformational 
change between the outward-open and the inward-open state [161-163].  
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1.2.4 Exporters of the SMR family 
Proton-motive-force driven SMR efflux transporters comprise the smallest group of exporter 
proteins. These hydrophobic proteins functioning as homodimers are only 100 -120 amino 
acid residues in length and composed of four TMS (Fig. 1.4) [136]. Considering the 
orientation of the dimer, contradictory results were published. Whereas X-ray 
crystallography of the E. coli SMR transporter EmrE showed an antiparallel arrangement of 
the two protomers, being embedded in opposite directions within the membrane [164], a 
parallel composition was achieved by chemical crosslinking [165]. However, the first three 
TMS of each monomer together form the substrate binding cavity whereas TMS4, which is 
almost perpendicular to the membrane, is responsible for dimer formation [164]. Similar to 
the other primary efflux pumps, it is suggested that substrates are moved across the 
membrane via the alternating access model [166]. Nuclear magnetic resonance studies of 
EmrE enabled the observation of the conformational change of the two protomers upon 
substrate binding [167]. Thereby, the configuration of the protomers is identical in the 
inward- and the outward-facing state, merely their orientation in the membrane is opposite. 
However, in contrast to the MATE and MFS superfamilies, two protons are exchanged for 
one substrate molecule. Furthermore, the substrate and the protons are competing for the 
same binding site (conserved Glu14 residue within TMS1) [168]. Upon substrate encounter, 
the protonated glutamate residue becomes deprotonated and binds the substrate instead. 
Antibiotic classes translocated by SMR pumps in Gram-negative bacteria include 
aminoglycosides in P. aeruginosa [169] and colistin, erythromycin, rifampicin and 
tetracycline in Klebsiella pneumoniae [170]. 
1.2.5 Efflux pumps of the RND family 
Among the efflux pump classes, members of the RND family exhibit the widest range of 
substrates including commonly used antibiotics, as well as antiseptics, detergents, bile salts, 
disinfectants and dyes, and thus show the highest clinical significance in Gram-negative 
bacteria [134, 137, 138]. No homologues of efflux pumps belonging to this family exist in 
mammals [171]. With the typical tripartite composition of these pumps, spanning the inner 
as well as the outer membrane, compounds are exported directly to the extracellular 
environment and the intracellular concentrations of compounds toxic for the bacterial cell is 
lowered efficiently. The best-characterized member of this family is the AcrAB-TolC system 
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in E. coli which in the following section will serve as the paradigm RND-type efflux pump. 
AcrAB-TolC is composed of three components – the transporter AcrB, an outer membrane 
pore TolC and a periplasmic adaptor protein, also called membrane fusion protein (MFP), 
AcrA [172]. It is suggested that the AcrAB-TolC system form a 3AcrA: 3AcrB: 3TolC complex 
(Fig. 1.7) [173]. 
The transporter AcrB is composed of a transmembrane and a periplasmic domain [174, 175]. 
The TMD spans the entire width of the inner membrane whereby each monomer of the AcrB 
trimer is arranged in a 12-stranded β-barrel. The transporter protrudes from the inner 
membrane into the periplasm by α-helical bundles forming an internal cavity.  
 
Figure 1.7 Tripartite assembly of the E. coli RND-type efflux pump AcrAB-TolC. AcrA is shown in 
green, AcrB subunits are depicted in blue and TolC barrels are coloured in yellow/orange. Membrane 
bound domains are grey. Reprinted from Blair et al. [176] with permission from Elsevier. 
The wide substrate range exhibited by RND-type pumps can be attributed to multiple 
binding sites within the transporter protein. Computer simulations and co-crystallization 
experiments have revealed three binding pockets within the periplasmic domain of AcrB, 
suggesting that RND-type efflux pumps bind their substrates from the periplasm and extrude 
them through the outer membrane pore [175, 177, 178]. It should be noted that AcrD, 
another RND-type efflux pump in E. coli, is able to transport aminoglycosides even from the 
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cytoplasm [179]. The proximal binding pocket lies at the surface of the periplasmic domain 
at the entrance of the internal cavity, whereas the distal binding pocket is situated deeper 
within the cavity (Fig. 1.9 A, B). Both binding pockets are connected by a flexible loop (Fig. 
1.9 C) [178]. Interactions with transported ligands are favoured by aromatic, charged and 
polar amino acid residues that are enriched within the binding pockets. Low-molecular-
weight drugs, such as minocycline, are predicted to directly bind to the deep distal binding 
pocket, without interacting with the proximal binding pocket [180]. In contrast, high-
molecular-weight substrates (e.g. chloramphenicol and ethidium) are believed to first bind 
to the proximal binding pocket and in the transport process they are forced to the distal 
pocket [181, 182]. The distal binding pocket is further divided into two different binding 
portions, a wider ‘cave’ portion and a narrower ‘groove’ portion (Fig. 1.8) [183]. 
Antimicrobial agents like minocycline, levofloxacin, erythromycin, rifampicin and tetracycline 
are predicted to bind to the upper ‘groove’ portion. Chloramphenicol, however, seems to 
bind to the lower ‘cave’ portion and ciprofloxacin seems to bind to both portions. Co-
crystallization of ampicillin with AcrB revealed another binding site within the central cavity 
[184-186]. As for high-molecular-weight ligands, it is predicted that after initial binding at 
this potential third binding site, drugs eventually translocate to the distal binding pocket. 
However, the functional significance of this third binding site has not been determined yet. 
 
Figure 1.8 Distal binding pocket within AcrB. The distal binding pocket (orange) is divided into two 
portions the wider cave binding portion and the narrow groove binding portion. Minocycline (green) 
is bound to the groove portion. AcrB protomer assembly is shown in the right corner. Taken from 
Nikaido et al. [187] by permission of Oxford University Press. 
The discoveries and investigations on efflux pump inhibitors gave further insights into the 
architecture of the distal binding pocket. The first two compounds discovered with inhibitory 
effects on broad substrate efflux pumps in Gram-negative bacteria are phenylalanine arginyl 
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β-naphtylamide (PAβN) and 1-(1-naphtylmethyl)-piperazine (NMP) [188, 189]. Investigations 
in E. coli have shown that PaβN and NMP act as RND substrates binding to the ‘groove’ 
portion of the distal binding pocket in AcrB [135, 190]. As it was impossible for minocycline 
to bind to any subsite of the pocket, it is suggested that binding of efflux pump inhibitors 
distorts the binding pocket, thereby inhibiting substrate binding. 
Regarding the transport mechanism, a ‘three step functional rotation’ model has been 
proposed (Fig. 1.9) [175, 191]. Thereby, AcrB is believed to show an asymmetrical 
configuration with each protomer sequentially rotating between three conformations. In the 
loose conformation, substrates are allowed to access the pump as the cavity within the 
protomer is opened to the periplasm. This cavity is connected to the binding pockets by a 
channel. In the tight configuration, the binding pocket expands to accommodate the 
substrates. In this way, drugs enter the cavity from the periplasm and move along the 
channel to bind to the different sites in the distal binding pocket. At this stage the exit tunnel 
from the binding site is blocked. Upon protonation, the extrusion configuration is triggered 
[192, 193]. The proton is thought to enter from the periplasm, binding to specific Asp 
residues in the TMD of AcrB, promoting the conformational change [193]. As a consequence, 
the periplasmic opening to the tunnel is closed, whereas the exit tunnel is opened. 
Furthermore, shrinking of the binding pocket leads to the extrusion of the substrate. 
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Figure 1.9 Three step functional rotation mechanism of AcrB shown (A) in a cross section (two 
protomers each of AcrB (blue, yellow, or red), AcrA (green), TolC (grey) , (B) from the aerial 
perspective  and (C) illustrating the paths of the drug along the vestibule/cavity (C). Upon drug 
binding and proton coupling, AcrB undergoes different conformational changes, access/loose (L; 
blue), binding/tight (T; yellow), extrusion/open (O; red), in order to export the encountered 
substrate. Adapted from Du et al. [136]. 
The MFP AcrA consists of a long α-hairpin domain and the N-and C-terminal ends together 
form a compact β-roll domain (Fig. 1.7) [194]. In between, a central lipoyl domain ensures 
flexibility of the two domains facilitating the assembly of the MFP to the other efflux pump 
components. AcrA is predicted to preassemble with AcrB via its N- and C- terminal ends 
close to the inner membrane [173]. Complete assembly of the tripartite RND complex is 
achieved by AcrA recruiting the outer membrane pore TolC via its α-hairpin domain. 
Each TolC monomer is characterized by three structurally distinct domains: the 12-stranded 
β-barrel lies within the outer membrane to form an open pore; the α-helical barrel is 
protruding from the outer membrane to the periplasm and a mixed α/β- folding is situated 
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in the periplasm (Fig. 1.7) [195]. Altogether these three domains form an exit tube for 
substrates. Before its assembly, the TolC tunnel is closed. Once recruited to the complex, 
conformational changes in AcrA are thought to trigger a shift in TolC so that the tip of the 
periplasmic end of the channel shifts from the closed to the open state [173]. Due to this 
transition it is likely that substrates pass through the TolC channel and ultimately are 
expelled to the extracellular environment. Until today, it has not yet been fully established 
whether only AcrA is assembled with the outer membrane pore, or if interactions between 
the top of the periplasmic domain of AcrB and the α-barrel domain of TolC are favoured 
[172, 196]. 
Regarding the gene composition of RND-type efflux systems, in E. coli the genes encoding 
AcrAB form an operon, whereas TolC is encoded elsewhere [197]. In other species like P. 
aeruginosa, a three gene operon with a specific outer membrane pore has been described 
for AcrAB-TolC homologs (e.g. MexAB-OprK) [140].  
1.2.6 Physiological function of efflux pumps 
Efficiently expelling a large number of noxious agents including antimicrobials, detergents, 
disinfectants, dyes, and antiseptics [198-200], the ancient function of efflux pumps has been 
attributed to aid the survival in competitive and hazardous environments [136]. In addition 
to the mentioned agents, host derived substrates like bile salts, fatty acids and steroid 
hormones have also been shown to be exported by efflux pumps, generally allowing 
adaption and survival within the host. In fact, among all substrates, E. coli AcrAB has been 
shown to exhibit the highest affinity for bile salts [201], which are abundant in the intestine 
of vertebrates – the natural habitat of E. coli.  
Investigations in E.coli suggest that efflux transporters, in particular AcrAB, are the first line 
of defence when bacteria are exposed to antibiotics. Serially challenging E. coli cells with 
increasing concentrations of tetracycline led to an increased expression of genes relevant for 
either regulating, or directly coding for components of AcrAB [202, 203]. Resistance to β-
lactams and quinolones increased concomitantly with tetracycline resistance. However, 
when the highest concentration of tetracycline was maintained, this increased expression of 
acrB declined in later cultures and instead cells developed mutations in genes usually 
targeted by antibiotics such as DNA gyrase or the 30S subunit of the ribosome [202]. These 
results suggest that polyspecific efflux systems are used as an initial strategy to combat 
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antibiotic exposure, but if bacteria are facing consistent concentrations of antibiotics, 
accumulated mutations in key antibiotic targets constitute the better survival strategy. 
In order to efficiently confer antimicrobial resistance, a synergistic interplay between drug 
influx and efflux is crucial [204, 205]. The influx of toxic compounds is controlled by the outer 
membrane permeability. In E. coli an effective permeability barrier is achieved by the 
regulation of porin expression – their expression is decreased when the influx of toxic 
compounds threatens cell survival and increased when a high concentration of nutrients is 
required [206]. As described in Chapter 1.1.5, P. aeruginosa and A. baumannii have a smaller 
number and size of porins, as compared to E. coli, leading to a very slow drug influx. This 
reduced uptake allows efflux pumps to successfully reduce the intracellular concentration of 
drugs to sub-inhibitory concentrations by extruding them out of the cell. In E. coli for 
example, a simultaneous reduction in porin synthesis and upregulation of efflux pumps was 
detected in the process of adapting to tetracycline exposure [207].  
Furthermore, the interplay between different efflux pump classes further enhances 
antimicrobial resistance [208, 209]. Thereby, toxic compounds are transported to the 
periplasm by primary pumps of the MATE, SMR, ABC or MFS family, residing in the inner 
membrane and pumping substrates from the cytoplasm. From there, ligands are expelled to 
the extracellular environment by RND systems. Once the intracellular concentration of toxic 
molecules exceeds the capacity of the transporters, overexpression of pumps is induced, 
leading to a resistant phenotype [204]. Crossing the inner and the outer membrane, mainly 
RND-type efflux systems contribute significantly to antibiotic resistance. In the last decades, 
an increasing number of enterobacterial species, isolated from patients undergoing 
antibiotic treatment, have been found to have their MDR phenotype associated with 
increased expression of either AcrAB or AcrAB-like transporters [138, 210]. Thus, under 
antibiotic pressure, extrusion of antimicrobials by RND transporters seems to be a very 
efficient bacterial survival strategy. 
The exporters’ capacity to extrude substrate also comes into play during cellular stress 
responses. Levels of AcrAB in E. coli have been found to be elevated during stress responses 
induced by exposure to high salt, ethanol or bile salt concentrations [211]. Regarding 
oxidative stress, promoted by high levels of H2O2, the ABC efflux pump MacAB of Salmonella 
was reported to be essential for cell survival [212]. Similarly in Stenotrophomonas 
maltophilia, SmeIJK contributes to oxidative stress resistance [213]. On the other hand, 
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reduced acrB expression in K. pneumonia correlated with reduced tolerance to bile salt, 
oxidative, and hyperosmotic stress [214].  
Various investigations suggest a correlation between efflux pump expression and biofilm 
formation. Inhibiting or deleting any of 9 efflux pumps that confer multidrug resistance in 
Salmonella typhimurium led to impaired biofilm formation [215]. However, this effect has 
not been observed in all species. In P. aeruginosa, deletion of RND pumps had no effect on 
the cells ability to form biofilms [216]. Moreover, considering an interplay between biofilms 
and efflux pumps, the investigation of gene expression during biofilm growth in E. coli 
revealed the upregulation of 20 transporter genes [217].  
A direct effect of efflux pumps on bacterial pathogenicity and virulence has been shown 
upon transporter inactivation. AcrB or tolC deficient S. typhimurium, for example, poorly 
colonized the avian gut and did not persist [218]. A reduced infection rate of mice was 
determined for K. pneumoniae strains lacking the acrAB genes [219]. Furthermore, by 
individually deleting 3 of the 4 best-studied efflux transporters in P. aeruginosa (MexAB-
OprM, MexEF-OprM, MexXY-OprM), its ability to invade epithelial cells declined significantly 
[220]. At the same time, an epidemic P. aeruginosa strain overexpressing MexAB-OprD 
displayed enhanced killing of fruit flies compared to a laboratory reference strain [221].  
The advantages that accompany the overexpression of efflux pumps allow bacteria to 
survive in hazardous environments. However, there are also disadvantages for the cell. 
Given the polyspecificity of these transporters, metabolites required for cell growth and 
division have also been reported to be substrates [222-224]. In addition, pump synthesis and 
functioning is an energy-driven process [183]. Investigations have shown that the 
unregulated overexpression of efflux pumps not only led to increased overall resistance but 
also to decreased cell growth [127, 225]. Therefore, transporters are usually tightly 
regulated. Nevertheless, upon exposure to toxic substrates, their expression has to be 
rapidly induced. 
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1.2.7 Efflux pump regulation 
The transcription of efflux systems is strictly regulated by a combination of local regulators, 
global response regulators or two-component regulatory systems, through either repression 
or activation. Mutations in the genes encoding regulators are often accompanied by 
overexpression of efflux pumps, and are thus often associated with an MDR phenotype. 
Local regulators are usually encoded adjacent to the structural components of the efflux 
pump (Fig. 1.10) and most of them are members of the MarR, MerR or TetR family, acting as 
transcriptional repressors [226-228]. MDR clinical isolates often harbour mutations in these 
local regulators supporting the fact that these regulators usually undermine the 
overexpression of efflux transporters. Under normal conditions, the local repressor binds to 
the promoter of an efflux pump operon and inhibits transcription (Fig. 1.10). However, 
specific effector molecules (e.g. antibiotics [229], bile salts [230], ethidium bromide [231], 
rhodamine 6G [232]) can bind to the repressor. The resulting conformational change in the 
regulator protein blocks its DNA binding, or releases the repressor from the bound 
promoter, so that the exporter gene is transcribed. This negative regulation of efflux pump 
expression is an advantage to the cell as no additional time and energy has to be spent in 
order to generate a transcriptional activator needed for a positive regulation. Thus, bacterial 
cells can respond more rapidly to environmental changes.  
In addition to, or instead of local regulators, efflux pump expression can be positively 
controlled by global regulators. The three global regulators MarA, Rob and SoxS, for 
example, regulate AcrAB and TolC of E. coli in addition to at least another 40 genes [233]. 
Although all three belong to the XylS/AraC regulator family and bind to the same DNA 
sequence in the promoter of acrAB, the so called marbox (Fig. 1.10), the activation of AcrAB 
by each regulator proceeds in response to different environmental conditions or stimuli. In 
the case of MarA, salicylate was reported to be a driving effector for acrAB gene 
transcription [234]. The marA gene is encoded within the marRAB operon, with marR and 
marB encoding local repressors of the operon [235]. Salicylate can bind to the MarR 
repressor, inducing a conformational change and thereby inhibiting its binding to the 
marRAB promoter. Mutations in the marR gene can have a similar effect. As a consequence, 
MarA is expressed and activates acrAB transcription.  
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Figure 1.10 Regulation of acrAB gene expression. In E. coli the expression of the RND pump 
encoding genes acrAB are regulated by the global regulators MarA, SoxS and Rob, and the local 
repressor AcrR. Adapted from Blair et al. [236] with permission. 
The Rob regulator is assumed to induce efflux pump expression once it undergoes a 
conformational change. Bile salts for example can bind Rob at its non-binding DNA domain 
[237]. The resulting conformational change allows the Rob regulator to bind to the marbox. 
Upon oxidative stress however, acrAB gene transcription dependents on the global 
regulators SoxRS [238]. In this case, reactive oxygen species oxidise SoxR, which in turn 
oxidises SoxS. Being in its oxidised active form, SoxS binds to the promoter of acrAB and 
promotes its expression. Under oxidative stress, the AcrAB pump of Salmonella has been 
shown to be regulated in the same manner [239]. 
The two-component regulatory system is widely distributed among prokaryotes, and senses 
and responds to various environmental signals and stimuli [240]. It is composed of two 
components, a sensor histidine kinase, and a cognate cytoplasmic response regulator, which 
each are composed of two domains. Environmental stimuli (e.g. changes in osmolarity, 
nutrients, presence of antibiotics) are sensed at the periplasmic sensor domain of the senor 
kinase leading to the autophosphorylation of the cytoplasmic kinase domain at a conserved 
histidine residue (H149; Fig. 1.11). This autophosphorylation is catalysed by the ATPase 
which is part of the cytoplasmic domain of the sensor kinase. Following, the kinase catalyses 
the transfer of its phosphoryl-group to the receiver domain of the response regulator via a 
conserved aspartate residue, rendering the regulator in its activated form. Upon activation, 
the regulator is now able to bind to the promoter region of the efflux pump genes with its 
effector domain to induce expression. Phosphorylation of the sensor kinase and the transfer 
of the phosphoryl-group can be reversed by its phosphatase activity; by switching between 
phosphorylation and dephosphorylation activities, the expression of downstream genes can 
further be controlled. 
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Figure 1.11 Signal transduction pathway of the two-component regulatory system. Upon 
environmental changes the sensor kinase gets autophosphorylated. The phosphoryl-transfer to the 
response regulator is bringing it to its active form, inducing differential gene expression. Taken from 
Cann [241].  
As an example, sensing an acidic environment, the PhoPQ two-component system of 
Salmonella activates the expression of the ABC-type efflux pump MacAB [242], whereas the 
BaeSR system responds to transition metals (copper or zinc) by inducing MdtABC and AcrD 
expression [243].   
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1.3. Efflux pumps in Acinetobacter spp. 
To date, efflux pumps have been reported in isolates of A. baumannii, A. baylyi, A. 
nosocomialis, A. pittii, A. radioresistens, A. oleivorans and the A. genomic species 17. But it is 
in A. baumannii that their overexpression has been associated with an MDR phenotype.  
1.3.1 The RND-type efflux pump AdeABC in A. baumannii 
The RND-type system AdeABC (Acinetobacter drug efflux) was the first efflux pump that was 
characterized in A. baumannii [126]. The genes encoding the pump are contiguous and 
directly orientated with overlapping stop and start codons for AdeAB, which is indicative of 
an operon (Fig. 1.12). The adeABC operon encodes the MFP AdeA, the transporter AdeB, and 
the outer membrane pore AdeC.  
 
Figure 1.12 Gene composition of the three characterized RND-type efflux pumps in A. baumannii. 
Genes encoding the RND efflux systems display an operon formation. Whereas the two-component 
system AdeRS and the LysR regulator AdeL are encoded directly upstream of the pump they control, 
AdeN is encoded >800 kbp upstream of adeIJK. 
Insertional inactivation of AdeB in an adeB-overexpressing MDR clinical A. baumannii isolate 
revealed that this RND system conferred antimicrobial resistance to aminoglycosides and 
low-level resistance to chloramphenicol, fluoroquinolones, erythromycin, tetracycline, and 
trimethoprim (Table 1.2) [126]. Later studies correlated adeB overexpression with decreased 
susceptibility to netilmicin, certain β-lactams (cefepime, cefpirome, cefotaxime) and 
tigecycline [244-246]. The impact on carbapenem susceptibility is still under debate; studies 
showing no efflux involvement in carbapenem susceptibility [247, 248] as well as 
observations attributing a 2-8-fold increase in the resistance to carbapenems to efflux have 
been published [89, 249, 250]. Expressing AdeABC in a heterologous E. coli strain, the efflux 
properties of the A. baumannii efflux system was compared to that of the E. coli pump 
AcrAB-TolC [251]. On the one hand, β-lactams could be identified as substrates of AdeABC, 
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which was impossible to detect in A. baumannii due to the expression of endogenous β-
lactamases. On the other hand, Sugawara et al. found out that the transport of cefepime, 
ciprofloxacin and tetracyclines is more efficient by AdeABC but weaker to benzylpenicillin, 
oxacillin, nitrocefin, ethidium bromide and novobiocin, compared to AcrAB-TolC.  
Analysing an internal 850-bp fragment of adeB amongst 50 A. baumannii isolates belonging 
to IC1–3, 11 adeB sequence types were detected, varying in 2 to 45 bases [252]. This 
sequence variability in adeB correlated well with genotypic clustering of these isolates 
performed beforehand. Thus, it was speculated whether adeB typing might be used as a 
method for rapid identification of distinct lineages in A. baumannii.  
Regarding the prevalence of the adeB gene in A. baumannii, controversial data have been 
published, ranging from 70% to 96% [105, 244, 253, 254]. These differences are mainly due 
to different study designs. Whereas in some studies species identification was not always 
performed using reference methods and/or the isolates investigated came from one 
particular hospital [253, 254], advanced studies included isolates from different European 
countries, that were divided into IC1, IC2, and genotypically unique isolates [105, 244]. Apart 
from the distinct study designs, in each study only one primer pair was used to detect the 
adeB gene. Owing to the high variability of the adeB sequence [252], false-negative results 
are likely to occur by this approach. Additionally, in the study of Nemec et al., adeC was 
detected in only 41% of the clinical isolates, in which adeAB was present [244]. These data 
suggest that AdeAB could recruit another outer membrane pore to form a functional 
tripartite system, as it has been reported before for other bacterial genera [255, 256].  
The AdeABC efflux system is regulated by the two-component regulatory system AdeRS, 
with AdeS being the sensor kinase and AdeR being the response regulator [257]. Both genes 
are located directly upstream of the adeABC operon and transcribed in the opposite 
direction (Fig. 1.12). AdeRS are suggested to be transcriptional activators of AdeABC, as their 
inactivation led to increased susceptibility [257]. However, to date no signal directly inducing 
adeABC expression via AdeRS has been described. Using the A. baumannii reference strain 
ATCC 19606, Bazyleu at al. reported downregulation of adeB, when A. baumannii cells were 
exposed to lower-than-normal incubation temperatures (30°C instead of 37°C), high 
osmolarity obtained by adding 0.3 M sucrose, or when 4 mM salicylate was supplemented to 
the growth medium [258]. There was no correlation between the decreased levels of adeB 
and adeR expression suggesting that the number of adeR transcripts is not crucial for adeB 
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regulation. Using the same reference strain, Fernando et al. reported a growth-phase 
dependent expression of adeB, with adeB being less expressed at high cell density [259]. 
Furthermore, adeA has been shown to be overexpressed upon NaCl exposure [260].  
Different substitutions in the positive regulators AdeRS have been associated with 
antimicrobial resistant phenotypes in A. baumannii clinical isolates mediated by increased 
expression of the AdeB transporter (Fig. 1.13). For example in AdeS, alterations within 
functional conserved domains like the periplasmic sensor domain (Gly30→Asp) [261], the 
HAMP region (histidine kinase, adenylyl cyclase, methyl-accepting chemotaxis protein and 
phosphatase; Ala94→Val, Gly103→Asp, Asn125→Lys) [91, 246] and the HAMP linker region 
(Met62→Ile) [246] as well as amino acid changes near to its autophosphorylation site 
(Thr153→Met) [257] have been described and allied with increased levels of adeB 
transcripts and antimicrobial resistance (Fig. 1.13). Further substitutions in the catalytic core 
of AdeS (Arg152→Lys, His189→Tyr) and the ATPase domain (Ile252→Ser, Gly336→Ser) 
catalysing the autophosphorylation were described by Yoon et al. [262]. Substitutions in 
AdeR associated with AdeABC overexpression have been described in the signal receiver 
domain (Asp20→Asn, Pro56→Ser, Ala91→Val) [89, 246, 262], the α5 helix of the receiver 
domain (Pro116→Leu) [257] as well as in the effector domain (Leu192→Arg, Glu219→Ala) 
[262] (Fig. 1.13). Furthermore, a truncated AdeS generated by the insertion of the IS element 
ISAba1 led to increased expression of adeB [99, 111]. In the latter study, Sun et al. were the 
first to describe a molecular mechanism behind the antimicrobial resistance phenotype by 
introducing several recombinant adeRS constructs into an adeRS-deficient A. baumannii 
strain. In contrast, with the insertion of ISAba1 in adeR, no expression of adeAB could be 
detected [263]. 
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Figure 1.13 Substitutions within the different AdeS and AdeR domains associated with increased 
adeB expression. The HAMP domain of AdeS transduces the signal sensed by the periplasmic sensor 
domain. ATP is bound in the ATPase domain which catalyses the autophosphorylation of the kinase 
domain. The signal is further transduced to the receiver domain of the response regulator AdeR by 
the kinase domain, transferring the phosphate-group from His149 of AdeS to Asp63 of AdeR. 
Subsequently, the effector domain of AdeR is activated and binds to its regulon. HAMP; histidine 
kinase, adenylyl cyclase, methyl-accepting chemotaxis protein and phosphatase domain. 
Nevertheless, adeB overexpressing A. baumannii have also been described without any 
mutations in the adeRS regulatory genes compared to the isogenic parents [246, 264]. Lin et 
al. proposed BaeSR to be another two-component system regulating adeABC expression 
[265], but direct binding of BaeR to the adeA promoter could not be demonstrated [266]. 
Recently, Yoon at al. reported several short nucleotide polymorphisms within adeRS 
characteristic for A. baumannii strains belonging to IC1 and IC2 [262]. Interestingly, in this 
context the mutation leading to the Ala94→Val substitution in the HAMP linker domain of 
AdeS was reported to be a polymorphism of isolates belonging to IC1, and thus was 
erroneously reported as responsible for increased adeABC expression. Therefore, it is 
necessary not to rely on associations, but to further investigate substitutions within the 
regulatory genes and their possible effect on adeB expression and antimicrobial 
susceptibility.  
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1.3.2 Other RND-type efflux pumps in A. baumannii 
The adeIJK operon encodes the second RND-type efflux pump in A. baumannii (Fig. 1.12) 
[127]. Pumping out β-lactams, carbapenems, cephalosporins, chloramphenicol, co-
trimoxazole, erythromycin fluoroquinolones, fusidic acid, novobiocin, rifampicin, 
tetracyclines, tigecycline as well as acridine, pyronine, safranin and SDS this system in part 
showed an overlapping substrate profile compared to AdeABC (Table 1.2) [127, 251]. Thus, it 
is not surprising that a synergistic effect of both pumps has been investigated on the 
extrusion of fluoroquinolones, tetracyclines and tigecycline [267]. In the initial report 
characterizing AdeIJK, it was indicated that this efflux system does not have a major effect 
on antimicrobial resistance, as its overexpression was toxic for the host cell [127]. 
Furthermore, adeIJK transcription levels in isolates overexpressing the pump have been 
reported to be lower than the level of overexpressed adeABC [261]. Nevertheless, using 
tetracycline gradients, spontaneous low-level resistance mutants overexpressing adeIJK 
were obtained, suggesting that AdeIJK can be overexpressed up to a certain threshold [261]. 
Expression above this threshold seems toxic to the cell.  
AdeIJK is negatively regulated by AdeN (Fig. 1.12) [133]. This TetR transcriptional repressor 
found 813 kbp upstream of the adeIJK operon, is constitutively expressed and does not 
regulate its own expression. In addition to A. baumannii, AdeN homologues could also be 
detected in A. calcoaceticus, A. nosocomialis and A. pittii [133]. 
In 2010, a third RND-efflux pump encoding operon, AdeFGH, was described (Fig. 1.12) [112]. 
Selecting an AdeABC- and AdeIJK-defective A. baumannii mutant in the presence of 
chloramphenicol and norfloxacin, Coyne et al. generated an adeFGH overexpressing mutant. 
This strain exhibited high-level resistance to chloramphenicol, fluoroquinolones and 
trimethoprim as well as decreased susceptibility to tetracyclines, tigecycline and co-
trimoxazole. The susceptibility to SDS and dyes like acridine orange, ethidium bromide and 
safranin O was also affected (Table 1.2). Structural components of the efflux system were 
detected in 40 of 44 clinical A. baumannii isolates. Unlike AdeIJK, AdeFGH is not thought to 
contribute to intrinsic resistance, as it is not constitutively expressed. As mutations in the 
LysR transcriptional regulator AdeL were detected in adeFGH overexpressing strains, it is 
thought to control the transcription of this pump [112]. AdeL is encoded directly upstream of 
the adeFGH operon, and is transcribed in the opposite direction (Fig. 1.12). Mutations in 
adeL have been described either in the C-terminal domain, possibly affecting the interaction 
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of the regulator with the RNA polymerase, or at a domain that is thought to be involved in 
signal recognition (Val139→Gly) and thus might lead to a signal-independent activation of 
AdeL. However, effector molecules or conditions which lead to an AdeL-dependent 
overexpression of adeFGH have not been described so far.  
Table 1.2 Chromosomally encoded efflux pumps in A. baumannii and their associated substrates. 
Efflux pump 
family 
Name of 
efflux pump 
Associated substrates References 
 
RND 
 
 
 
AdeABC 
amikacin, benzalkonium, benzylpenicillin, cefepime, 
cefotaxime, cefpirome, chloramphenicol , 
chlorhexidine,  ciprofloxacin, cloxacillin, erythromycin, 
ethidium bromide, gentamycin, imipenem, 
kanamycin, levofloxacin, meropenem, methyl 
viologen, minocycline, netilmicin, nitrocefin, 
novobiocin, norfloxacin, ofloxacin, oxacillin, 
pefloxacin, SDS, sparfloxacin, tetracycline, tigecycline, 
tobramycin, trimethoprim  
[89, 244-
246, 249-
251, 268] 
 
 
AdeIJK 
acridine orange, benzalkonium, cefepime, 
chloramphenicol, ciprofloxacin, cloxacillin, co-
trimoxazole, crystal violet, doripenem, doxycycline, 
ertapenem, ethidium bromide, fusidic acid, 
levofloxacin, meropenem, methyl viologen, 
minocycline, moxifloxacin, nitrocefin, novobiocin, 
oxacillin, pyronine, SDS, safranin, tetracycline, 
ticarcillin, tigecycline, trimethoprim 
[127, 133, 
251, 268, 
269]  
AdeFGH 
acridine orange, chloramphenicol, fluoroquinolones, 
ethidium bromide, safranin, SDS, tetracycline, 
tigecycline ,trimethoprim, 
[112] 
 
MFS 
CraA chloramphenicol [270] 
AmvA 
acridine orange, acriflavine, benzalkonium chloride, 
deoxycholate, erythromycin, ethidium bromide, 
methyl viologen  
[271] 
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Table 1.2 contd. Chromosomally encoded efflux pumps in A. baumannii and their associated  
                               substrates. 
Efflux pump 
family 
Name of 
efflux pump 
Associated substrates References 
MATE AbeM 
acriflavine, ciprofloxacin, chloramphenicol, 
doxorubicin, erythromycin, ethidium bromide, 
gentamicin, norfloxacin, ofloxacin, rhodamine 6G, 
triclosan, trimethoprim  
[272] 
SMR AbeS 
acridine orange, acriflavine, benzalkonium chloride, 
ciprofloxacin, deoxycholate, erythromycin, ethidium 
bromide, methyl viologen, novobiocin, rhodamine 
123, SDS 
[273] 
PACE AceI chlorhexidine [274] 
 
1.3.3 Non RND-type efflux pumps in A. baumannii 
In addition to the three RND-type efflux pumps that are predominantly associated with an 
MDR phenotype, two MFS pumps, as well as one member each of the MATE or the MFS 
superfamily have been characterized in A. baumannii. 
CraA, standing for chloramphenicol resistance Acinetobacter, is one of the MFS-type efflux 
exporters with chloramphenicol being the only substrate of the pump (Table 1.2) [270]. It is 
believed to contribute to intrinsic resistance to this fenicol, however it has not yet been 
established if craA is constitutively expressed. However, it is overexpressed in response to 
NaCl, thus osmotic stress might constitute a stimulus for its expression [260]. Regarding its 
prevalence, it was present in all of 82 tested A. baumannii strains [270]. 
The second MFS pump, AmvA, is associated with decreased susceptibility to mainly, 
detergents, disinfectants and dyes, with erythromycin being the only antibiotic affected 
(Table 1.2) [271]. AmvA was described with 4-TMS and reported to be overexpressed in 
isolates that display elevated antimicrobial resistance.  
The role of AbeM, a member of the MATE-type efflux family, on antimicrobial resistance in 
A. baumannii still remains to be elucidated as its functionality has only been investigating in 
E. coli strains defective in their main RND-type efflux pump AcrAB [272]. Thereby, 
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aminoglycosides, chloramphenicol, erythromycin, fluoroquinolones, trimethoprim as well as 
dyes and triclosan were exported (Table 1.2). A. baumannii isolates overexpressing abeM did 
not display a specific resistance phenotype, suggesting for a very weak effect of this pump 
[245, 275]. 
Inactivation of the SMR efflux pump AbeS followed by subsequent complementation 
affected the MIC values of chloramphenicol, erythromycin, fluoroquinolones, nalidixic acid, 
novobiocin, dyes and detergents (Table 1.2) [273]. Recently, Lytvynenko et al. determined 
residues involved in the substrate recognition of AbeS [276]. Amino acid substitution at 
position 3, 16 and 42 revealed increased resistance to acriflavine and ethidium, but not 
benzalkonium.  
In 2013 a new type of efflux pump, called AceI (Acinetobacter chlorhexidine efflux) was 
identified in A. baumannii [274]. Expression of aceI was induced by chlorhexidine, which is 
also a substrate of the pump (Table 1.2). Thus, AceI was described as a representative of a 
new transporter family, called proteobacterial antimicrobial compound efflux (PACE) family 
[277]. 
1.3.4 Chromosomally encoded efflux systems in other Acinetobacter spp. 
There are only a few studies focusing on efflux systems in Acinetobacter species other than 
A. baumannii. In A. pittii the efflux pump AdeXYZ was detected [253]. Chu et al. did not 
succeed in their attempts to disrupt adeY, thus, based on hydrophobicity analysis, protein 
sequence similarity and gene organisation, AdeXYZ is assumed to be a RND-type efflux 
system. Using a PCR-based approach, adeY was detected in 90% of A. pittii isolates collected 
in a hospital in Hong Kong between 1997-2000 [253]. Furthermore, the gene was found in 
one isolate each of A. nosocomialis and the Acinetobacter genomic species 17. BLAST 
analysis revealed a similar efflux system in the A. baylyi strain ADP1.  
AdeDE, encoding the MFP AdeD and the transporter AdeE, is another system identified in A. 
pittii, with AdeE sharing 50% amino acid identity to AdeB. Inactivating AdeE, Chau et al. 
demonstrated decreased susceptibility to aminoglycosides, carbapenems, ceftazidime, 
chloramphenicol, fluoroquinolones, erythromycin, rifampicin and tetracycline [278]. Within 
the aforementioned isolate collection from the hospital in Hong Kong, 70% of A. pittii 
isolates carried adeE. Moreover, adeE was detected in the same A. nosocomialis and 
Acinetobacter genomic species 17 isolate that harboured adeY [253].  
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In 2011, Roca et al. found a tripartite efflux pump including an upstream encoded two-
component system in A. nosocomialis with high similarity to AdeRSABC (99%, 94%, 96%, 
99%, 95% amino acid identity, respectively) [279]. This finding contradicts previous studies, 
which suggest that AdeABC is an A. baumannii specific pump. The substrate profile of the 
pump was investigated by insertional inactivation of “AdeB” and included aminoglycosides, 
β-lactams, chloramphenicol, quinolones, tetracycline, tigecycline and trimethoprim. Except 
for ceftazidime, this substrate profile matched with that of the A. baumannii AdeABC efflux 
system (Table 1.2). Additionally, gene amplicons highly similar to adeJ and adeY were 
detected in their strain. However, as AdeJ and AdeY share an amino acid identity of 99%, 
Roca et al. propose that AdeXYZ does not represent an independent pump but rather the 
same as AdeIJK.  
Homologs of the new PACE-family transporter protein AceI were found in A. radioresistens 
and A. baylyi [277]. 
1.3.5 Acquired efflux pumps in Acinetobacter spp. 
In A. baumannii, acquired efflux determinants are mainly associated with the AbaR1 
resistance island (see 1.1.4). These include the MFS pumps CmlA and FloR conferring 
resistance to fenicols, and the qacE gene, encoding an SMR transporter that was shown to 
extrude quaternary ammonium compounds in E. coli [37].  
Regarding tetracycline resistance, several acquired transporters of the MFS-type superfamily 
have been characterized in A. baumannii, with TetA and TetB being the most prevalent 
[280]. TetA, which is only exporting tetracycline, is encoded on a Tn1721-like transposon 
together with its regulatory protein TetR [106]. This part of the Tn1721-like transposon was 
also identified within the AbaR1 resistance island [37]. In contrast, TetB is pumping out 
minocycline in addition to tetracycline, and the gene is located on plasmids in MDR A. 
baumannii [281]. Moreover, the tetH gene was found on a plasmid in an A. radioresistens 
strain isolated from a fish farm [282] and in the oil degrader A. oleivorans [283]. 
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1.4 Aim of the study 
 
1) Different study designs have been used to investigate the prevalence of RND-type efflux 
transporters among A. baumannii isolates. The origin of isolates investigated was limited to a 
specific hospital, a city or single countries and species identification was not always 
performed using reference methods. In order to determine the prevalence of genes 
encoding the RND transporters AdeB, AdeJ and AdeG in isolates of worldwide origin, 144 
geographically diverse and epidemiologically characterized A. baumannii isolates, 
representing IC1–8 and genotypically unique isolates, were investigated using a PCR-based 
detection method. Applying an in silico approach, five putative RND-type transporter genes 
were identified and also included in the prevalence study.  
 
2) The RND efflux pump with the locus tag A1S_2660 in A. baumannii ATCC 17978, which 
displayed the highest amino acid similarity to AdeB amongst the five putative exporters 
identified in silico, was chosen for further characterization. Substances inducing the 
expression of A1S_2660 (referred to as rnd1) were determined using a β-galactosidase 
reporter assay. Furthermore, substrates of the putative pump should be identified.  
 
3) The amino acid substitution Asp20→Asn in the response regulator AdeR (see 1.3.1) was 
previously reported in our research group. This replacement, residing in the acidic triad 
making up the active site for phosphorylation, was associated with adeB overexpression and 
reduced susceptibility to the antimicrobials levofloxacin, tigecycline, and co-trimoxazole. As 
most amino acid changes in the regulatory genes have only been allied to increased 
expression of adeB, in the present study, it was aimed to further characterize the effect of 
the substitution on antimicrobial susceptibility, the expression of the efflux genes adeB, 
adeJ, and adeG, bacterial growth, and substrate accumulation by the use of recombinant 
adeR(Asp20)S, adeR(Asn20)S, or adeR(Asp20)SABC, and adeR(Asn20)SABC constructs, 
respectively. 
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2. Materials & Methods  
2.1 Materials 
Materials used within the course of the study are listed in Table 2.1-2.5.  
2.1.1 Antimicrobials 
Antimicrobial discs (Table 2.1) were purchased from Oxoid (Wesel, Germany). Antimicrobials 
used for determination of the minimal inhibitory concentration, for selection of 
transformants and for induction of efflux pump expression are indicated in Table 2.2.  
Table 2.1 Antimicrobial discs 
Antimicrobial disc Abbreviation 
Amikacin AK 
Amoxacillin/Clavulanic acid AMC 
Ampicillin AMP 
Ampicillin/Sulbactam SAM 
Aztreonam ATM 
Azithromycin AZM 
Cefepime FEP 
Cefsulodine CFS 
Ceftriaxone CRO 
Chloramphenicol C 
Ciprofloxacin CIP 
Clindamycin DA 
Doxycycline DO 
Ertapenem ETP 
Erythromycin E 
Gentamicin CN 
Imipenem IPM 
Meropenem MEM 
Ofloxacin OFX 
Oxacillin OX 
Penicillin P 
Piperacillin/Tazobactam TZP 
Rifampicin RD 
Tetracycline TE 
Ticarcillin TIC 
Ticarcillin/Clavulanic acid TIM 
Trimethoprim/Sulfamethoxazole SXT 
Vancomycin VA 
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    Table 2.2 Antimicrobial powder 
Antimicrobial Abbreviation Manufacturer 
Amikacin sulfate AMK Molekula, Munich 
Ampicillin sodium salt AMP Sigma-Aldrich; Steinheim 
Azithromycin AZI Pfizer, Berlin 
Chloramphenicol CHL Serva, Heidelberg 
Ciprofloxacin CIP Bayer, Leverkusen 
Erythromycin ERY AppliChem, Darmstadt 
Gentamicin sulfate GEN Sigma-Aldrich 
Kanamycin sulfate KAN AppliChem 
Levofloxacin LEV Sanofi Aventis, Frankfurt 
Meropenem MEM Molekula, Munich 
Minocycline hydrochloride MIN Molekula 
Moxifloxacin MOX Bayer 
Nalidixic acid NAL Sigma-Aldrich 
Novobiocin NOV Sigma-Aldrich 
Rifampicin RIF Sigma-Aldrich 
Tetracycline hydrochloride TET Sigma-Aldrich 
Ticarcillin TIC Roth, Karlsruhe 
Tigecycline TGC Sigma-Aldrich 
2.1.2 Equipment 
In Table 2.3 the equipment used and the manufacturers are listed. 
Table 2.3 Equipment 
Equipment Manufacturer 
96-well plate BIOplastics BV, Landgraaf, The Netherlands 
Disc Dispenser Oxoid, Wesel, Germany 
Gene Pulser II System BioRad, Munich, Germany 
Gel Doc XR+ System BioRad 
LightCycler® 480 Roche, Mannheim, Germany 
Multipoint inoculator Mast Laboratories, Liverpool, United Kingdom 
NanoDrop 2000 Spectrophotometer Thermo Fisher Scientific, Schwerte, Germany 
Plate Reader Infinite M1000 Tecan, Crailsheim, Germany 
Thermal Cycler C1000 Touch® BioRad 
VITEK Densicheck Biomerieux, Nürtingen, Germany 
2.1.3 Chemicals and other materials 
All chemicals and other materials and their abbreviations used for the purpose of the study 
are presented in Table 2.4.  
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Table 2.4 Chemicals and other materials 
Chemical Abbreviation Manufacturer 
100 bp and  1 kb ladder  New England Biolabs, Frankfurt 
1-(1-naphtylmethyl)-piperazine NMP Sigma-Aldrich 
5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside  
X-Gal AppliChem, Darmstadt 
Acriflavine  Sigma-Aldrich  
Agarose  Sigma-Aldrich  
BBLTM Mueller Hinton II Agar  BD Clonetech, Heidelberg 
BBLTM Mueller Hinton II Broth  BD Clonetech 
β-mercaptoethanol  Merck, Darmstadt  
Benzalkonium chloride  Sigma-Aldrich  
Carbonyl cyanide m-chlorophenyl 
hydrazone 
CCCP Sigma-Aldrich 
Comassie blue  Serva, Heidelberg 
Difco Agar Noble Agar BD Clonetech 
Dimethyl sulfoxide  DMSO Merck 
Di-potassium hydrogen phosphate K2HPO4 Roth, Karlsruhe 
DNA Gel loading dye  New England Biolabs 
Ethidium bromide powder  Merck 
Ethidium bromide solution  Roth 
Ethanol 96% absolute  Th. Geyer, Hamburg 
Glucose monohydrate  Merck 
Isopropyl β-D-1-thiogalactopyranoside IPTG Sigma-Aldrich 
Isopropanol  Roth 
Magnesium sulfate  MgSO4 Sigma-Aldrich 
Manganese chloride tetrahydrate Mn(II)Cl Sigma-Aldrich 
Potassium dihydrogen phosphate KH2PO4 AppliChem 
Potassium tellurite hydrate  Tellurite Sigma-Aldrich 
RNA Protect Bacteria Reagent  Qiagen, Hilden 
Rhodamine 6G  Sigma-Aldrich 
Rothiphorese® 50x TAE Buffer  Roth, Karlsruhe 
Safranin O  Sigma-Aldrich 
Sodium chloride  NaCl Sigma-Aldrich 
Sodium dodecyl sulfate  SDS AppliChem 
Sodium deoxycholate   Sigma-Aldrich 
Sucrose  Sigma-Aldrich 
Sulbactam  Pfizer, Berlin 
Triclosan  Molekula, München 
Tris-acetate EDTA buffer TAE buffer Qiagen, Hilden 
Tryptone  Oxoid, Wesel 
Ultrapure H2O  Sigma-Aldrich 
Yeast extract  Oxoid 
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2.1.4 Culture media 
All culture media were resuspended in demineralised water and autoclaved for 20 min at 
120°C and 100 kPa. In addition to the listed self-made media (recipe for 1 L), commercially 
available blood agar and Mueller-Hinton agar plates (Oxoid, Wesel) were used.  
Luria-Bertani Agar Luria-Bertani Broth 
10g Tryptone 10g Tryptone 
10g NaCl 10g NaCl 
  5g Yeast extract 
16g Agar 
  5g Yeast extract 
Mueller-Hinton Agar Mueller-Hinton Broth 
38g BBLTM Mueller Hinton II Agar 22g BBLTM Mueller Hinton II Broth 
2.1.5 Master Mix and enzymes 
The enzymes listed in Table 2.5 were used for PCR, qRT-PCR or cloning.  
Table 2.5 Enzymes and Master Mix 
Enzymes or Master Mix Manufacturer 
Antarctic phosphatase + buffer New England BioLabs, Frankfurt, Germany 
Blunting enzyme mix + Deoxynucleotide 
Solution Mix 
New England BioLabs 
DNase Qiagen, Hilden, Germany 
Endonucleases (PstI-HF, SmaI, EagI-HF, 
HindIII-HF, EcroRV-HF,  EcoRI-HF, NcoI-HF, 
PvuII-HF, ScaI-HF) + buffer 
New England BioLabs 
In-Fusion® HD Enzyme Premix  ClonTech, Saint-Germain-en-Laye, France 
Lysozyme Sigma-Aldrich, Steinheim, Germany 
Q5 High-Fidelity Hot Start Master Mix New England BioLabs 
Quantiscript Reverse Transcriptase Qiagen 
Quick Ligase + buffer New England BioLabs 
SYBR Green Master Mix Qiagen 
T4 polynucleotide kinase + buffer New England BioLabs 
Taq PCR Master Mix Qiagen 
2.1.6 Bacterial strains and growth conditions 
Plasmids and routinely used bacterial strains are listed in Table 2.6.  A. baumannii strains 
were routinely grown on blood agar at 37°C or in LB broth at 37°C and 220 rpm shaking. NEB 
5-alpha E. coli cells were used for transformation of plasmid constructs. For plasmid 
selection and maintenance, E. coli and A. baumannii transformants were grown on media 
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supplemented with tetracycline, ampicillin or ticarcillin, depending on the introduced 
plasmid. 
Table 2.6 Bacterial strains and plasmids 
Strain  Relevant characteristics Reference 
E. coli NEB 5-alpha Chemically competent  
New England 
BioLabs, Frankfurt 
A. baumannii 
ATCC 17978 Reference strain [17, 284] 
ATCC 19606 
Reference strain, relatively high 
adeB expression (105-106 µg RNA) 
[17] 
BMBF 320 
Clinical isolate; moderate adeB 
expression (104-105 µg RNA) 
[65] 
Isolate F 
Clinical isolate, adeR(Asp20) 
variant 
[89] 
Isolate G 
Clinical isolate, adeR(Asn20) 
variant 
[89] 
NIPH 60* Clinical isolate; adeRSABC-deficient [244] 
Scope 23 
Clinical isolate; low adeB 
expression (101-102 µg RNA) 
[285] 
 
pMC1871 LacZ, TetR 
Fungal Biodiversity 
Centre, Utrecht, 
The Netherlands 
 
pWH1266 
E. coli-A. baumannii shuttle vector, 
A. baumannii replication origin, 
TetR 
ATCC Catalog No. 
77092 
[286] 
 
pQE80L 
IPTG-inducible lac-promoter 
expression vector; AmpR 
Qiagen, Hilden 
 
pBHR1 KanR 
MoBiTec, 
Göttingen 
Plasmids 
pIG14/09 
pWH1266 backbone with lacZ 
insertion obtained from pMC1871 
This study 
 
pIG14/09::rnd1 
pIG14/09 backbone, rnd1-lacZ 
fusion obtained by insertion 
This study 
 
pIG14/09::adeA 
pIG14/09 backbone, adeA-lacZ 
fusion obtained by insertion 
This study 
 
pBA03/05 
pQE80L backbone with A. 
baumannii ori obtained from 
pWH1266 
This study 
 
pBA03/05::rnd1_oe 
pBA03/05 backbone with complete 
A1S_2660 ORF fused in-frame to 
IPTG-inducable lac-promoter 
This study 
 
pBA03/05::rnd1_oof 
pBA03/05 backbone with complete 
A1S_2660 ORF fused out-of-frame 
to IPTG-inducable lac-promoter 
This study 
 
pJN17/04 
pBHR1 backbone with A. 
baumannii ori obtained from 
pWH1266 
This study 
*kindly provided by Alexandr Nemec
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2.1.7 Primers 
 Primers were designed using Primer3 software (http://bioinfo.ut.ee/primer3/) or with the help of the Clontech primer design tool 
(http://www.clontech.com/US/Products/Cloning_and_Competent_Cells/Cloning_Resources/Online_In-Fusion_Tools). 
 
Table 2.7 Primers 
 
Materials and Methods 
- 45 - 
2.2 Methods 
2.2.1 General methods 
2.2.1.1 PCR amplifications 
Standard PCR amplifications were performed using either purified plasmids or crude lysates 
as DNA template. Crude lysates were prepared by heat-lysis: one colony was resuspended in 
100 µl pure water and incubated at 99°C for 10 min and snap-cooled on ice; cells were 
pelleted at 13000 rpm for 1 min and the supernatant was used as template. For 
amplification, either the 2x Taq PCR Master Mix or the Q5® Hot Start High-Fidelity 2x Master 
Mix was used. With the 2x Taq PCR Master Mix the reaction was prepared as follows: 
12.5 µl Taq PCR Master Mix (2x) 
  0.5 µl primer 1 (10 pmol/µl)  
  0.5 µl primer 2 (10 pmol/µl) 
     1 µl DNA template 
10.5 µl RNase-free H2O 
   25 µl final volume 
 
The reaction mixture was subjected to the following conditions: 
     Step Temperature Time 
1 Initial denaturation 95°C 3 min 
2 Denaturation 95°C 30 sec 
3 Annealing 55-57°C* 20 sec 
4 Extension 72°C 1- 4 min** 
5 Final elongation 72°C  5 min 
6 Storage 4°C ∞ 
 *dependent on primer sequence 
 **dependent on amplicon size 
 
 
 
 
 
35 cycles 
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Using the Q5® Hot Start High-Fidelity 2x Master Mix, the reaction was set up in the following 
way: 
   25 µl Q5® Hot Start High-Fidelity Master Mix (2x) 
  2.5 µl primer 1 (10 pmol/µl)  
  2.5 µl primer 2 (10 pmol/µl) 
     2 µl DNA template 
   18 µl RNase-free H2O 
   50 µl final volume 
 
The reaction mixture was subjected to the following conditions: 
     Step Temperature Time 
1 Initial denaturation 98°C 3 min 
2 Denaturation 98°C 30 sec 
3 Annealing 55-57°C* 20 sec 
4 Extension 72°C 1- 4 min** 
5 Final elongation 72°C  5 min 
6 Storage 4°C ∞ 
*dependent on primer sequence 
 **dependent on amplicon size 
After thermal cycling, amplicons were mixed with 6x DNA Loading Dye and electrophoresis 
of PCR amplicons was performed in 1% agarose in 1% TAE buffer at 100 V for 30 min. DNA 
was stained with 0.5 ng ethidium bromide and visualised using the Gel Doc XR+ System. If 
necessary, PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, 
Hilden, Germany) unless otherwise stated. 
2.2.1.2 Restriction digest 
DNA restriction was performed according to the manufacturer’s recommendation. 
Restriction enzymes with their respective restriction buffer, incubation time and 
temperature are listed in Table 2.8.  
 
 
 
 
35 cycles 
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Table 2.8 Restriction enzymes 
Restriction  
enzyme 
Buffer Incubation 
time 
Incubation 
temperature 
EagI-HF NEB4 5 min 37°C 
EcoRI-HF NEB4 5 min 37°C 
EcroRV-HF NEB4 5 min 37°C 
HindIII-HF NEB4 5 min 37°C 
NcoI-HF NEB4 5 min 37°C 
PstI-HF NEB4 5 min 37°C 
PvuII-HF NEB4 5 min 37°C 
ScaI-HF NEB4 5 min 37°C 
SmaI NEB4 1 h 25°C 
Amplicon restrictions for subsequent cloning, or plasmid restrictions after cloning (to 
confirm the correct size) were prepared as follows:  
650 ng purified plasmid DNA 
     1 µl enzyme (5 U) 
     2 µl restriction buffer 
     x µl RNase-free H2O 
  20 µl final volume 
If plasmids were linearized for subsequent cloning, the reaction was set up in the following 
way: 
   1 µg purified plasmid DNA 
   3 µl enzyme (15 U) 
   7 µl restriction buffer  
   x µl RNase-free H2O 
 70 µl final volume 
The restricted plasmids were mixed with 6x DNA Loading Dye, subjected to a 1% agarose gel 
and electrophoresis was run for 45 min to check whether the plasmid was properly 
restricted. 
2.2.1.3 Cloning  
Cloning was performed using either the Quick ligation kit or the In-fusion® HD cloning kit. 
In the case of Quick ligation, purified PCR amplicons were phosphorylated using T4 
polynucleotide kinase, restricted plasmids were dephosphorylated using the Antarctic 
phosphatase. Insert and donor were ligated according to the manufacturer’s 
recommendation. 
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The In-fusion® HD cloning kit uses a recombinase which recognizes complementary overlaps 
and fuses them together. Therefore, no phosphatase treatment or ligation is necessary. 
Plasmids were linearized by restriction and DNA inserts were amplified using primers that 
generate a 15 bp overhang complementary to the linearized vector (unless otherwise 
stated). In this case, primers were designed with the help of the Clontech primer design tool. 
Restricted vectors and amplified DNA fragments were purified using the NucleoSpin Extract 
II PCR clean-up kit (Macherey-Nagel, Düren) and mixed with 5x In-Fusion HD Enzyme Premix 
according to the manufacturer’s recommendation. 
Transformation of plasmids into competent E. coli NEB5-alpha was conducted by heat shock 
and transformants were selected on LB plates supplemented with the appropriate 
antimicrobial. Plasmids were isolated using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany) and analysed by restriction and/or by sequencing to confirm the correct insertion. 
100 ng of purified plasmids were used to transform electro-competent A. baumannii cells as 
previously described for P. aeruginosa (28) using the Gene Pulser II system (settings: 25 µF; 
200Ω; 2.5 kV). All kits were used according to the manufacturer’s instructions. 
2.2.1.4 DNA sequencing 
DNA sequencing was performed by LGC (Berlin) and the sequencing reaction was prepared 
according to their instructions. Primers used for sequencing are listed in Table 2.9. Primers 
were named after their position in the freezer box. 
Table 2.9 Sequencing primers 
Target Primer name Primer sequence (5´-3´) 
rnd1-lacZ in pIG14/09 A15 TACGCGTACTGTGAGCCAGA 
adeA-lacZ in pIG14/09 E18 TTGCCGGGAAGCTAGAGTAA 
rnd1 in pBA03/05 
E33 AAGTTGGCCGCAGTGTTATC 
JE76 ATGCTATCTAAATTTTTTATTCAAC 
JE3 ATGAAGTTCAACGCCAAGGT 
C13 ATTGCCGTTTTTACGCTGTT 
JE63 CTTGATTTGATGCCCGTTTT 
JE38 CCTGCGATGTGTGTAGCACT 
B42 CTGTGCCCGAATAATTTCGT 
adeR in pJN17/04 
JE23 TTTGAGAAGCACACGGTCAC 
D5 GCTCAGCTTGAGCGACTTCT 
D2 AATCCAGCCTTTTTCAATCG 
D4 ATCGCTTGCTTTCCATTCAT 
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Table 2.9 contd. Sequencing primers 
Target Primer name Primer sequence (5´-3´) 
adeS in pJN17/04 
C81 GAGGGAGTGCTCGAATTTGT 
D3 TGCATGAATGATAGCGATGC 
D13 TTAGTCACGGCGACCTCTCT 
JE24 TCATCCTGCCCTTATGTTCC 
adeRS in pJN17/04 
C81 GAGGGAGTGCTCGAATTTGT 
D3 TGCATGAATGATAGCGATGC 
D31 GGAGTAAGTGTGGAGAAATACGG 
adeRS of ATCC 17978,      
                 ATCC 19606,     
                 BMBF 320 and  
                 Scope 23 
C79 CCGAGCACAGTCCATTTACA 
D1 GGCACAGGTTTAGGTCTTGC 
D2 AATCCAGCCTTTTTCAATCG 
D3 TGCATGAATGATAGCGATGC 
D4 ATCGCTTGCTTTCCATTCAT 
D5 GCTCAGCTTGAGCGACTTCT 
F79 AGGAAAATGCCACAAAATGG 
mutated adeS in pJN17/04 
D3 TGCATGAATGATAGCGATGC 
D13 TTAGTCACGGCGACCTCTCT 
JE24 TCATCCTGCCCTTATGTTCC 
adeR(Asn20)S(17978) in 
pJN17/04 
JE23 TTTGAGAAGCACACGGTCAC 
H18 AATCCAGCCTTTTTCAATTG 
D3 TGCATGAATGATAGCGATGC 
JE24 TCATCCTGCCCTTATGTTCC 
adeABC in pJN17/04 
JE23 TTTGAGAAGCACACGGTCAC 
D6 TGGGTTAAAAGGCTTCACCA 
D5 GCTCAGCTTGAGCGACTTCT 
JE1 AAGAATGATCAAACATAGAAAATCTG 
C5 CGGAAATTCGTCCTATCGAA 
C1 GATGTGGAAATGGCTCAGGT 
A2 CATGTTCGGTATGGTGCTTG 
A3 AATACTGCCGCCAATACCAG 
A48 GTATGAATTGATGCTGC 
C26 TTTCGCAATCAGTTGTTCCA 
D64 CTGGTCAGTTTCCGCAATTT 
JE24 TCATCCTGCCCTTATGTTCC 
adeRSABC in pJN17/04 
F79 AGGAAAATGCCACAAAATGG 
JE67 ACGCCATCAATAATTCCCTG 
D3 TGCATGAATGATAGCGATGC 
JE1 AAGAATGATCAAACATAGAAAATCTG 
C5 CGGAAATTCGTCCTATCGAA 
C1 GATGTGGAAATGGCTCAGGT 
A2 CATGTTCGGTATGGTGCTTG 
A3 AATACTGCCGCCAATACCAG 
A48 GTATGAATTGATGCTGC 
C26 TTTCGCAATCAGTTGTTCCA 
D64 CTGGTCAGTTTCCGCAATTT 
JE24 TCATCCTGCCCTTATGTTCC 
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2.2.1.5 Semi-quantitative reverse transcription PCR (qRT-PCR) 
Gene expression was measured using the real-time, two-step RT-PCR approach. Total RNA 
was prepared using RNA Mini Prep Kit (Qiagen, Hilden) and extracted from A. baumannii 
cells that were grown until mid-log phase (optical density (OD) OD 0.7 - 0.8). 500 µl of the 
cell culture was mixed with 1 ml of RNAprotect Bacteria Reagent and incubated for 5 min. 
Following centrifugation at 8000 rpm for 12 min, the supernatant was carefully removed and 
RNA was extracted according to the manufacturer’s recommendations. The RNA 
concentration was measured with the NanoDrop 2000 spectrophotometer. For the synthesis 
of cDNA, 1 µg of RNA was reverse-transcribed using the QuantiTect Reverse Transcription Kit 
(Qiagen, Hilden). Standard curves for each measured gene were prepared using PCR 
fragments. These were generated by PCR using the Q5® Hot Start High-Fidelity 2x Master 
Mix (elongation time: 30 sec) and the respective primers listed in Table 2.10. After amplicon 
purification and quantification, 5 dilutions were prepared in RNase free water so that the 
amount of unknown target was within the range (Table 2.11). rpoB, encoding the β-subunit 
of bacterial RNA polymerase, was used as a reference gene and quantified concurrent with 
efflux pump expression. qRT-PCR reactions, including the samples of interest and the 
standard curves, were prepared in 96-well plates using the QuantiFast SYBR Green RT-PCR 
Kit as follows:  
  12.5 µl SYBR Green master mix  
        1 µl freshly synthesised cDNA 
        1 µl primer 1 (10 pmol/µl) 
        1 µl primer 2 (10 pmol/µl) 
     9.5 µl RNase free H2O 
      25 µl final volume 
Gene specific primers are listed in Table 2.10. qRT-PCR was run in triplicates using the 
LightCycler® 480. Experiments were independently repeated at least three times. The 
reaction mixtures were subjected to the conditions recommended by the supplier and run 
for 30 cycles.  
 
 
 
Materials and Methods 
- 51 - 
Table 2.10 Primer and standard curve range used for expression analysis 
Target gene Primer name  Primer sequence (5'-3') 
Amplicon 
size (bp) 
A1S_2660 
ACICU_02904 2_F ATTGCCGTTTTTACGCTGTT 147 
ACICU_02904 2_R ATATTGGCGGACTTGCTCAC 
adeB 
adeB 2_F GAATAAGGCACCGCAACAAT 
TTTCGCAATCAGTTGTTCCA 
124 
adeB 2_R 
adeJ 
adeJ_qRT_F GCGAATGGACGTATGGTTCT 
113 
adeJ_qRT_R CATTGCTTTCATGGCATCAC 
adeG 
adeG 2_F GCGTTGCTGTGACAGATGTT 
TTGTGCACGGACCTGATAAA 
104 
adeG 2_R 
rpoB 
rpoB_qRT_F GAGTCTAATGGCGGTGGTTC 
ATTGCTTCATCTGCTGGTTG 
110 
rpoB_qRT_R 
 
Table 2.11 Standard curve range for expression analysis of efflux pump genes 
  
Target Gene Strain 
Range for 
standard curve  
  
Target Gene    Strain 
Range for 
standard curve  
adeB 
ATCC 17978 101-105 
adeG 
ATCC 17978 102-106 
ATCC 19606 103-107 ATCC 19606 101-105 
BMBF 320 103-107 BMBF 320 101-105 
Scope 23 101-105 Scope 23 101-105 
NIPH 60 103-107 NIPH 60 101-105 
adeJ 
ATCC 17978 103-107 
rpoB 
ATCC 17978 103-107 
ATCC 19606 102-106 ATCC 19606 103-107 
BMBF 320 103-107 BMBF 320 103-107 
Scope 23 102-106 Scope 23 103-107 
NIPH 60 102-106 NIPH 60 104-108 
A1S_2660 
ATCC 17978 104-108 
 
  
NIPH 60 104-108   
2.2.1.6 Growth kinetics 
Growth kinetics of transformants were determined by recording their colony forming units 
per microliter (cfu/ml) for 4 h. Fresh overnight cultures of each transformant were diluted to 
a McFarland 0.5 suspension and 100 µl were used to inoculate a fresh 10 ml MH broth, and 
incubated at 37°C with 220 rpm shaking. At hourly intervals, a 200 µl aliquot was taken, 
which was serially diluted 1:10 in saline solution (0.45% NaCl). 0.1 ml aliquots of the 10-fold 
serial dilutions were plated on MH agar. Colonies were counted after overnight incubation, 
and cfu/ml was calculated using the following equation:  
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cfu/ml =  
cfu ∗ x
dilution
 
         x=10; as 0.1 ml of diluted aliquots were plated on agar 
2.2.1.7 Antimicrobial susceptibility testing 
Antimicrobial susceptibility was determined by agar dilution or disc diffusion.  
For agar dilution, two-fold serial dilutions (of antimicrobials) were performed according to 
the current guidelines of the Clinical Laboratory Standards Institute [287]. For sample 
preparation, overnight cultures were diluted 1:10 in 0.85% saline solution, and MH agar 
plates, supplemented with serial dilutions of antimicrobial agents, were inoculated using a 
multipoint inoculator. The minimal inhibitory concentration (MIC; concentration of 
antimicrobial agent that completely inhibited visible growth of bacteria) was determined 
after overnight incubation at 37°C.  
Regarding disc diffusion, a McFarland 0.5 suspension of the respective transformant was 
spread onto the surface of MH agar plates. Antimicrobial discs were applied on the agar 
plate using the Disc Dispenser. The diameter of inhibition was measured after overnight 
incubation at 37°C.  
2.2.1.8 Accumulation studies  
Accumulation kinetics of ethidium bromide was monitored by a fluorimetric assay as 
described previously with minor changes (30). Cells were grown aerobically in LB broth until 
mid-log phase, harvested at 4000 x g for 5 min at 4°C, washed twice in potassium phosphate 
buffer (50 mM potassium phosphate buffer, 1 mM MgSO4, pH 7.4) and resuspended to an 
OD of 20 at 600 nm. The suspension was transferred into a 96-well plate with 0.2% (w/v) 
glucose, and ethidium bromide was added to a final concentration of 10 µM. The 
fluorescence of the supernatant was recorded at λexcite 530nm and λemit 600nm using the 
Infinite M1000 PRO plate reader every 10 sec for 30 min after ethidium bromide addition. 
The change in fluorescence intensity was directly proportional to the accumulation of 
ethidium. 
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2.2.2 Prevalence of eight resistance-nodulation-cell division-type efflux pump  
          genes in epidemiologically characterized A. baumannii of worldwide  
          origin 
2.2.2.1 Bacterial isolates and growth conditions 
One hundred and forty-four MDR A. baumannii isolates (Suppl. Table II) were selected from 
a global cohort (n = 492) which was part of the larger Tigecycline Evaluation and Surveillance 
Trial programme [288]. To accomplish a wide geographical origin, isolates recovered from 68 
centres in 26 countries in Africa, Asia, Europe, North and South America were included. 
Molecular typing of the isolates was performed during a previous study using DiversiLab 
[65], a semi-automated strain typing system using repetitive sequence-based PCR to 
discriminate bacteria at the subspecies level. Using these data, isolates belonging to IC1–8 
and genotypically unique (GtU) isolates were chosen to cover a wide epidemiological 
background (Fig. 2.1). Multiple isolates from single centres were only included where 
multiple clonal lineages were present. All isolates, with the exception of three, were 
carbapenem resistant and therefore exhibited a high clinical relevance.   
Figure 2.1 Distribution of ICs among selected A. baumannii isolates. 
 
IC; international clone, GtU; Genotypically unique  
2.2.2.2 Identification of putative RND efflux pump genes 
An in-silico approach was taken to identify putative RND-type pumps and to determine their 
prevalence among published A. baumannii genomes. For their identification, open reading 
frames (ORFs) from A. baumannii genomes ACICU (CP000863.1), AB0057 (CP001182.1) and 
ATCC 17978 (CP000521.1), published at the National Center for Biotechnology Information 
IC1; 11 
IC2; 38 
IC3; 9 
IC4; 16 IC5; 16 
IC6; 11 
IC7; 5 
IC8; 10 
GtU; 28 
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(NCBI) database, were analysed using the A. baumannii pump AdeB (GI:16118478) as a 
search query for BLAST search. To determine the prevalence, the amino acid and nucleotide 
sequence of the putative RND pumps were used for a BLAST search against all published 
complete A. baumannii genomes listed in the NCBI database. 
2.2.2.3 Detection of RND efflux pump genes 
A PCR-based detection was used to investigate the presence of the genes encoding the efflux 
pumps AdeB, AdeG, AdeJ and the five putative RND-type efflux pumps identified in silico 
amongst the 144 selected A. baumannii isolates. For amplification, crude lysates of the 
isolates were used as DNA template and the PCR was set-up using the Taq PCR Master Mix 
(55°C annealing temperature and 1 min extension time). Primers are listed in Table 2.12. To 
avoid false-negative results due to small genetic variations of DNA regions targeted by the 
first primer pair, a second primer pair was designed for each gene and used where 
necessary.  
Table 2.12 List of primers used for the detection of efflux pump genes. 
.         Adapted from Nowak et al. [289]. 
 Efflux pump gene Primer name Primer sequence (5'-3') Expected size (bp) 
adeB 
O3† GTATGAATTGATGCTGC 
981 O4† CACTCGTAGCCAATACC 
adeB 2_F GAATAAGGCACCGCAACAAT 
124 
adeB 2_R TTTCGCAATCAGTTGTTCCA 
adeG 
adeG 1_F TGAACGATGCTGCTCAAAAC 
681 adeG 1_R CTCCAGCTGTCAACCAGACA 
adeG 2_F GCGTTGCTGTGACAGATGTT 
104 
adeG 2_R TTGTGCACGGACCTGATAAA 
adeJ 
adeJ 1_F CTTGGTGTAACTGCCGGATT 
605 
adeJ 1_R TGAGCACCAGACTCACGTTC 
ACICU_02904* 
ACICU_02904 1_F ATGACGCGATTGTGGTTGTA 
623 
ACICU_02904 1_R CTGTGCCCGAATAATTTCGT 
ACICU_02904 2_F ATTGCCGTTTTTACGCTGTT 
147 
ACICU_02904 2_R ATATTGGCGGACTTGCTCAC 
ACICU_00143* 
ACICU_00143 1_F TTCCGCTCAATATTCCGAAC 
646 
ACICU_00143 1_R AGTGTCGTGGTTCCTTGGAC 
ACICU_00143 2_F GGTATTGGTGCGGATTATGC 
134 
ACICU_00143 2_R GTCGCGACAAAAAGAGAAGC 
† previously described by Magnet et al. [126] 
*locus tag in A. baumannii ACICU 
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Table 2.12 contd. List of primers used for the detection of the efflux pump genes.  
                                  Adapted from Nowak et al. [289]. 
 Efflux pump gene Primer name Primer sequence (5'-3') Expected size (bp) 
 
ACICU_03412 1_F TATGGGCTTTCCCAAGTCAC 
734 
ACICU_03412* ACICU_03412 1_R CGGTCATAAACCGTCTCGAT 
 
ACICU_03412 2_F ACCAATGGGTGGTAAAAGCA 
135 
 
ACICU_03412 2_R TAATTTCGGCCACACCTTTC 
 
ACICU_03066 1_F TCCGCGATGAAATTGATACA 
660 
ACICU_03066* ACICU_03066 1_R CAATAATGGTGCGAACAACG 
 
ACICU_03066 2_F AAAAAGTTCCGATGCCAATG 
118 
 
ACICU_03066 2_R TTTAGAGCTGTCAGCGACGA 
ACICU_03646* 
ACICU_03646 1_F AGAATATGCCGATCGTTTGC 
793 
ACICU_03646 1_R AATTCGGCTATACCCCTGCT 
† previously described by Magnet et al. [126] 
*locus tag in A. baumannii ACICU  
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2.2.3 Characterization of the putative RND-type efflux pump A1S_2660 
2.2.3.1 Construction of the reporter plasmid pIG14/09 
A 3340 bp DNA fragment containing the promoterless β-galactosidase encoding lacZ gene 
flanked by PstI restriction sites was amplified from pMC1871 by PCR using the primer pair 
lacZ_F and lacZ_R (Table 2.7). The reaction mixture contained 60 ng of purified plasmid as 
DNA template and for amplification with the Q5® Hot Start High-Fidelity 2x Master Mix was 
used (55°C annealing temperature and 1.5 min elongation time). 
The purified amplicon was digested with 5 U of PstI-HF and ligated into the similarly digested 
and dephosphorylated shuttle vector pWH1266. Transformed E. coli cells were selected on 
LB agar supplemented with 10 mg/L tetracycline. Restriction of the resulting plasmid 
pIG14/09, to confirm the correct insertion, was performed using the endonucleases SmaI 
and EagI-HF. The reaction was first incubated with 5U SmaI at 25°C for 1h, followed by the 
addition of 5U of EagI-HF and incubation at 37°C for 10 min.  
2.2.3.2 Construction of pIG14/09::rnd1-lacZ 
To determine the natural expression of the putative RND-type efflux pump A1S_2660, a 
reporter system was constructed. A 451 bp DNA fragment containing the predicted 
promoter region and the first 21 nucleotides of A1S_2660 was amplified from heat-lysed 
ATCC 17978 using the primer rnd1_F and rnd1_R (Table 2.7) and the Q5® Hot Start High-
Fidelity 2x Master Mix. Using the In-Fusion® HD Enzyme Premix, the amplicon was cloned in-
frame to the promoterless β-galactosidase gene lacZ of the SmaI restricted pIG14/09 (Fig. 
2.2), yielding pIG14/09::rnd1-lacZ (Suppl. Fig. I). In ATCC 17978, it was previously found that 
adeA was constitutively expressed. Therefore, as a positive control for lacZ expression, a 
construct containing the promoter region of adeA and its first 21 nucleotides was generated 
using the primers adeA_F and adeA_R (Table 2.7) as described above leading to 
pIG14/09::adeA-lacZ.  
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Figure 2.2 pIG14/09::rnd1-lacZ in-fusion cloning 
 
PCR primers rnd1_F and rnd1_R amplifying the promoter region and the first 21 nucleotides of A1S_2660 were extended by 15 nucleotides 
which are homologous to the ends of the SmaI linearized plasmid pIG14/09. In this way, the PCR fragment is elongated by the sequence 
homology ensuring a successful insertion into the plasmid by In-Fusion cloning (Section 2.2.3.2).  
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E. coli transformants were selected on LB plates supplemented with 10 mg/L tetracycline. To 
confirm the insertion, restriction of pIG14/09::rnd1-lacZ and pIG14/09::adeA-lacZ was 
performed using the endonuclease PstI-HF. In addition, successful cloning was confirmed by 
sequencing using primer E18 and A15 (Table 2.9). Both pIG14/09 constructs and empty 
vector control were introduced into competent A. baumannii 17978, and transformants 
were selected on LB plates supplemented with 30 mg/L tetracycline.  
2.2.3.3 Reporter assay 
To determine the effect of different antimicrobials and potential efflux substrates on the 
expression of A1S_2660, A. baumannii ATCC 17978 transformants harbouring rnd1-lacZ or 
adeA-lacZ, respectively, were grown on gradient plates or were tested by disc diffusion.  
In the case of the gradient plates, two different MH agar layers were poured successively 
into the petri dish (Fig. 2.3). The bottom layer (1; 20 ml), supplemented with a test substance 
(antimicrobial, bile salt, detergent, dye or salt; see Table 2.13) and 40 mg/L X-gal, was 
solidified on a slant so that the agar covered the whole plate, but not with an even thickness; 
the top layer (2, 20 ml), supplemented with 40 mg/L X-gal only, was poured and the plate 
was placed horizontally. This resulted in an antimicrobial gradient from low to high 
concentration (Fig. 2.3). In order to check whether selective pressure has an effect on 
A1S_2660 induction, the antimicrobial concentration supplemented to layer 1 was adjusted 
in a way that the transformants grew until half the plate (if applicable; Table 2.13). 
 
Figure 2.3 Schematic depiction of a gradient plate. 
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Table 2.13 List of substances used for the reporter assay applying gradient plates. 
Substance category Substance class Substance Concentration 
 
 
 
 
 
 
Antimicrobials 
 
Aminoglycosides 
Amikacin 2 mg/L 
Gentamicin 0.5 mg/L 
Kanamycin 2 mg/L 
ß-lactams 
Ampicillin 64 mg/L 
Ticarcillin 32 mg/L 
Carbapenems Meropenem 2 mg/L 
Fenicols Chloramphenicol 64 mg/L 
 
Fluoroquinolones 
Ciprofloxacin 0.25 mg/L 
Levofloxacin 0.125 mg/L 
Moxifloxacin 0.125 mg/L 
Glycylcyclines Tigecycline 0.5 mg/L 
Macrolides 
Azithromycin 2 mg/L 
Erythromycin 16 mg/L 
Tetracyclines Minocycline 1 mg/L 
ß-lactamase inhibitors  Sulbactam 2 mg/L 
Bile salts  Sodium deoxycholate 20 mM 
Disinfectants 
 Benzalkonium chloride 
Ethanol 
256 mg/L 
10 % 
Detergents  SDS 1% 
 
Dyes 
 Acriflavine 16 mg/L 
 Comassie blue 8 mg/L 
 Rhodamine 6G 256 mg/L 
 Safranin O 1 mg/L 
Metal salts  Tellurite 2 mg/L 
Salts 
 Mn(II) Cl 20 mM 
NaCl 170 mM, 200 mM 
For inoculation, a McFarland 0.5 suspension of cells was streaked along the gradient, starting 
from the lowest to the highest concentration. Gradient plates were incubated for 16 – 48 h 
at 37°C. During incubation, the substance in layer 1 diffused into the upper layer and was 
diluted proportional to the thickness of the second layer. As a consequence, a uniform 
concentration gradient was established (described previously by Szybalski et al. [290]). The 
empty vector control was used as a negative control, whereas the pIG14/09::adeA-lacZ 
transformant was used as a positive control. 
X-gal is an analogue of lactose and can therefore be hydrolysed to galactose by β-
galactosidase. As a by-product, 5-bromo-4-chloro-3-hydroxyindole forms dimers and is 
oxidised to 5,5’-dibromo-4,4’-dichloro-indigo, which is blue in colour. As the promoterless β-
galactosidase gene lacZ was cloned in-frame to A1S_2660 or adeA, respectively, its 
expression could be detected by blue colouring of the media. 
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In the case of disc diffusion, square MH agar plates, supplemented with 40 mg/L X-gal, had a 
McFarland 0.5 suspension of cells spread evenly on the plate. Antimicrobial discs were 
applied using a Disc Dispenser. A. baumannii transformants were tested with the following 
compounds; aminoglycosides (amikacin, gentamicin), β-lactams (ampicillin, cefepime, 
ertapenem, imipenem, meropenem, ticarcillin), β-lactam/β-lactamase inhibitor 
(ampicillin/sulbactam, piperacillin/tazobactam), chloramphenicol, clindamycin, 
fluoroquinolones (ciprofloxacin, ofloxacin), macrolides (azithromycin, erythromycin), 
rifampicin, tetracyclines (doxycycline, tetracycline), and vancomycin.  
2.2.3.4 Construction of the E. coli – A. baumannii expression plasmid pBA03/05 
A 1300 bp DNA fragment containing the A. baumannii origin of replication was amplified by 
PCR from pWH1266 using the primer pair ori_F_EcoRI and ori_R_NcoI (Table 2.7). The 
reaction mixture containing Q5® Hot Start High-Fidelity 2x Master Mix and 110 ng purified 
plasmid pWH1266 as DNA template was amplified using the following conditions: 
 
 
 
 
 
The plasmid pQE80L was linearized using HindIII_HF. The resulting 3’ overhangs were 
blunted and phosphorylated using 1.7 µl of the blunting enzyme mix with 7 µl of 
deoxynucleotide solution mix. The reaction mixture was incubated for 15 min at room 
temperature followed by heat inactivation at 70°C for 10 min. The purified amplicon was 
cloned into the linearized plasmid using the Quick ligation kit. Transformed E. coli cells were 
selected in LB agar supplemented with 50 mg/L ampicillin. Restriction of pBA03/05 to 
confirm the correct insertion was performed using the endonuclease EcoRV-HF. 
Step  Temperature Time 
1 Initial denaturation 98°C   3 min 
2 Denaturation 98°C 30 sec 
3 Annealing 55°C 20 sec 
4 Extension 72°C   1.5 min 
5 Denaturation 98°C 30 sec  
6 Annealing 60°C 20 sec 
7 Extension 72°C 1.5min 
8 Final elongation 72°C 5 min 
9 Storage 4°C ∞ 
5 cycles 
25 cycles 
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2.2.3.5 Construction of pBA03/05::rnd1_oe and pBA03/05::rnd1_oof 
To overexpress A1S_2660 (rnd1), the gene-encoding A1S_2660 was cloned in-frame to the 
IPTG-inducible lac-promoter encoded on the expression vector pBA03/05. The complete ORF 
including the start codon was amplified from crude lysates of ATCC 17978 using the Q5® Hot 
Start High-Fidelity 2x Master Mix and the primers rnd1_oe_F and rnd1_oe_R (Table 2.7). The 
purified amplicon and the shuttle vector pBA03/05 were restricted using BamHI-HF and PstI-
HF (15 Units each). After purification of the linearized pBA03/05, the amplicon was fused to 
the plasmid using the In-fusion® HD cloning kit leading to pBA03/05::rnd1_oe. (Suppl. Fig. II). 
E. coli transformants were selected on LB plates supplemented with 50 mg/L ampicillin. In 
addition to the pBA03/05::rnd1_oe construct, a control out-of-frame construct (rnd1_oof) 
was generated by deleting one nucleotide (in red) of primer rnd1_oe_F, resulting in the 
primer oof_F: TCACCATCACGGATCCATGCTATCTAAATTTTTTATTCAAC. The 
pBA03/05::rnd1_oe construct and its oof control pBA03/05::rnd1_oof were introduced into 
competent A. baumannii ATCC 17978 and NIPH 60 and selected on LB plates supplemented 
with 150 mg/L ticarcillin. Restriction of the plasmids to confirm the correct amplicon 
insertion was performed using the endonuclease PstI-HF. In addition, successful cloning was 
confirmed by sequencing using the primers E33, JE76, JE3, C13, JE63, JE38, B42 (Table 2.9).  
Expression of rnd1 could be induced by the addition of IPTG. Usually, the lac repressor 
encoded on pBA03/05 binds to the lac operator when transcribed, thereby preventing the 
transcription of downstream encoded genes (Fig. 2.4). In E. coli, repressor-operator binding 
is naturally prevented by lactose, which allosterically binds to the repressor, changing its 
conformation. IPTG, a molecular analogue of lactose, can therefore be used for a controlled 
gene expression of rnd1. 
Figure 2.4 Schematic depiction of the mechanism of action of IPTG 
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2.2.3.6 Semi-quantitative reverse transcription PCR (qRT-PCR) 
Expression of the efflux pump gene A1S_2660 in pBA03/05::rnd1_oe transformants was 
measured using the real-time, two-step RT-PCR approach described in 2.2.1.5 with minor 
modifications. ATCC 17978 and NIPH 60 transformants were grown until mid-log phase and 2 
ml of the cultures were split into 5 tubes supplemented with 0, 0.005, 0.01, 0.1, and 1 mM 
IPTG. After 20 min incubation, 500 µl of the cell suspension was mixed with 1 ml of 
RNAprotect Bacteria Reagent as described in 2.2.1.5. Gene specific primers for qRT-PCR as 
well as the range for the standard curves are listed in Tables 2.10 and 2.11, respectively. 
2.2.3.7 Growth kinetics 
Growth kinetics of ATCC 17978 and NIPH 60 pBA03/05::rnd1_oe and rnd1_oof transformants 
were performed as described in 2.2.1.6 with minor modifications; each transformant was 
diluted to a McFarland 0.5 suspension and 100 µl were used to inoculate 5 fresh 10 ml MH 
broth. After 2 hours of incubation, 0, 0.005, 0.01, 0.1, or 1 mM IPTG, respectively, was added 
and serial dilutions were plated as described previously.  
2.2.3.8 Antimicrobial susceptibility testing 
To identify substrates of A1S_2660, antimicrobial susceptibility of A. baumannii ATCC 17978 
and NIPH 60 transformed with pBA03/05::rnd1_oe and rnd1_oof was determined by agar 
dilution or disc diffusion as described in 2.2.1.7. MH agar plates were supplemented with 
0.05, 0.1 or 1 mM IPTG, respectively. 
The MIC to the following antimicrobial agents was determined by agar dilution: acriflavine, 
benzalkonium chloride, deoxycholic acid, meropenem, nalidixic acid, novobiocin, tigecycline 
and triclosan. Antimicrobial concentrations tested ranged from 0.125 to 512 mg/l.  
Furthermore, antimicrobial susceptibility to aminoglycosides (amikacin, gentamicin), 
aztreonam, β-lactams (imipenem, meropenem, penicillin), β-lactam/β-lactamase inhibitor 
(ampicillin/sulbactam), cephalosporins (ceftriaxone), chloramphenicol, fluoroquinolones 
(ciprofloxacin, ofloxacin), macrolides (erythromycin), tetracyclines (doxycycline, 
tetracycline), co-trimoxazole and vancomycin was performed by disc diffusion.  
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2.2.3.9 Accumulation studies 
Accumulation kinetics of ethidium bromide in all NIPH 60 transformants was monitored by a 
fluorimetric assay as described in 2.2.1.8 with a minor modification; after ethidium bromide 
addition, 1 mM IPTG was added, followed by fluorescence readings.  
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2.2.4 Characterization of the Asp20→Asn substitution in the response  
          regulator AdeR 
2.2.4.1 Construction of the E. coli – A. baumannii shuttle vector pJN17/04 
A DNA fragment containing the A. baumannii origin of replication from pWH1266 was 
amplified by PCR as described in 2.2.3.4. The purified amplicon was double digested with 
NcoI-HF and EcoRI-HF (5 U each), ligated into the similarly digested and dephosphorylated 
pBHR1, which does not replicate in A. baumannii.  Transformed E. coli cells were selected on 
LB agar supplemented with 10 mg/L kanamycin. Restriction of the constructed plasmid 
pJN17/04 to confirm the correct insertion was performed using the endonuclease PvuII-HF. 
Electro-transformation of the resulting shuttle vector in competent A. baumannii ATCC 
17978, using 50 mg/L kanamycin for selection, confirmed the replication of the shuttle 
vector.  
2.2.4.2 Construction of pJN17/04::adeR, pJN17/04::adeS, pJN17/04::adeRS,   
             pJN17/04::adeRSABC and pJN17/04::adeABC 
To elucidate the individual impact of the adeABC regulators AdeRS, eight different plasmids 
were generated (Table 2.14). The two variants of adeR [referred to as adeR(Asp20) and 
adeR(Asn20)], including 233 bp upstream of the adeR start codon, were amplified alone or in 
combination with adeS [adeR(Asp20)S or adeR(Asn20)S] from A. baumannii isolate F and 
isolate G (Table. 2.6), respectively. Furthermore, adeR(Asp20)SABC and adeR(Asn20)SABC 
fragments (7977bp) were obtained using the primer pair adeRSABC_F and adeABC_R (Fig. 
2.5;). adeS including 190 bp upstream of the adeS start codon and adeABC including the 
promoter region of adeA were amplified from isolate F using the primer pairs adeS_F/R or 
adeABC_F/R, respectively. The PCR reaction was set up using the Q5® Hot Start High-Fidelity 
2x Master Mix and 2 µl of crude lysates as DNA template. Annealing was set to 57°C and 
extension times of each PCR were adjusted to the expected size of the PCR product (Table 
2.14).  
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Figure 2.5 Schematic illustration of primer binding sites for cloning of the adeRSABC genes 
 
The purified amplicons were individually ligated into the ScaI (8 Units) linearized and 
dephosphorylated pJN17/04 using Quick ligase. Transformed E. coli cells were selected on LB 
agar supplemented with 10 mg/L kanamycin. Restriction of constructed plasmids to confirm 
the correct amplicon insertion was performed using the endonucleases PvuII-HF 
(pJN17/04::adeS), EcoRI-HF (pJN17/04::adeR variants, pJN17/04::adeRS variants and 
pJN17/04::adeABC) or EagI-HF for pJN17/04::adeRSABC constructs. Successful cloning of the 
generated plasmids was confirmed by sequencing (see Table 2.9 for primers). All eight 
constructs and the empty vector were introduced into competent A. baumannii as indicated 
in Table 2.14 by electroporation and transformants were selected on LB plates 
supplemented with kanamycin.   
2.2.4.3 Site-directed mutagenesis in adeS of A. baumannii ATCC 17978 
Single point mutations in adeS of A. baumannii ATCC 17978 leading to L173P, Y303F and 
double point mutations leading to L173P/Y303F were introduced using PCR in combination 
with the In-fusion® HD cloning kit. To introduce the single mutations, 2 amplicons were 
spliced together (Fig. 2.6), for the introduction of double mutations, 3 amplicons were 
ligated. Primers for each site-directed mutagenesis are listed in Table 2.15 (57°C annealing 
temperature and 80 sec elongation). For higher yields of the adeS gene carrying the 
particular mutation, the ligated product was re-amplified using 2 µl of the ligation mixture, 
Q5® Hot Start High-Fidelity 2x Master Mix and the primers adeRS2_R and adeS_F. Following, 
the purified amplicons were individually ligated into the ScaI-linearized vector pJN17/04 
generating pJN17/04::adeS(L173P), pJN17/04::adeS(Y303F) and 
pJN17/04::adeS(L173P/Y303F).  
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Table 2.14 Cloning information on various pJN17/04 constructs 
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Figure 2.6 Generation of adeS(L173P) 
 
Specific primers were designed to generate adeS(L173P) (Section 2.2.4.3). adeS was amplified in two parts using primer adeS_F/1SDM_R 
(Amplicon 1) and 1SDM_F/adeRS2_R (Amplicon 2). The wildtype nucleotide was replaced by incorporation of the desired nucleotide (marked in 
red) within the primer sequence of primer 1SDM_R and 1SDM_F, resulting in the amino acid substitution L173→P. Furthermore these primers 
were designed homologous to each other (underlined). As a result, both amplicons were fused together using the In-fusion enzyme mix yielding 
adeS(L173P).  
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To confirm successful cloning, restriction digests using the endonuclease PvuII-HF and 
sequencing (see Table 2.9 for primers) were performed. Purified plasmids were electro-
transformed into ATCC 17978. 
Table 2.15 Primers used for site-directed mutagenesis in adeS of ATCC 17978 
Amino acid 
substitution Primer name Primer sequence (5´-3´) 
L173P 
adeS_F TGCATGAATGATAGCGATGC 
1SDM_R TCATCAGGTTTAAAAACGCCATCAATAATTCCCTG 
1SDM_F AATTATTGATGGCGTTTTTAAACCTGATGAAGTTCT 
adeRS2_R GAGGGAGTGCTCGAGTTTGT 
Y303F 
adeS_F TGCATGAATGATAGCGATGC 
2SDM_R AGGCTTAAATAAATCGTCTTGGAACTCGGTTGCAA 
2SDM_F AACCGAGTTCCAAGACGATTTATTTAAGCCTTTCT 
adeRS2_R GAGGGAGTGCTCGAGTTTGT 
L173P/Y303F 
adeS_F TGCATGAATGATAGCGATGC 
1SDM_R TCATCAGGTTTAAAAACGCCATCAATAATTCCCTG 
1SDM_F AATTATTGATGGCGTTTTTAAACCTGATGAAGTTCT 
2SDM_R AGGCTTAAATAAATCGTCTTGGAACTCGGTTGCAA 
2SDM_F AACCGAGTTCCAAGACGATTTATTTAAGCCTTTCT 
adeRS2_R GAGGGAGTGCTCGAGTTTGT 
In red: introduced mutation 
2.2.4.4 Construction of pJN17/04::adeR(Asn20)S(17978) 
To determine, whether increased expression of adeB is induced by a specific interaction 
between AdeR(Asn20) and its cognate sensor kinase AdeS, the sequence of a ‘foreign’ adeS 
(from A. baumannii ATCC 17978) was fused to adeR(Asn20). For the construction of the 
pJN17/04::adeR(Asn20)S(17978) plasmid a two-step approach using PCR and the In-fusion® 
HD cloning procedure was taken. First, adeR(Asn20), including 233 bp upstream of the adeR 
start codon, and adeS(17978) (1086 bp) were amplified from isolate G or ATCC 17978, 
respectively. For adeR(Asn20) the primer pair JE70/JE72, and for adeS(17978) the primer 
pair JE71/JE73 was used (Table 2.16). The PCR reaction was set up using the Q5® Hot Start 
High-Fidelity 2x Master Mix and 2 µl of crude lysates as DNA template (57°C annealing, 90 
sec extension time).  
In the second step, the two purified amplicons were fused in frame into the ScaI (15 Units) 
linearized and dephosphorylated vector pJN17/04 using the In-Fusion® HD cloning kit. The 
reaction was set up as follows:  
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150 ng adeS(17978) amplicon 
                130 ng adeR(Asn20) amplicon 
  75 ng restricted pJN17/04 
     x µl RNase free H2O 
   10 µl final volume 
Table 2.16 Primers used to amplify adeR(Asn20) and adeS(17978) 
Primer 
name 
Primer sequence (5´-3´) Purpose 
JE70 ATTTTTTAATATTATTTAGGCATCATCTTTTACAG 
Amplify adeR(Asn20); underlined 
tail complementary to JE71 tail; 
italicized tail complementary to 
ScaI cut pJN17/04 
JE72 GCCACTCATCGCAGTGCTCAGCTTGAGCGACTTCT 
JE71 
JE73 
ATAATATTAAAAAATAGCTAGGGAATATTTTATGA 
ATGAATTACAACAGTGAGGGAGTGCTCGAGTTTGT 
Amplify AdeS(17978); underlined 
tail complementary to JE70 tail; 
italicized tail complementary to 
ScaI cut pJN17/04 
 
Thereby, JE70 and JE71 were extended by 15 nucleotides, which are homologous to each 
other reflecting the intergenic region of adeS(17978) and adeR(Asn20), so that they fused 
together (Table 2.16). As the nucleotide sequence of intergenic region between adeR and 
adeS was identical in isolate G and 17978, no additional changes had to be added. Primers 
JE72 and JE73 each had tails homologous to the ScaI linearized plasmid pJN17/04. In this 
way, the fusion product of adeR(Asn20) and adeS(17978) could ligate to the vector.  
Transformed E. coli cells were selected on LB agar supplemented with 10 mg/L kanamycin. 
Restriction of constructed plasmids to confirm the correct amplicon insertion was performed 
using the endonuclease EcoRI-HF. Successful cloning of the generated plasmid was 
confirmed by sequencing (see Table 2.9 for primers). The construct was introduced into 
competent A. baumannii ATCC 17978 by electroporation and transformants were selected 
on LB plates supplemented with 50 mg/L kanamycin.  
2.2.4.5 Antimicrobial susceptibility testing 
Antimicrobial susceptibility of A. baumannii parent strains and transformants was 
determined by agar dilution as described in 2.2.1.7. The MICs to the following 12 
antimicrobial agents was determined: amikacin, azithromycin, chloramphenicol, 
ciprofloxacin, erythromycin, gentamicin, levofloxacin, meropenem, minocycline, rifampicin, 
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tetracycline, and tigecycline. Antimicrobial concentrations tested ranged from 0.03 to 256 
mg/l. Where stated, 100 mg/L of the efflux pump inhibitor NMP was added to the medium. 
2.2.4.6 Semi-quantitative reverse transcription PCR (qRT-PCR) 
Expression of the efflux pump genes adeB, adeJ and adeG was measured using the real-time, 
two-step RT-PCR approach as described in 2.2.1.5. Gene specific primers for qRT-PCR are 
listed in Table 2.10 and the dilution range of PCR fragments for standard curves are listed in 
Table 2.11.  
2.2.4.7 Growth kinetics 
Growth kinetics were performed for all adeRS and adeRSABC transformants and empty 
vector control as described in 2.2.1.6. 
2.2.3.8 Accumulation studies 
Accumulation kinetics of ethidium bromide in all NIPH 60 transformants were performed as 
described in 2.2.1.8. With the addition of azithromycin (32 mg/L), gentamicin (4 mg/L), 
tetracycline (2 mg/L) or tigecycline (2.5 mg/L) at sub-inhibitory concentrations immediately 
after ethidium bromide addition, competition assays were accomplished.  
To check whether changes in the accumulation of ethidium were caused by a proton-motive 
force, the proton uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) was added 
to the mixture (final concentration: 500 µM) 15 minutes after the measurement of ethidium 
accumulation was started. For this experiment, cells were prepared to an OD of 2 at 600nm. 
In addition to ethidium bromide, accumulation studies were also performed using acriflavine 
at a final concentration of 5 µM or rhodamine 6G (50 µM final concentration) as substrates. 
Thereby, the fluorescence of the supernatant was recorded at λexcite 416 nm and λemit  
514 nm for acriflavine or λexcite 480 nm and λemit 558 nm for rhodamine 6G. The 
fluorescence intensity was inversely proportional to the accumulation of acriflavine and 
rhodamine 6G.
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3. Results  
3.1 Prevalence of eight resistance-nodulation-cell division-type efflux pump   
       genes in epidemiologically characterized A. baumannii of worldwide  
       origin 
3.1.1 Identification of putative RND efflux pumps 
BLAST analysis identified five putative RND pumps in the three A. baumannii genomes 
ACICU, AB0057 and ATCC 17978 with the A. baumannii ACICU accession numbers 
ACICU_02904, ACICU_00143, ACICU_03412, ACICU_03066 and ACICU_03646 (Table 3.1, Fig. 
3.1). ACICU_02904, annotated as a cation/multidrug efflux pump, was 1031 amino acid 
residues in size and was 40% identical to the AdeB amino acid sequence. No further genes 
characteristic for the RND-type complex (MFP or outer membrane pore) were encoded 
immediately upstream or downstream of the pump. The same was true for the RND 
superfamily exporter ACICU_00143, 1216 amino acid residues in size and 23% identical to 
the AdeB amino acid sequence. For both RND family cation/multidrug efflux pumps 
ACICU_03066 and ACICU_03646, a MFP was encoded upstream of the pump. Additionally, in 
the case of ACICU_03646, a TetR-type transcriptional regulator was found adjacent to the 
MFP. The latter pump was 1041 amino acids in size and 24% identical to the AdeB amino 
acid sequence, whereas ACICU_03066 was 1011 amino acids in size and displayed 29% 
similarity to AdeB. Regarding the efflux transporter ACICU_03412, both the MFP and outer 
membrane pore were encoded upstream of the pump displaying a putative tripartite RND 
efflux system, as the outer membrane pore does not necessarily have to be encoded next to 
the transporter. Similar to adeAB, the start and the stop codon of the genes encoding the 
MFP and the pump ACICU_03412 overlapped, which is indicative of an operon organization. 
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Table 3.1 Features of the five uncharacterized RND efflux pump genes. Adapted from Nowak et al. [289]. 
               
 
Results 
- 73 - 
Figure 3.1 Schematic illustration of the five uncharacterized RND efflux pump genes and their    
                   surrounding 
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3.1.2 Prevalence of RND-type efflux pumps in A. baumannii isolates 
The prevalence of the eight RND efflux pumps amongst sequenced A. baumannii genomes 
was determined in silico using the NCBI database. Twenty-five complete A. baumannii 
genomes were available to compare against A. baumannii ACICU. Unassembled whole-
genome-shotgun sequences were not considered as complete genomes, as they might have 
gaps and thus sequence validity was not given. Due to the incomplete sequence, draft 
genomes were also excluded. Efflux pumps showing >95% sequence similarity were rated as 
present in the query isolate. Under these conditions, adeG, adeJ, ACICU_3066 and 
ACICU_3646 were present in all of the twenty-five fully sequenced A. baumannii genomes. 
Twenty-four isolates (96%) harboured ACICU_2904 and ACICU_00143, whereas 23 (92%) 
harboured adeB. In contrast, ACICU_03412 was present in less than half of the isolates 
(44%). The results were the same regardless of whether the amino acid sequence or the 
nucleotide sequence was compared. 
The PCR-based detection of the eight RND efflux pump encoding genes amongst our 144 A. 
baumannii isolates revealed that five of the pump genes (adeG, adeJ, ACICU_02904, 
ACICU_03066 and ACICU_03646) were present in all of the A. baumannii isolates (Table 3.2). 
The gene encoding AdeB, the pump most often associated with MDR, was present in 97% of 
all isolates; one isolate each in IC5 and IC8, and three of the genotypically unique isolates 
were missing the gene. Similarly, the uncharacterized ACICU_00143 was present in all A. 
baumannii isolates of IC2, IC3, IC6 and IC7, whereas one to three isolates were negative for 
this pump in IC1, IC4, IC5 isolates and in the genotypically unique isolates. In IC8, less than 
50% of the isolates were positive for this gene. The highest diversity in the prevalence of the 
eight investigated RND efflux pumps was observed with ACICU_03412; ≥ 90% of the IC1, IC3, 
IC6 and IC8 isolates carried the gene, while 60% of the genotypically unique isolates and IC5 
gave a positive PCR product. Furthermore, only 40% of isolates in IC7, 29% in IC2 and 6% in 
IC4 isolates amplified ACICU_03412. Overall, there was no association between the presence 
of one or multiple pumps to a specific clonal lineage. However, all isolates of IC3 and IC6 
were positive for all the genes investigated. With an overall prevalence of 56%, 
ACICU_03412 was detected least of all (for IC2, IC4 and IC7 the prevalence was <50%).  
In cases when no amplicon was achieved with the first primer pair, a separate second primer 
pair per gene was used. For adeJ and ACICU_03646 no second primer pair was necessary; a 
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positive amplicon was detected with all isolates using the first primer pair. With regards to 
adeB and adeG, 5 isolates had to be re-tested with the second primer pair which revealed 
that all isolates were positive for adeG, whereas the adeB gene was still missing in 4 isolates. 
However, the use of both primer sets was frequently required for the remaining efflux pump 
genes. Re-testing 80 strains for ACICU_02904 and 58 strains for ACICU_03066, all strains 
were found positive for the respective putative RND pump. On the other hand, only 3 of 66 
and 1 of 16 retested strains were positive for ACICU_03412 and ACICU_00143. BLAST 
analysis of whole genomes revealed that polymorphisms within the second primer-binding 
sites were rare. 
The total prevalence of the efflux pumps amongst our strain collection showed a high 
similarity to the prevalence in the publicly available completely sequenced A. baumannii 
genomes in the NCBI database. Therefore, the PCR-based method to determine the 
prevalence of RND-type efflux pumps was reliable.  
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Table 3.2 Prevalence of efflux pump genes (%) for each of the eight international clones as determined by PCR. Adapted from Nowak et al. [289]. 
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3.2 Characterization of the putative RND-type efflux pump A1S_2660 
3.2.1 Induced expression of A1S_2660 (rnd1) 
The putative RND-type efflux pump ACICU_02904 was one of five uncharacterized pumps 
identified in A. baumannii ACICU during BLAST analysis, which was present in all 144 isolates 
we tested (Table 3.2). Showing the highest similarity to the AdeB amino acid sequence 
amongst all other putative pumps, we wanted to further characterize this pump (annotated 
as a cation/multidrug efflux pump), with regards to its expression and substrate specificity. 
For this investigation we used the A. baumannii reference strain ATCC 17978, in which 
A1S_2660 is the equivalent to ACICU_02904. Henceforth, A1S_2660 will be referred to as 
rnd1. 
In contrast to the RND-type efflux pumps already described in A. baumannii, no further 
genes characteristic for the RND complex (MFP or outer membrane pore) were encoded 
immediately upstream or downstream of rnd1. To determine whether rnd1 is constitutively 
expressed in ATCC 17978, reverse transcription was performed with freshly prepared cDNA 
using nested primers specific to the rnd1 sequence. As a positive control genomic DNA was 
taken.  
 
Figure 3.2 Expression of rnd1 in A. baumannii ATCC 17978. Primers ACICU_02904 2_F and 
ACICU_02904 2_R were used to amplify rnd1 from freshly synthetized cDNA as well as gDNA 
obtained from crude lysates. A positive amplicon of the gDNA sample confirmed the presence of 
rnd1, but the lack of an amplicon with the cDNA sample showed that it is not constitutively 
expressed. 
In contrast to the genomic DNA sample of ATCC 17978, no amplified product could be 
detected using cDNA (Fig. 3.2). This indicated that rnd1 is not constitutively expressed and 
we suggest that it is a cryptic pump. 
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In order to identify conditions or substances, which induce the expression of the putative 
pump, the β-galactosidase reporter assay was used fusing the promoter region of rnd1 and 
its first 21 nucleotides to the β-galactosidase encoding gene lacZ. As adeA is constitutively 
expressed in ATCC 17978, an adeA-lacZ construct was generated as a positive control. The 
empty vector served as a negative control. All three constructs were transformed into the A. 
baumannii reference strain ATCC 17978 and streaked on gradient agar plates which were 
supplemented with different antimicrobial agents, disinfectants, detergents, chemicals or 
salts (Table 2.13). In addition, the LacZ substrate X-gal was added to the agar.  
No colouring of the agar was observed under any of the tested conditions, neither with the 
wildtype strain nor the empty vector transformant (Fig. 3.3). In contrast, the agar around the 
adeA-lacZ transformants was constantly blue, confirming a constitutive expression of adeA 
in ATCC 17978. With the rnd1-lacZ transformants, expression could not be observed under 
most of the tested conditions and substances (exemplified by ampicillin in Fig.3.3 E), 
suggesting that the pump was not constitutively expressed. However, blue colouring of the 
agar was observed when meropenem (Fig. 3.3 A), chloramphenicol (B), ethanol (C) or 
sodium chloride (D), respectively, were supplemented, indicating that these substances were 
inducers of rnd1 expression. rnd1 was already expressed at low concentrations of 
meropenem, chloramphenicol and ethanol. However, its expression was induced at a NaCl 
concentration of ~80-100 mM and was further increased up to a final concentration of 200 
mM, visible through a light blue to dark blue colour shift of the agar. Nevertheless, 
expression was considered low as the colour change was visible only after ≥ 24 hours of 
incubation. In contrast, with the adeA-lacZ transformant a strong colour change could be 
observed already after 16 h of incubation. 
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Figure 3.3 Detection of rnd1 expression 
in A. baumannii ATCC 17978 rnd1-lacZ 
transformants using gradient plates. A 
0.5 McFarland suspension of [1] ATCC 
17978, [2] rnd1-lacZ transformants, [3] 
empty vector control and [4] adeA-lacZ 
transformants were streaked on gradient 
agar plates supplemented with X-gal and 
A. 2 mg/L meropenem, B. 32 mg/L 
chloramphenicol, C. 10% ethanol,             
D. 200 mM NaCl, E. 64 mg/L ampicillin and 
incubated for 44 h. AB, antibiotic. 
A B
 
 A 
D C 
E 
AB 
gradient 
(1)  (2)   (3)  (4) 
high 
low 
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To further confirm the induction of rnd1 expression by meropenem and chloramphenicol, 
disc diffusion was performed with the rnd1-lacZ transformants. The agar was again 
supplemented with X-gal. 
 
Figure 3.4 Detection of rnd1 expression in A. baumannii ATCC 17978 rnd1-lacZ transformants using 
disc diffusion. A 0.5 McFarland suspension of rnd1-lacZ transformants was plated on a MH plate 
supplemented with X-gal. After antimicrobial discs were applied, the plate was incubated for 42 h. 
Blue colouring of the agar indicates induced expression of rnd1. The MH plate shown is a 
representative of three independent experiments. 
Similar to the results of the gradient agar plates, a blue coloured inhibition zone was 
observed around the meropenem discs after 36 h incubation (Fig. 3.4 G). Additionally, 
imipenem (E) and ertapenem (J) also induced the expression of the reporter gene which led 
to blue colouring. Likewise, expression of rnd1 was induced by ampicillin/sulbactam (P), but 
as ampicillin (K) itself did not cause any colour change, the effect could be induced by 
sulbactam. Using the disc diffusion method, induction could only very weakly be observed by 
chloramphenicol (F). With other antimicrobials tested, no colour change occurred.  
           A                              B                               C                               D  
 
           E                             F                                 G                               H  
 
           I                                J                                 K                               L  
 
       M                              O                                P                                 Q  
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3.2.2 Induced overexpression of rnd1 for substrate identification 
rnd1 expression was considered low as the colour change was visible only after prolonged 
incubation. In order to identify substrates of Rnd1, the complete ORF of rnd1 was cloned 
into an IPTG inducible expression vector for overexpression, generating rnd1_oe. As a 
control, an out-of-frame rnd1_oof construct was generated. Both constructs were 
transformed into A. baumannii ATCC 17978. IPTG-induced expression of rnd1 was 
determined by qRT-PCR. 
 
Figure 3.5 Relative rnd1 expression in A. baumannii ATCC 17978 rnd1_oe transformants after IPTG 
addition. Transformants were grown until mid-log phase and IPTG was added for 20 min. Total RNA 
was isolated and cDNA was synthesized. rnd1 expression was determined by qRT-PCR. The number of 
rnd1 transcripts was related to the zero control after being normalized to the expression of the 
reference gene rpoB. Data displayed are representative of three independent experiments and 
results are shown as mean ± standard error of the mean. 
After the addition of 0.005 or 0.01 mM IPTG for 20 minutes, minor changes in the rnd1 
expression by 2.5- and 3.2-fold, respectively, were determined compared to the zero control 
(Fig. 3.5). However, adding 0.1 or 1 mM IPTG a maximum expression was reached, which 
was ~300-fold higher than the rnd1 expression of the control sample. Further experiments, 
which required overexpression of rnd1 were performed adding 0.1 mM IPTG. 
Substrate identification of rnd1 was performed by disc diffusion. If increased expression of 
the pump leads to increased efflux of antimicrobials, disc diameter should be reduced 
compared to the control. However, after overnight incubation of the test plates, we 
observed less growth of the rnd1_oe transformants compared to the oof control. 
Supplementing the agar with 0.1 mM IPTG, growth of rnd1_oe transformants was reduced to 
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single colonies, whereas the rnd1_oof transformants showed confluent growth on the plate. 
These results suggested that overexpression of rnd1 might be toxic for A. baumannii ATCC 
17978. Thus, growth curves were conducted to determine bacterial fitness at different levels 
of rnd1 expression.  
 
Figure 3.6 Growth of A. baumannii ATCC 17978 rnd1_oe transformants before and after IPTG 
addition. Growth was recording at hourly intervals for 4 hours; after 2 hours IPTG was added. Data 
displayed are representative of two independent experiments and results are shown as mean ± 
standard error of the mean. 
Inducing rnd1 expression with the addition of 0.005 or 0.01 mM IPTG, no difference in the 
growth of the transformants was observed compared to the control (Fig. 3.6). These results 
indicated that low-level expression of rnd1 had little or no impact on survival of the 
transformants. However, high-level expression induced by 0.1 mM IPTG had a bacteriostatic 
effect, inhibiting further growth after IPTG addition. Although no further increase in rnd1 
expression was detected by qRT-PCR when raising the IPTG concentration by another 10-fold 
(Fig. 3.5), a bactericidal effect could be observed after 1 mM IPTG was added (Fig. 3.6). 
These results suggest that high-level expression of rnd1 had a negative impact on the 
transformants’ fitness, explaining why single colonies were visible on solid media after 
overnight incubation. 
AdeB was originally considered to be a cryptic RND-type efflux pump, however in ATCC 
17978 the adeB gene is constitutively expressed. Therefore, we hypothesised that the 
overexpression of another efflux pump might influence bacterial fitness in this strain. In 
order to investigate a possible correlation between adeB and rnd1 expression, the rnd1_oe 
and the rnd1_oof construct were introduced into the clinical A. baumannii isolate NIPH 60. 
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Whole-genome sequencing previously revealed that NIPH 60 is deficient in the AdeRSABC 
encoding genes but is carrying adeIJK and adeFGH on the chromosome [244].  
Reverse transcription of NIPH 60 gDNA and cDNA revealed that rnd1 is also not 
constitutively expressed in this strain (Fig. 3.7).  
 
Figure 3.7 Expression of rnd1 in A. baumannii NIPH 60. Primers ACICU_02904 2_F and ACICU_02904 
2_R were used to amplify rnd1 from freshly synthetized cDNA as well as gDNA obtained from crude 
lysates. A positive amplicon of the gDNA sample confirmed the presence of rnd1, but the lack of an 
amplicon with the cDNA sample showed that it is not constitutively expressed. 
IPTG-induced expression of rnd1 in NIPH 60 rnd1_oe transformants was determined by qRT-
PCR. Similar to the rnd1_oe transformants in ATCC 17978 (Fig. 3.5), only a 6-fold change in 
expression of rnd1 was induced with the addition of 0.01 mM IPTG compared to the control 
(Fig. 3.8). With the addition of 0.1 or 1 mM IPTG a maximum expression of ~300-fold higher 
compared to the control was observed. 
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Figure 3.8 Relative rdn1 expression in A. baumannii NIPH 60 rnd1_oe transformants after IPTG 
addition. Transformants were grown until mid-log phase and IPTG was added for 20 min. Total RNA 
was isolated and cDNA was synthesized. rnd1 expression was determined by qRT-PCR. The number of 
rnd1 transcripts was related to the zero control after being normalized to the expression of the 
reference gene rpoB. Data displayed are representative of three independent experiments and 
results are shown as mean ± standard error of the mean. 
Growth kinetics were performed to determine if the overexpression of rnd1 had a negative 
effect on bacterial growth of adeRSABC-deficient NIPH 60 transformants as seen with ATCC 
17978 (Fig. 3.6).  
 
Figure 3.9 Growth of A. baumannii NIPH 60 rnd1_oe transformants before and after IPTG addition. 
Growth kinetics were performed recording growth at hourly intervals, for 4 hours; after 2 hours IPTG 
was added. Data displayed are representative of two independent experiments and results are 
shown as mean ± standard error of the mean. 
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In contrast to the ATCC 17978 rnd1_oe transformants (Fig. 3.6), no impact on the survival of 
NIPH 60 transformants was determined irrespective of which IPTG concentration was added 
(Fig. 3.9). Further experiments which required overexpression of rnd1 were performed 
adding 1 mM IPTG, as the highest expression of rnd1 was achieved at this concentration. 
As bacterial growth of NIPH 60 rnd1_oe transformants was not affected by rnd1 
overexpression, substrate identification of the putative pump was performed by disc 
diffusion adding 1 mM IPTG to the medium. Using disc diffusion, no difference in the 
susceptibility to any of the tested antimicrobials was observed with the NIPH 60 rnd1_oe 
transformants compared to the rnd1_oof control (Table 3.3). 
Further antimicrobials were tested by agar dilution. 
 
   
Table 3.3 Antibiotic disc diameter (mm) of NIPH 60 transformants 
 
 
 
NIPH60 
pBA03/05::rnd1_oof 
NIPH60 
pBA03/05::rnd1_oe 
Antimicrobial class Antimicrobial 0 mM 
IPTG 
1 mM 
IPTG 
0 mM 
IPTG 
1 mM 
IPTG 
Aminoglycosides Amikacin 20 19 19 19 
Gentamicin 20 20 20 20 
ß-lactams Penicillin 9 9 9 9 
Carbapenems Imipenem 29 30 29 29 
Meropenem 26 25 26 26 
Cephalosporins Ceftriaxone 18 18 18 18 
Fenicols Chloramphenicol 11 11 10 10 
Fluoroquinolones Ciprofloxacin 29 29 29 29 
Ofloxacin 30 31 30 30 
Quinolones Nalidixic acid 23 23 22 23 
Macrolides Erythromycin 16 17 16 17 
Rifamycines Rifampicin 17 17 16 16 
Tetracyclines Doxycycline 26 26 26 26 
Tetracycline 23 24 23 23 
ß-lactam/β-
lactamase inhibitor 
Ampicillin/Sulbactam 14 14 13 14 
Folate pathway 
inhibitors 
Co-trimoxazole 23 23 23 23 
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Table 3.4 MIC values (mg/L) of NIPH 60 transformants 
 
 
Likewise, no change in the susceptibility to any of the tested substances was detected 
between rnd1_oe and rnd1_oof transformants using agar dilution (Table 3.4). 
As there was no difference in susceptibility, we conclude that the substances tested are not 
substrates of this pump. Following, the accumulation assay performed in liquid culture was 
used as another approach, with which ethidium was tested as a potential substrate. The 
levels of ethidium accumulation of NIPH 60 rnd1_oof transformants and rnd1_oe 
transformants are summarized in Figure 3.10. No difference in ethidium accumulation was 
observed between rnd1_oof and rnd1_oe transformants (Fig. 3.10).  
 
Figure 3.10 Ethidium accumulation of NIPH 60 rnd1_oe and rdn1_oof transformants. The 
fluorescence intensity was recorded after ethidium bromide (10 µM) and IPTG (1 mM) addition at 
excitation and emission wavelengths of 530 and 600 nm, respectively, every 10 seconds over a 30 
min incubation period. Data displayed are representative of two independent experiments and 
results are shown as mean ± standard error of the mean. 
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As a consequence it can be said that although overexpression of the cryptic A1S_2660 
(Rnd1) RND-type efflux pump was induced in the AdeRSABC-deficient isolate NIPH 60, and 
no negative effect on the growth rate was detected, we did not observe any difference in 
the susceptibility to any of the tested compounds, nor did its overexpression affect ethidium 
accumulation. These results implied that either I) a compound other than the applied ones 
might be a substrate of this pump, II) Rnd1 has another function within the cell or III) the 
pump, as we tested it, is not functional.  
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3.3 Characterization of the Asp20→Asn substitution in the response   
       regulator AdeR 
3.3.1 Synergistic interaction of AdeR(Asn20) and AdeS leads to increased  
          expression of adeB 
To determine the contribution of the Asp20→Asn substitution in AdeR on adeB expression 
and decreased antimicrobial susceptibility, two recombinant variants of adeR [adeR(Asp20) 
and adeR(Asn20)] were introduced into the A. baumannii reference strain ATCC 17978. As 
ATCC 17978 has the Asp20 variant encoded on the chromosome, any detectable differences 
in adeB expression measured by qRT-PCR or in antimicrobial susceptibility could be 
correlated to the substitution in AdeR. Testing the transformants against eight structurally 
diverse antimicrobial classes, the introduction of the empty vector control pJN17/04 into 
ATCC 17978 had no effect on antimicrobial susceptibility with the exception of amikacin and 
chloramphenicol where the MIC was reproducibly reduced from 4 mg/L to 2 mg/L, and 128 
mg/L to 64 mg/L, respectively, compared to the reference strain (Table 3.5). Therefore, MIC 
values of all ATCC 17978 transformants were henceforth compared to the empty vector 
control. With the adeR(Asp20) variant only a minor reproducible increase in the MIC by 2-
fold was seen with amikacin, gentamicin, tigecycline and azithromycin (Table 3.5). For 
amikacin and azithromycin these changes were further increased by another 2-fold with the 
adeR(Asn20) construct leading to an MIC of 8 mg/L for amikacin and 16 mg/L for 
azithromycin. Furthermore, levofloxacin and tetracycline MICs of the adeR(Asn20) 
transformants were 2-fold higher compared to the empty vector transformants.  
Measuring the adeB expression, the number of transcripts increased by 5.5-fold with the 
adeR(Asp20) variant or by 7.5-fold with the adeR(Asn20) transformant relative to the vector 
only control (Fig 3.11). However, comparing the two adeR transformants with each other to 
catch the effect which is only due to the missense mutation in adeR, no significant difference 
in the number of adeB transcripts could be detected. 
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Table 3.5 MIC values (mg/L) of A. baumannii ATCC 17978 transformants 
Antimicrobial 
class Antimicrobial 17978 
 
pJN17/04 
 
adeR(Asp20) adeR(Asn20) 
Aminoglycosides Amikacin 4 2 4 8 
 
Gentamicin 1 1 2 2 
Carbapenems Meropenem 1 1 1 1 
Fenicols Chloramphenicol 128 64 64 64 
Fluoroquinolones Ciprofloxacin 0.5 0.5 0.5 0.5 
 
Levofloxacin 0.125 0.125 0.125 0.25 
Glycylcyclines Tigecycline 0.25 0.25 0.5 0.5 
Macrolides Azithromycin 4 4 8 16 
 Erythromycin 16 16 16 16 
Rifamycins Rifampicin 4 4 4 4 
Tetracyclines Tetracycline 1 1 1 2 
 
Minocycline 0.125 0.125 0.125 0.125 
 
                          
Figure 3.11 Relative adeB expression in the A. baumannii ATCC 17978 adeR transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. Data displayed are representative of six independent 
experiments and results are shown as mean ± standard error of the mean. Statistical analysis was 
carried out with the recorded absolute values by performing an unpaired t-test. n.s. not significant.  
In contrast to the previous study with isolate F and G [89], no significant change in the 
expression of adeB (Fig. 3.11) and only minor MIC changes were detected (Table 3.5) 
when introducing the adeR(Asn20) construct compared to adeR(Asp20). These results 
suggested that the response regulator AdeR alone does not affect adeB expression and 
subsequently the susceptibility phenotype observed previously. Therefore, we took a 
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closer look at the amino acid sequence of the sensor kinase AdeS of the clinical isolate F 
and the reference strain ATCC 17978. 
Comparing the AdeS amino acid sequence of isolate F with ATCC 17978, eleven 
differences were detected, e.g. V94A, L214F, R299Q (Fig. 3.12). 
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Figure 3.12 Comparison of the AdeS amino acid sequence of A. baumannii ATCC 17978 and isolate F and G. 
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To elucidate the effect of these amino acid changes, adeS from the clinical isolate F was 
introduced into ATCC 17978 and adeB expression was determined. This introduction led 
to a 22-fold increase in adeB expression compared to the vector only transformants (Fig. 
3.13). Regarding susceptibility, amikacin, levofloxacin, tigecycline and tetracycline MICs 
increased slightly by 2-fold. In addition, an increase in the MICs to gentamicin by 4-fold 
and by 8-fold with azithromycin was found. 
 
Figure 3.13 Relative adeB expression and MICs (mg/L) of ATCC 17978 adeS transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. Data displayed are representative of three independent 
experiments and results are shown as mean ± standard error of the mean. Statistical analysis was 
carried out with the recorded absolute values by performing an unpaired t-test. *, P < 0.05. 
Antimicrobial susceptibility was determined by agar dilution. 
In comparison to the adeR transformants (Table 3.5), susceptibilities to a larger number of 
antimicrobials were affected when introducing adeS of isolate F into ATCC 17978. Having a 
closer look at the amino acid differences between both strains, in particular the substitutions 
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at position 173 and 303 might have an impact on adeB expression as they lie within 
functional domains (other substitutions were not considered as relevant compared to the 
sequence of A. baumannii ATCC 19606, BMBF 320, Scope 23; see Fig. 3.25). The amino acid 
difference at position 173 lies within the histidine kinase domain close to the 
autophosphorylation site, which might affect the phosphorylation of AdeR and thus its 
activation (Fig. 3.12). The substitution at position 303 on the other hand, lies within the ATP 
binding site which is equally important for the phosphoryl-transfer to the response 
regulator. To elucidate whether one of these amino acid changes or both combined affect 
adeB expression, the adeS sequence of ATCC 17978 was altered by applying a site-directed 
mutagenesis approach. The following recombinant adeS constructs were generated: 
adeS(L173P), adeS(Y303F) and adeS(L173P/Y303F). These adeS variants were transformed 
into the reference strain ATCC 17978, and adeB expression was recorded by qRT-PCR. The 
chosen amino acid differences alone or in combination did not affect the number of adeB 
transcripts compared to the empty vector control (Fig. 3.14). 
                   
Figure 3.14 Relative adeB expression in ATCC 17978 adeS site-directed mutagenesis transformants. 
The number of adeB transcripts was related to the empty vector control after being normalized to 
the expression of the reference gene rpoB. Data displayed are representative of three independent 
experiments and results are shown as mean ± standard error of the mean. 
Nevertheless, the fact that the susceptibilities to a larger number of antimicrobials were 
decreased when introducing adeS of the clinical isolate F, as well as the accompanying 22-
fold increase in adeB expression (Fig. 3.13), led us to the question of whether AdeR is 
dependent on its cognate sensor kinase and if their interaction is synergistic or additive. 
Thus, adeR(Asp20)S or adeR(Asn20)S genes from isolates F or G, respectively, were 
transformed into ATCC 17978 and adeB expression as well as their antimicrobial 
susceptibility were determined. The introduction of the adeR(Asp20)S construct led to a    
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78-fold increase in adeB expression, compared to the empty vector control (Fig. 3.15). 
However, no further changes in the MICs to the tested antimicrobials were detected in 
addition to the elevated MICs seen previously with the adeS transformant (Fig. 3.13). With 
the adeR(Asn20)S construct, adeB expression was increased by over 400-fold and MICs to 
ciprofloxacin, levofloxacin, and tetracycline increased by 4-fold, while amikacin and 
tigecycline MICs increased by 8-fold compared to the control (Fig. 3.15). Furthermore, 
gentamicin and azithromycin MICs increased by 16-fold from 1 mg/L to 16 mg/L and 4 mg/L 
to 64 mg/L, respectively. Comparing both adeRS constructs with each other to catch the 
effect which is only due to the mutation in adeR, a 5-fold increase in adeB expression and a 
4-fold increase of the MIC to antimicrobials belonging to the three different antimicrobial 
classes aminoglycosides, fluoroquinolones and glycylcyclines was detected.  
 
Figure 3.15 Relative adeB expression and MICs (mg/L) of the ATCC 17978 adeRS transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. Data displayed are representative of three independent 
experiments and results are shown as mean ± standard error of the mean. Statistical analysis was 
carried out with the recorded absolute values by performing an unpaired t-test. **, P < 0.01. 
Antimicrobial susceptibility was determined by agar dilution. 
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In conclusion, the introduction of both adeR and adeS combined show a synergistic effect on 
the number of adeB transcripts as well as on reduced antimicrobial susceptibility, especially 
with the adeRS transformant harboring the Asn20 variant. However, introducing adeS and 
adeR(Asp20) of isolate F together, no further changes in the MICs compared to the adeS only 
transformants were detected. These results indicated that the Asn20 substitution in AdeR 
has a specific effect on the interaction with its cognate sensor kinase leading to the 
significant increase in adeB expression and decrease in the susceptibility profile. To 
investigate the dependence of AdeR(Asn20) on its cognate sensor kinase, a plasmid was 
constructed harboring adeS of ATCC 17978 in frame with adeR(Asn20) of isolate G, rendering 
adeR(Asn20)S(17978). The intergenic region between adeRS of ATCC 17978 was the same 
compared to isolate F and G, therefore the only difference to adeR(Asn20)S was the ‘new’ 
adeS sequence downstream of adeR(Asn20). The adeR(Asn20)S(17978) was introduced into 
ATCC 17978 and adeB expression was determined by qRT-PCR.  
           
Figure 3.16 Relative adeB expression in ATCC 17978 adeR(Asn20)S(17978) transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. Data displayed are representative of two independent 
experiments and results are shown as mean ± standard error of the mean. Statistical analysis was 
carried out with the recorded absolute values by performing an unpaired t-test. **, P < 0.01. 
With the introduction of the adeR(Asn20)S(17978) construct adeB expression was increased 
by almost 54-fold compared to the empty vector control (Fig. 3.16). This increase is 
comparable to the effect of the adeR(Asp20)S transformant (Fig. 3.15). These results suggest 
that the 400-fold increase in the number of adeB transcripts observed for the adeR(Asn20)S 
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transformant (Fig. 3.15) is due to the Asp20→Asn substitution in AdeR which might 
specifically affect the interaction with its cognate AdeS.  
Concluding these results, with the introduction of the different adeR, adeS and adeRS 
constructs of isolate F and G a stepwise increase in the expression of adeB and a stepwise 
decrease in the susceptibility to multiple antibiotics was achieved in the A. baumannii 
reference strain ATCC 17978 (Fig. 3.17). The adeR transformants showed a 5.5-7.5 fold 
increase in the number of adeB transcripts but minor changes in the MICs by 2-fold were 
observed compared to the empty vector control. With the adeS and the adeR(Asp20)S 
construct, which led to elevated adeB transcription levels by 22- to 78-fold, respectively, an 
identical susceptibility profile could be observed; a 4-fold increase in the MIC to gentamicin 
and an 8-fold increase in azithromycin MIC (Fig. 3.17). Although adeR(Asp20)S had a 
synergistic effect on adeB expression compared to the adeS and adeR(Asp20) single 
transformants, it was the synergistic effect of adeR(Asn20) in combination with its cognate 
sensor kinase that increased the adeB expression by over 400-fold compared to the control 
and thereby caused a significant decrease in the susceptibility to antimicrobials belonging to 
three different classes in A. baumannii strain ATCC 17978. 
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Figure 3.17 Relative adeB expression and MICs of the ATCC 17978 transformants. The number of 
adeB transcripts was related to the empty vector control after being normalized to the expression of 
the reference gene rpoB. Results are shown as mean ± standard error of the mean. Antimicrobial 
susceptibility was determined by agar dilution and is shown in mg/L for the empty vector 
transformant and as fold-increase for the other transformants compared to the control.  
As the overexpression of the other two efflux pump genes adeG and adeJ have also been 
associated with decreased susceptibility in A. baumannii isolates, their expression was also 
investigated.  
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Figure 3.18 Relative adeG and adeJ expression in the ATCC 17978 adeRS transformants. The 
number of adeG or adeJ transcripts was related to the empty vector control after being normalized 
to the expression of the reference gene rpoB. Data displayed are representative of three 
independent experiments and results are shown as mean ± standard error of the mean. 
No significant difference in the expression of adeG or adeJ was detected between the adeRS 
transformants and the empty vector control (Fig. 3.18).  
To determine if the increased expression of adeB was accompanied by a fitness cost for the 
transformants, growth curves were conducted. No difference in growth rates between either 
of the adeRS transformants and the empty vector control were observed (Fig. 3.19).  
                   
Figure 3.19 Growth of the A. baumannii ATCC 17978 adeRS transformants. Growth kinetics were 
performed recording growth at hourly intervals, for 4 hours. Data displayed are representative of two 
separate experiments and results are shown as mean ± standard error of the mean. 
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3.3.2 The effect of adeR(Asn20)S differs among A. baumannii strains 
To investigate whether the downstream effects of the introduced adeRS constructs are 
uniform among other A. baumannii strains, both adeRS variants [adeR(Asp20)S, 
adeR(Asn20)S] were transformed into three further isolates; the A. baumannii reference 
strain ATCC 19606, which naturally has a relatively high number of adeB transcripts (105-
106µg RNA); the A. baumannii isolate BMBF 320 with a moderate number of adeB transcripts 
(104-105µg RNA) and the clinical isolate Scope 23, which has the lowest number of adeB 
transcripts (101-102 µg RNA). adeB expression was determined by qRT-PCR and antimicrobial 
susceptibility by agar dilution.  
3.3.2.1 ATCC 19606 
 
Figure 3.20 Relative adeB expression and MICs (mg/L) of the ATCC 19606 adeRS transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. qRT-PCR data displayed are representative of four 
independent experiments and results are shown as mean ± standard error of the mean. Statistical 
analysis was carried out with the recorded absolute values by performing an unpaired t-test. **, P < 
0.01. Antimicrobial susceptibility was determined by agar dilution. 
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Introducing the adeR(Asp20)S construct into ATCC 19606, the number of adeB transcripts 
was reduced by almost 70% compared to the empty vector control (Fig. 3.20). Correlating, 
the MICs to gentamicin, meropenem, tigecycline, azithromycin and minocycline were 
reproducably reduced by 2-fold. The susceptibility to the other tested antimicrobials was not 
affected. In contrast, adeB expression was increased by 2.5-fold with the adeR(Asn20)S 
construct (Fig. 3.20). Compared to the control, MICs of gentamicin, ciprofloxacin, 
levofloxacin and tetracycline were reproducably increased by 2-fold from 8 mg/L to 16 mg/L, 
1 mg/L to 2 mg/L, 0.25 mg/L to 0.5 mg/L, and 2 mg/L to 4 mg/L, respectively. Comparing 
both adeRS transformants with each other, adeB expression was significantly elevated by 
7.4-fold with the adeR(Asn20)S variant. Regarding the susceptibility data, a minor increase in 
the MIC by 2-fold was induced for 5 of the 8 tested antimicrobial classes (carbapenems, 
fluoroquinoloes, glycylcyclines, macrolides and tetracylines). A reduced susceptibility by 4-
fold was observed for gentamicin.  
3.3.2.2 BMBF 320 
With the adeR(Asp20)S construct, no changes in the number of adeB transcripts was 
determined in the A. baumannii isolate BMBF 320 compared to the empty vector control 
(Fig. 3.21). Similarly, the susceptibility to all tested antimicrobials was unaffected with the 
exception of ciprofloxacin, where the already high MIC value of 64 mg/L was reproducibly 
increased by 2-fold to 128 mg/L. However, adeB expression was elevated by 18-fold in the 
adeR(Asn20)S transformant compared to the control and 12-fold compared to the 
adeR(Asp20)S construct. Regarding susceptibility, comparing both adeRS constructs minor 
changes in the MIC to amikacin, the tested fluoroquinolones, macrolides and tetracyclines by 
2-fold were observed (Fig. 3.21). Furthermore, the MIC to tigecycline increased by 4-fold 
from 2 mg/L to 8mg/L.  
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Figure 3.21 Relative adeB expression and MICs (mg/L) of the BMBF 320 adeRS transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. qRT-PCR data displayed are representative of three 
independent experiments and results are shown as mean ± standard error of the mean. Statistical 
analysis was carried out with the recorded absolute values by performing an unpaired t-test. *, P < 
0.05. Antimicrobial susceptibility was determined by agar dilution. 
3.3.2.3 Scope 23 
In the A. baumannii isolate Scope 23, introducing both adeRS variants led to a stepwise 
increase in adeB expression and a stepwise decrease in antimicrobial susceptibility, 
compared to the empty vector control (Fig. 3.22). The 40-fold increase in the number of 
adeB transcripts induced with the adeR(Asp20)S construct was accompanied by minor 
changes in the MICs of amikacin, the fluoroquinolones and minocycline by 2-fold. In 
addition, susceptibilities to gentamicin and azithromycin were decreased by 4- and 8-fold, 
respectively. With the introduction of adeR(Asn20)S the increase in adeB expression by 
almost 350-fold was reflected by a 4-fold increase in the MIC to amikacin, the 
fluoroquinolones and tigecycline compared to the empty vector control. Gentamicin and 
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azithromycin MICs were increased by 16- or 32-fold, respectively from 1 mg/ml, and 4 mg/L, 
to 16 mg/L and 128 mg/L, respectively. Comparing both adeRS transformants to catch the 
effect of the Asp20→Asn substitution, adeB expression significantly differed by 8.6-fold. 
Furthermore, the susceptibility to 8 of 10 tested antimicrobials was affected, with 
reproducible minor changes by 2-fold for amikacin, the fluoroquinolones, erythromycin and 
tetracycline. The MICs to gentamicin, azithromycin and tigecycline were increased by 4-fold. 
 
Figure 3.22 Relative adeB expression and MICs (mg/L) of the Scope 23 adeRS transformants. The 
number of adeB transcripts was related to the empty vector control after being normalized to the 
expression of the reference gene rpoB. qRT-PCR data displayed are representative of three 
independent experiments and results are shown as mean ± standard error of the mean. Statistical 
analysis was carried out with the recorded absolute values by performing an unpaired t-test. **, P < 
0.01. Antimicrobial susceptibility was determined by agar dilution. 
In addition to adeB expression and the susceptibility testing, adeG and adeJ expression were 
determined and growth curves were conducted for all adeRS and empty vector 
transformants. Results are shown in Figure 3.23 and 3.24.  
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A. ATCC 19606     B. BMBF 320 
 
C. Scope 23 
 
. 
As observed previously for the A. baumannii ATCC 17978 transformants (Fig. 3.18), no 
significant change in either adeG or adeJ expression was observed in the other A. baumannii 
transformants (Fig. 3.23). Similarly, no fitness cost could be detected for the ATCC 19606, 
BMBF 320 or Scope 23 adeRS transformants compared to their empty vector controls (Fig. 
3.24). 
 
 
 
 
 
Figure 3.23 Relative adeG and adeJ 
expression in (A) ATCC 19606, (B) BMBF 
320, and (C) Scope 23 adeRS 
transformants. The number of adeG or 
adeJ transcripts was related to the empty 
vector control after being normalized to 
the expression of the reference gene rpoB. 
Data displayed are representative of three 
independent experiments and results are 
shown as mean ± standard error of the 
mean.  
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     A. ATCC 19606             B. BMBF 320 
 
C. Scope 23 
 
Having determined both adeB expression and antimicrobial susceptibility, in three further A. 
baumannii strains transformed with both adeRS constructs, we observed that the 
downstream effects were not equal in each isolate. Whereas the introduction of 
adeR(Asp20)S lowered the number of adeB transcripts by 70% compared to the empty 
vector control in the A. baumannii reference strain ATCC 19606 (Fig. 3.20), no change was 
observed in BMBF 320 (Fig. 3.21), and in Scope 23 adeB expression was elevated (Fig. 3.22; 
comparable to ATCC 17978, Fig. 3.15). With the adeR(Asn20)S construct, adeB expression 
was increased in all A. baumannii strains, with the lowest fold-difference in ATCC 19606, and 
the highest in Scope 23, relative to the empty vector control. Overall it can be said that the 
lower the initial adeB expression of the recipient strain, the higher the adeB expression after 
introducing adeR(Asn20)S. Furthermore, we could show that by increasing the number of 
adeB transcripts, the susceptibilities to multiple classes of antimicrobials was affected. 
Figure 3.24 Growth of the A. baumannii 
(A) ATCC 19606, (B) BMBF 320, and (C) 
Scope 23 adeRS transformants. Growth 
kinetics were performed recording growth 
at hourly intervals, for 4 hours. Data 
displayed are representative of at least 
two independent experiments and results 
are shown as mean ± standard error of the 
mean. 
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Neither adeG or adeJ expression, nor the fitness were changed in any of the four A. 
baumannii strains. 
However, as we introduced the adeRS copies of the clinical isolates F and G on top of the 
chromosomally encoded genes of each recipient strain, we cannot rule out possible 
interactions between the plasmid and chromosomally encoded proteins and the impact it 
might have. Furthermore, looking at the AdeS amino acid sequence of all tested A. 
baumannii strains, we could determine 20 amino acid differences (Fig. 3.25). Whereas 
certain polymorphisms were common in all strains compared to isolate F and G (e.g. V94A, 
R299Q, K339Q), others might be strain specific (e.g. P172L for ATCC 17978, T153A for ATCC 
19606, S179I for BMBF 320 and N273H for Scope 23). Regarding AdeR, the amino acid 
sequence was found to be more conserved, as only three polymorphisms were found (L241P 
for ATCC 19606, L142I and V243I in BMBF 320) (Fig. 3.26).  
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Figure 3.25 Comparison of the AdeS amino acid sequences among the tested A. baumannii strains. 
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Figure 3.26 Comparison of the AdeR amino acid sequences among the tested A. baumannii strains. 
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3.3.3 Investigation of the Asp20→Asn substitution in the adeRSABC deficient  
          isolate NIPH 60 
In order to test the impact of the Asp20→Asn substitution in AdeR without the influence of 
AdeRS encoded on the chromosome, in the next step we chose the clinical isolate NIPH 60. 
Whole-genome sequencing revealed that NIPH 60 is deficient in the AdeRSABC cassette 
[244]. In this way, any detectable differences could directly be correlated to the mutation in 
the introduced adeR gene. The two forms of adeRS alone or in combination with the whole 
adeABC operon were introduced and their impact on antimicrobial susceptibility was 
investigated for the previously used eight structurally diverse antimicrobial classes. In 
addition, a control adeABC construct (without the regulators adeRS) was generated and 
transformed into NIPH 60. Results are summarized in Table 3.6.  
With the introduction of adeRS, no change in antimicrobial susceptibility was observed in 
either the adeR(Asp20)S or the adeR(Asn20)S transformant compared to the empty vector 
control. The same was true for the adeABC construct. With the adeR(Asp20)SABC construct 
an increase in the MICs to six antimicrobials was recorded compared to the empty vector 
control; minor changes in the MICs of amikacin, ciprofloxacin, levofloxacin, tigecycline and 
erythromycin by 2-fold, as well as an 8-fold and 32-fold increase in gentamicin and 
azithromycin MIC, respectively, were observed. However, the introduction of the 
adeR(Asn20)SABC construct had a greater impact on the susceptibility to six of eight tested 
antimicrobial classes. Besides a 2-fold increase in the meropenem MIC, a 4-fold increase in 
the MIC was observed for amikacin, levofloxacin, erythromycin and tetracycline. 
Ciprofloxacin, tigecycline and gentamicin MICs increased by 6-, 8- and 16-fold, respectively, 
and azithromycin increased by 64-fold. Comparing the two adeRSABC transformants with 
each other to catch the effect which is only due to the missense mutation in adeR, the Asn20 
transformants recorded higher MICs compared to the Asp20 transformants especially with 
ciprofloxacin, tetracycline and tigecycline, where a 4-fold increase in the MIC was observed. 
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Table 3.6 MIC values (mg/L) of A. baumannii NIPH 60 transformants. Adapted from Nowak et al. [292]. 
      
             
 
Figure 3.27 Relative adeB expression in NIPH 60 adeRSABC transformants. 
The number of transcripts of the adeR(Asn20)SABC and adeABC 
transformants have been related to the adeR(Asp20)SABC transformants after 
being normalized to the expression of the reference gene rpoB. Data 
displayed are representative of four independent experiments and results are 
shown as mean ± standard error of the mean. Statistical analysis was carried 
out with the recorded absolute values by performing an unpaired t test. ***, 
P < 0.001.  
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To confirm whether the difference in the susceptibility profile between the two adeRSABC 
transformants is due to a different expression of adeB, qRT-PCR was performed. As a 
control, the adeABC construct was included in the expression measurement. A 6.8-fold 
increase in adeB expression of the adeR(Asn20)SABC transformants was recorded compared 
to the adeR(Asp20)SABC transformants (Fig. 3.27). Very low adeB expression was recorded 
with the transformants harbouring only the adeABC operon. 
The efflux pump inhibitor NMP has been shown to effectively inhibit antimicrobial extrusion 
in adeB-overexpressing A. baumannii strains [291]. To further investigate whether the MIC 
changes induced by our adeRSABC constructs are reversible, 100 mg/L NMP was added to 
the agar during agar dilution. Results are shown in Table 3.7.  
 
Table 3.7 MIC values (mg/L) of NIPH 60 transformants with and without the addition of the efflux  
                  pump inhibitor NMP 
 
With the addition of efflux pump inhibitor NMP, no reduction in the MICs to amikacin, 
meropenem, levofloxacin and rifampicin was observed compared to the control values in the 
absence of NMP (Table 3.7). In the case of chloramphenicol and minocycline, the MICs were 
consistently reduced from 128 mg/L and 0.125 mg/L to 16 mg/L and 0.03 mg/L, respectively, 
for all NIPH 60 transformants, including the vector control. Based on the fact that 
chloramphenicol and minocycline MICs did not increase with the introduction of the 
adeRSABC constructs, compared to the empty vector control, these result suggest that efflux 
pumps other than AdeABC (targeting chloramphenicol and minocycline) are also inhibited by 
NMP. Minor reductions in the MICs to gentamicin, ciprofloxacin, and erythromycin by 2-fold 
and a 4-fold reduction in the azithromycin MICs were observed compared to the control 
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values of the adeRSABC transformants. However, the susceptibility to tigecycline and 
tetracycline (that was initially decreased by the adeRSABC constructs) was increased in the 
presence of NMP. Tigecycline and tetracycline MICs were reduced 4- to 8-fold in comparison 
to the control values in the absence of NMP, from 1 or 4 mg/L to 0.25 mg/L in the case of 
tigecycline and from 8 mg/L to 1 mg/L in the case of tetracycline.  
In order to get a complete picture of RND-pump expression, expression of adeG and adeJ 
was also investigated with NIPH 60 transformants. No significant difference in the expression 
of adeG or adeJ was detected between the adeRS, adeABC and adeRSABC transformants 
compared to the empty vector control (Fig. 3.28).  
 
Figure 3.28 Relative adeG and adeJ expression in NIPH 60 transformants. The number of adeG or 
adeJ transcripts was related to the empty vector control after being normalized to the expression of 
the reference gene rpoB. Data displayed are representative of three independent experiments 
results are shown as mean ± standard error of the mean. 
To determine if increased expression of adeB was accompanied by fitness costs for the 
transformants, growth curves were performed. In this case, only the adeRSABC 
transformants were considered, as they were the only transformants expressing adeB. 
Although growth of the adeRSABC transformants was slightly decreased after 1h, no 
difference in growth rates between either of the adeRSABC transformants and the empty 
vector control was observed over the recording course of 4h (Fig. 3.29), suggesting that the 
introduced pump had no effect on the overall fitness of NIPH 60. 
Results 
- 112 - 
 
Figure 3.29 Growth of the A. baumannii NIPH 60 adeRSABC transformants. Growth kinetics were 
performed recording growth at hourly intervals, for 4 hours. Data displayed are representative of 
three independent experiments and results are shown as mean ± standard error of the mean. 
To determine whether the substitution in AdeR has an impact on substrate extrusion, an 
ethidium accumulation assay was performed using all NIPH 60 transformants. The levels of 
ethidium accumulation of the empty vector control and the different transformants are 
summarized in Figure 3.30 and 3.31. There was no significant difference between the adeRS 
and the adeABC transformants as all three showed a similar ethidium accumulation 
compared to the empty vector control (Fig. 3.30).  
 
Figure 3.30 Ethidium accumulation of NIPH 60 adeRS and adeABC transformants. The fluorescence 
intensity was recorded at excitation and emission wavelengths of 530 and 600 nm, respectively, 
every 10 seconds over a 25 min incubation period. Data displayed are representative examples of 
four independent experiments and results are shown as mean ± standard error of the mean.  
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However, ethidium accumulation was significantly reduced in the adeRSABC transformants 
(Fig. 3.31). At steady state, which was reached approximately 15 min after ethidium bromide 
addition, the adeR(Asp20)SABC transformant accumulated about 12% less ethidium 
compared to the empty vector control whereas with the adeR(Asn20)SABC construct, 
ethidium accumulation was approximately 72% of that observed for the control.  
 
Figure 3.31 Ethidium accumulation of NIPH 60 adeRSABC transformants. The fluorescence intensity 
was recorded at excitation and emission wavelengths of 530 and 600 nm, respectively, every 10 
seconds over a 25 min incubation period. Data displayed are representative examples of four 
independent experiments and results are shown as mean ± standard error of the mean. Taken from 
Nowak et al. [292]. 
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Addition of the proton motive force uncoupler CCCP induced a rapid increase in 
accumulated ethidium in all three transformants, so that their accumulation of ethidium was 
nearly identical (Fig. 3.32). This indicated that the reduced ethidium accumulation observed 
before (Fig. 3.31) was due to the activity of the proton motif force-driven transporter 
AdeABC. 
 
Figure 3.32 Ethidium accumulation of NIPH 60 adeRSABC transformants after CCCP addition. Cells 
were resuspended to an OD of 2 at 600 nm. CCCP (500 μM) was added at the time indicated by the 
arrow. Data displayed are representative examples of three independent experiments and results are 
shown as mean ± standard error of the mean. Taken from Nowak et al. [292]. 
In addition to ethidium, the accumulation of the efflux substrates acriflavine and rhodamine 
6G was also assayed. However, no significant difference in their accumulation was detected 
comparing the adeR(Asn20)SABC transformant with the empty vector control during two  
independent runs (Fig. 3.33), suggesting that acriflavine and rhodamine 6G are not 
substrates of AdeABC. 
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A. Acriflavine accumulation       B.  Rhodamine 6G accumulation 
       
Figure 3.33 Acriflavine (A) and rhodamine 6G (B) accumulation of NIPH 60 adeR(Asn20)SABC 
transformants. The fluorescence intensity was recorded at excitation and emission wavelengths of 
416 and 514 nm in the case of acriflavine or 480 nm and 558 nm for rhodamine 6G, respectively, 
every 10 seconds over a 20 to 30 min incubation period. Data displayed are representative examples 
of two independent experiments and results are shown as mean ± standard error of the mean. 
Furthermore, competition assays were performed adding sub-inhibitory concentrations of 
antimicrobials to the cell suspension in addition to ethidium. In this way, it could be 
determined whether one of the antimicrobials is preferably exported over ethidium. As 
tetracycline and tigecycline showed the greatest difference in MIC values between both 
adeRSABC transformants (Table 3.6), they were chosen as promising potential competitors. 
No change in the accumulation of ethidium could be detected with either antimicrobial (Fig. 
3.34 C and D). Additionally, competition experiments were performed using azithromycin 
and gentamicin at sub-inhibitory concentrations. Similar to tetracycline and tigecycline, with 
the addition of 32 mg/L azithromycin or 4 mg/L gentamicin, respectively, no change in 
ethidium accumulation was observed (Fig. 3.34 A and B), suggesting that ethidium is 
preferably extruded or both substrates (ethidium and the respective antimicrobial) do not 
compete for the same binding site within AdeB.  
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    A. Azithromycin      B. Gentamicin 
  
    C. Tetracycline        D. Tigecycline 
  
Figure 3.34 Ethidium bromide competition assay. (A) 32 mg/L azithromycin, (B) 4 mg/L gentamicin, 
(C) 2 mg/L tetracycline and (D) 2.5 mg/L tigecycline were added to the cell suspension shortly after 
ethidium bromide addition. The fluorescence intensity was recorded at excitation and emission 
wavelengths of 530 and 600 nm, respectively, every 10 seconds over a 30 min incubation period. 
Data displayed are representative examples of three independent experiments and results are shown 
as mean ± standard error of the mean. 
Concluding this chapter, the Asn20 substitution in AdeR leads to an increased expression of 
adeB (Fig. 3.27). Accumulation assays revealed that the accompanied decrease in multiple, 
structurally unrelated antimicrobials (Table. 3.6) seems to be due to the enhanced efflux 
activity of the proton-motive force-dependent AdeABC efflux system (Fig. 3.31-32).  
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4. Discussion  
4.1 Prevalence of eight resistance-nodulation-cell division-type efflux pump   
       genes in epidemiologically characterized A. baumannii of worldwide  
       origin 
Investigating the prevalence of RND-type efflux pump encoding genes, we report that these 
efflux systems are widely distributed in A. baumannii; 5 of 8 RND-efflux pump encoding 
genes were present in all 144 tested isolates and the other 3 genes had a prevalence varying 
between 56% and 97%. To our knowledge, this is the first report describing the distribution 
of both characterized and uncharacterised RND efflux pumps in a genotypically diverse pool 
of clinically relevant A. baumannii isolates of worldwide origin.  
In 2006, Chu et al. reported the presence of three efflux systems in different Acinetobacter 
genomic DNA groups. In their collection of 56 A. baumannii isolates 70% were positive for 
adeB by PCR [253]. However these isolates came from only one hospital in Hong Kong and 
might include duplicate strains. Similarly, working with isolates from one hospital in Sichuan, 
China, Lin et al. reported that 84% and 90% of their 112 non-repetitive isolates carried adeB 
or adeJ, respectively [254]. Yet, the isolates they investigated belonged to the Acb-complex 
and thus did not only include A. baumannii. Focusing on a predominantly European 
collection, Nemec et al. investigated 116 A. baumannii isolates belonging to IC1-3 as well as 
genotypically unique strains [244]. Eighty-two percent of the isolates carried adeB. In 
another European study that included related and unrelated isolates belonging to IC1, IC2 
and genotypically unique strains, 49 out of 51 isolates harboured adeB [105].  
In these previous studies, only one primer pair was used. However, if there are nucleotide 
polymorphisms within the primer annealing site that lead to no amplicon, a false negative 
result can occur. The finding of 11 adeB sequence types among 50 A. baumannii isolates 
belonging to European clones 1-3 (IC1-3) demonstrate the sequence variability in this gene 
[252]. For this reason we used two separate primer pairs per gene, when necessary. 
Whereas no second primer pair was necessary for the detection of adeJ and ACICU_03646; 
the use of both primer sets was frequently required for the remaining efflux pump genes. In 
66% of cases, in which a negative result was obtained with the first pair of primers, using the 
second pair gave a positive result. While it still is possible that nucleotide polymorphisms 
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within the second primer annealing sites could result in a false negative result, when we 
analysed available genome sequences, these polymorphisms were rarely found. 
We found no association between the epidemiological background of an isolate and its 
efflux gene profile. It is noteworthy that 5 of the 8 investigated RND-family genes were 
present in all isolates tested. The other three pumps, including adeB, showed a high 
prevalence in our diverse pool of isolates. As bacterial genomes are highly plastic and genes 
of no need or function are rapidly removed or replaced [293], this finding supports a defined 
function of each individual pump that has still to be determined. In P. aeruginosa it has been 
shown that MexAB, MexCD, MexEF and MexXY each have fixed functions, e.g. MexCD 
functions as part of the envelope stress response (expression is induced in response to 
membrane damage) [294], while MexEF is linked to the organism’s nitrosative stress 
response (if reactive nitrogen and oxygen species cause cell damage) [295], and oxidative 
stress activates MexXY expression [296]. Except for the overlapping substrate profile of 
AdeB, AdeJ and AdeG, and a growth phase-dependent expression of these genes [259] little 
is known about regulation of the RND-type efflux systems in A. baumannii. A synergy of 
efflux combined with other resistance mechanisms has been observed to achieve high-level 
antimicrobial resistance [89, 245, 297]. Investigating 40 isolates endemic to New York, Bratu 
et al. for example detected increased levels of β-lactamases and adeABC expression, the 
presence of aminoglycoside-modifying enzymes as well as mutations in DNA gyrase, which in 
combination were responsible for cephalosporin, meropenem, aminoglycoside and 
fluoroquinolone resistance, and reduced susceptibilities to cefepime and tigecycline [245]. 
Further insight into the functionality of each pump including a characterization of the 
reported putative RND-type efflux pumps might reveal their individual importance in this 
organism.  
In conclusion, the presence of the eight RND-efflux pumps in our geographically and 
genotypically diverse collection of worldwide A. baumannii isolates varied between 56 and 
100%. No association between IC clusters and the presence or absence of the pumps was 
observed. However, the fact, that at least another five uncharacterised RND-pumps are 
encoded on the chromosome illustrates the need for further investigations to gain a better 
understanding of their contribution to the ever-increasing emergence of multidrug resistant 
A. baumannii.  
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4.2 Characterization of the putative RND-type efflux pump A1S_2660 
To date three RND-type efflux systems have been characterized in A. baumannii [112, 126, 
133]. Whereas AdeABC seems to be the predominant transporter system most often 
associated to an acquired MDR phenotype in clinical isolates worldwide, AdeIJK is involved in 
intrinsic resistance having a minor effect on high-level resistance as its overexpression is 
toxic to the cell [127]. The role and clinical significance of AdeFGH has not yet been 
elucidated. It is not expressed constitutively and strains overexpressing this pump have 
rarely been reported. However, depending on the strain and genome annotation, 7-19 RND 
pumps are encoded on the chromosome of A. baumannii [90, 284]. Using the sequenced 
genomes of A. baumannii ACICU, AB0057 and ATCC 17978 and the amino acid sequence of 
AdeB as a reference, we identified 5 putative RND transporters in addition to the previously 
characterized ones. Showing the highest amino acid identity to AdeB among all of the 
putative exporters (40% similarity), it was the aim to further characterize the pump 
ACICU_02904/A1S_2660 (locus tag in A. baumannii ACICU and A. baumannii ATCC 17978, 
respectively) by determining its inducers and substrates. According to our prevalence study, 
this pump was present in all of the 144 tested genotypically and geographically diverse 
clinically relevant A. baumannii isolates as well as in 25 fully sequenced and annotated 
genomes available in the NCBI database, suggesting a function relevant to A. baumannii.  
RT-PCR revealed that this putative transporter is not constitutively expressed in A. 
baumannii ATCC 17978. Using the β-galactosidase reporter assay, we were able to confirm 
the cryptic nature of this pump and identify substances inducing its transcription. Expression 
of A1S_2660 was induced by antimicrobial agents (carbapenems and chloramphenicol) as 
well as ethanol, NaCl and sulbactam.  
To date, practically no data have been published linking specific substances or 
environmental changes to the induced expression of characterized RND-type efflux pumps in 
A. baumannii. Merely, adeA has been reported to be overexpressed upon NaCl exposure 
[260]. However, in other bacterial genera a wide variety of stimuli and effector molecules 
could be linked to the induced transcription of RND transporters in order to export these 
toxic substances, including different stress signals (oxidative stress, envelope stress; see 
Chapter 4.1.), antimicrobials, detergents, disinfectants and bile salts, [199, 298]. Especially of 
concern is the induction of A1S_2660 by carbapenems, which may constitute a significant 
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threat to the hospital environment as these are the antibiotics of choice to treat infections 
with MDR Gram-negative bacteria, including A. baumannii. Additionally, NaCl at 
physiological concentrations (170-200 mM) is not only present in health care environments 
(as a constituent of drug formulations, wound dressings, intravenous fluids) but also in the 
human host (e.g. in body fluids and on the skin surface) [260]. Thus, expression of this 
putative pump could easily be induced in hospital settings as well as in the community. 
However, the induced expression of A1S_2660 was still relatively low, as with the β-
galactosidase assay the expression was only visible after ≥24 hours. With this induced low-
level expression, possible changes in the resistance phenotype of the cell would not have 
been detectable with conventional susceptibility testing methods.  
Overexpression of A1S_2660 in the A. baumannii reference strain ATCC 17978 using an 
expression plasmid reduced cell growth, suggesting that the energy consumed for the 
synthesis and/or functioning of the transporter resulted in a fitness cost to the cell. This was 
supported by experimental findings, which correlated the overexpression of some exporters 
to decreased cell growth [225, 299]. For AdeIJK a similar phenomenon has been described; 
overexpression of adeJ up to a certain threshold led to low-level resistance, whereas 
overexpression above this undefined threshold was toxic to the cell and led to impaired 
growth [127]. Additionally, nutrients essential to the cell could be substrates of the pump, so 
that extruding them could lead to cell stasis [222, 223]. In A. baumannii ATCC 17978 adeABC, 
adeIJK and adeFGH are constitutively expressed. Although overexpression of more than one 
efflux pump at the same time has been shown without any negative effect on cell survival 
[300-302], it is possible that ATCC 17978 could not compensate the (over-) production of 
another efflux pump.  
Several RND-type efflux systems of P. aeruginosa (MexPQ-OpmE, Mex MN-OprM, Mex VW-
Oprm, and TriABC-OpmH) have been shown to confer antimicrobial resistance if the host 
was deficient in the major RND pumps like MexAB, MexCD-OprJ, MexEF-OprN and MexXY 
[303-305]. Due to overlapping substrate profiles, it is possible that the impact of these 
‘minor’ transporters on antimicrobial resistance is dwarfed by the major pumps making their 
contribution difficult to detect. Furthermore, the expression of minor exporters might 
especially be enhanced when major pumps are not present. Supporting the latter 
assumption, Eaves et al. reported increased expression of acrD in Salmonella when acrB or 
acrF were inactivated [306]. To mimic such a scenario, A1S_2660 was overexpressed in the 
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A. baumannii clinical isolate NIPH 60, which is deficient in the adeRSABC genes. As AdeIJK 
and AdeFGH show only minor effects on resistance, their presence could be neglected. 
Under these conditions, overexpression of A1S_2660 did not lead to impaired growth of 
NIPH 60 cells. It remains speculative whether NIPH 60 has a low overall energy cost, so that 
the overexpression of A1S_2660 was not harmful to the cell, or whether it can adapt better 
to this new condition and compensate the additional energy consumed. In MexEF-OprN-
overproducing P. aeruginosa for example, the accompanied fitness cost (due to cytoplasmic 
acidification caused by MexEF-mediated proton influx) was metabolically compensated by 
increasing the oxygen uptake and enhancing the expression of the nitrate respiratory chain 
[307]. In this way, cytoplasmic acidification was prevented.  
When overexpressing A1S_2660 in NIPH 60, we could not detect any changes in the 
resistance phenotype to the tested compounds which included antibiotics (aminoglycosides, 
aztreonam, β-lactams, cephalosporins, chloramphenicol, fluoroquinolones, macrolides, 
nalidixic acid, novobiocin, and tetracyclines), disinfectants (benzalkonium chloride, 
triclosan), bile salts (deoxycholic acid) and organic dyes (acriflavine, ethidium). All of these 
substances used have been reported to be extruded by various efflux pumps in other 
bacteria [199, 308, 309]. It has been reported that substrates of an efflux pump might as well 
induce its expression [310]. However, identified as inducers of A1S_2660, carbapenems and 
chloramphenicol could not be identified as substrates. It is possible, that compounds other 
than the applied ones are substrates of this pump, including bacitracin, chlorhexidine, 
doxorubicin, fatty acids, metal salts, protamine, puromycin, quaternary ammonium 
compounds, and toluene. Furthermore, this putative exporter could be involved in cellular 
responses that were not tested in this study, e.g. responses to nitrosative or oxidative stress 
as reported for efflux pumps in P. aeruginosa [295, 296]. Given that the expression is 
induced by carbapenems and ethanol, compounds which disrupt the cell wall, this could 
indicate a function during envelope stress responses.  
Based on current knowledge about RND-type efflux pumps, it is possible that A1S_2660 is 
not functional under the tested conditions. Usually, RND-efflux systems are composed of a 
periplasmic adaptor protein, the transporter and an outer membrane pore in order to 
facilitate the extrusion of compounds to the extracellular environment [138]. It is common 
that the three components are encoded as an operon with a cognate MFP upstream and a 
cognate outer membrane pore downstream of the transporter. We could neither detect an 
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MFP nor an outer membrane pore encoded close to this putative pump in the three A. 
baumannii genomes ACICU, AB0057 and ATCC 17978. As these strains belong to diverse 
epidemiological groups, it is likely that no A. baumannii strain has an MFP adjacent to 
A1S_2660. In P. aeruginosa and Vibrio cholera it has been demonstrated that a cognate 
outer membrane pore is not essential for the composition of a functional RND system as the 
pores can be sequestered from elsewhere. A substrate-dependent utilization of either OprM 
or OpmH by the MexJK complex was reported, whereby neither outer membrane pore was 
encoded adjacent to mexIJ [255]. In the case of V. cholerae the tolC encoded outer 
membrane pore seems to interact with six different RND systems [311, 312]. Even in the 
case of the major RND efflux system AcrAB-TolC in E. coli, TolC is encoded elsewhere on the 
chromosome [197]. However, the MFP is required for the functionality of the tripartite 
complex. On the one hand, the MFP is thought to recruit the outer membrane pore to the 
transporter and assembling them together [173]. On the other hand, conformational 
changes in the MFP seem to induce a shift within the inner channel of the pore from a closed 
to an open state in order to let substrates be extruded from the inner cleft of the pump 
through the pore to the extracellular environment [173]. To date, no RND-type efflux pump 
has been reported without an associated MFP. In fact, even RND transporters requiring two 
adaptor proteins have been identified, e.g. the TriABC-OmpH exporter with the two MFPs 
TriA and TriB [305]. Nevertheless, it is possible that MFPs can be sequestered by A1S_2660, 
like it has been shown for outer membrane pores. Compounds inducing A1S_2660 
expression (carbapenems, chloramphenicol, ethanol and NaCl) might also induce the 
expression of a specific MFP that is required for A1S_2660 functioning. A transcriptomic 
approach used under the conditions tested initially (e.g. non-induced vs. NaCl-induced) 
might help identify an MFP. Subsequently, the MFP could be overexpressed together with 
A1S_2660, and susceptibility testing of the transformants might reveal substrates of the 
pump. Thus, further investigations are needed to elucidate the function of this putative 
efflux pump, which is highly prevalent in A. baumannii.  
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4.3 Characterization of the Asp20→Asn substitution in the response   
       regulator AdeR 
To date, numerous substitutions within every functional domain of the AdeRS two-
component regulatory system have been associated with the overexpression of the genes 
encoding AdeABC (Fig. 1.13). Changes in the periplasmic input domain [261] or near to the 
autophosphorylation site [257] of AdeS for example, could lead to a permanent signal 
transduction including a constitutive activation of the sensor kinase. Consequently, AdeR 
would constitutively be activated leading to elevated adeABC expression. Similarly, 
substitutions in the HAMP domain (e.g. G103D) or the ATPase domain could affect signal 
transduction, ATP binding and/or the autophosphorylation of AdeS, promoting an enhanced 
transcription of adeABC [257, 262]. Amino acid substitutions within the signal receiver 
domain of AdeR [246, 257] or at its effector domain [262] could further lead to its 
constitutive activation or enhanced binding to the adeABC promoter, respectively. However, 
these substitutions were merely associated with increased adeB expression (and decreased 
antimicrobial susceptibility) and the detailed mechanisms were not further investigated.  
Complementing adeRS in an adeRS knockout strain, Sun et al. were the first to describe the 
mechanism behind elevated adeB expression levels and the concomitant antimicrobial 
resistance phenotype, which were caused by insertion of the IS element ISAba1 in adeS [99]. 
In addition, Yoon et al. revealed that the mutation leading to the Ala94→Val substitution in 
the HAMP linker domain of AdeS is a polymorphism of isolates belonging to IC1 and thus was 
erroneously reported to be responsible for increased adeABC expression [262]. Based on 
these findings, deeper investigations are necessary in order to unravel the direct impact of 
the individual mutations on efflux pump expression and the concomitant susceptibility 
phenotype, instead of speculating on the effect they might have.  
The previously reported Asp20→Asn substitution in the response regulator AdeR, which was 
investigated in thirteen isogenic isolates from one patient, was associated with increased 
expression of adeB and with decreased susceptibility to co-trimoxazole, levofloxacin and 
tigecycline [89]. The Asp20 residue corresponds to Asp10 in the response regulator PhoB in 
E. coli which has been described to be part of an acidic triad making up the active site for 
phosphorylation [313, 314]. A mutation at this functionally important phosphorylation site 
may alter the interaction between AdeS and AdeR mediating the overexpression of adeABC. 
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In order to further characterize this amino acid change, we determined its effect on 
antimicrobial susceptibility, the expression of the efflux genes adeB, adeJ, and adeG, 
bacterial growth, and substrate accumulation. 
Usually, when investigating the effect of mutations, a knock-out of the specific gene by 
insertional inactivation, often followed by complementation, is performed in the isolate the 
mutation was initially detected [111, 126]. In our previous study, the clinical isolate G, in 
which the Asp20→Asn substitution was recorded, was multidrug resistant [89], rendering it 
difficult to find a selective marker to generate a knock-out. Therefore, other approaches 
were taken.    
As a first approach adeR(Asp20), adeR(Asn20) and adeS constructs were introduced into the 
A. baumannii reference strain ATCC 17978 on top of the chromosomally encoded genes. 
Surprisingly, no significant change in adeB expression and antimicrobial susceptibility was 
detected with the mutant adeR(Asn20) construct compared to adeR(Asp20). However, by 
introducing only the adeS construct, the number of adeB transcripts increased significantly. 
Insertional inactivation of adeS, performed by Marchand et al., provided evidence for an 
essential role in regulating adeABC expression [257]. As the sensor kinase AdeS is the key 
component in sensing environmental stimuli and transmitting the signal to the response 
regulator which in turn drives different gene expression, elevated transcripts of adeB as a 
result of additional copies of adeS are reasonable. On the other hand, inactivation of adeR 
would impair the signal transduction induced by adeS, thus the role of the response 
regulator alone could not be determined [257].  
As the combination of the chromosomally encoded adeS and the plasmid encoded 
adeR(Asn20) did not significantly impact adeB expression in comparison to adeR(Asp20), we 
suggested that the synergistic interplay specifically driven by adeR(Asn20) and its cognate 
sensor kinase is responsible for increased adeB expression. Introducing the adeR(Asn20)S 
construct this assumption could be verified. Thereby, the fold-difference in the relative 
number of adeB transcripts induced by the adeR(Asp20)S and adeR(Asn20)S variants was 
similar to that previously observed for the clinical isolates F and G [89]. Transformants with 
an adeR(Asn20)AdeS(17978) construct, which showed a comparable adeB expression and 
antimicrobial susceptibility as the adeR(Asp20)S transformants, further supported the 
assumption that the Asp20→Asn substitution specifically enhances the interaction of 
AdeR(Asn20) with its cognate AdeS. Evidence supporting this hypothesis comes from 
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investigations on the response regulator Spo0F, responsible for initiating sporulation in 
Bacillus subtilis. McLaughlin et al. propose that the recognition of sensor kinases and their 
respective response regulators is driven by residues in the core of the response regulator 
[315]. They suggest that specific buried residues are responsible for presenting the correct 
surface to the specific sensor kinase, facilitating a defined discrimination of binding partners 
among multiple kinases in the cell. Thus, it is possible that the Asp20→Asn substitution 
within the acidic triad of AdeR has an impact on AdeS binding, showing greater specificity for 
AdeS of the clinical isolates F and G than for the A. baumannii reference strains ATCC 17978 
(which differs by 11 amino acids). 
Introducing the two adeRS constructs into three additional A. baumannii isolates that differ 
in their adeB expression level [low- (Scope 23), medium- (BMBF 320) to high-level expression 
(ATCC 19606)], a limited rise in adeB expression was detected - the higher the initial 
expression level, the least increased expression was observed in the adeRS transformants. As 
the synthesis and the function of efflux transporters is an energy-consuming process, it is 
possible that the cells reach a maximum of adeABC expression and concomitant AdeABC 
synthesis that they can maintain without resulting in a fitness cost. Furthermore, in 
correlation with the limited increase in adeB expression, there was no further decrease in 
antimicrobial susceptibility. The impact of RND transporters on the susceptibility phenotype 
is limited to the amount of antimicrobials that enter the periplasm via membrane diffusion 
and antimicrobials that are extruded from the cytoplasm to the periplasm by primary efflux 
pumps. As no additional changes in the membrane permeability or the expression of primary 
efflux transporters were introduced, the contribution of elevated levels of the RND-type 
exporter AdeABC on the susceptibility phenotype of the cell was restricted.  
However, there are limitations to our first approach. Introducing additional adeRS copies 
(from the isolates F and G) on top of the chromosomally encoded ones, we cannot rule out 
possible interactions between the plasmid and the chromosomally encoded proteins. 
Furthermore, differences in the genetic background of the strains leading to minor or major 
distinctions in cellular processes (e.g. stability of mRNA, influx, protein half-life, adeB 
sequences, second regulators not yet identified) may also impact the expression and/or the 
susceptibility outcome. It had been previously determined in our laboratory that BMBF 320 
belongs to IC4, whereas the other three A. baumannii strains are genotypically unique. Thus, 
they cannot directly be compared to one another. In order to test the impact of the 
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Asp20→Asn substitution in AdeR without the influence of AdeRS encoded on the 
chromosome, in our next approach the adeRSABC-deficient clinical isolate NIPH 60 was used. 
In this way, the two forms of AdeRS alone or in combination with the whole adeABC operon 
were introduced and specifically investigated with regards to their impact on antimicrobial 
susceptibility, efflux pump expression, and substrate accumulation. Any detectable 
differences could directly be correlated to the substitution in AdeR.  
Based on the susceptibility data, AdeRS did not appear to regulate any other resistance 
mechanisms than AdeABC. In the absence of the efflux pump encoding genes adeABC, the 
two-component regulatory system had no effect on antimicrobial susceptibility in NIPH 60. 
Differences in the MIC values to structurally unrelated antimicrobials, in the number of adeB 
transcripts and ethidium accumulation were only observed when the genes encoding the 
regulators AdeRS were combined with the adeABC operon. Nevertheless, this system might 
still regulate other genes or cellular processes, which were not addressed in this study. In 
E.coli, the two-component system BaeSR for example does not only regulate gene 
expression of the RND efflux genes mdtABC [316], but more than 60 other genes involved in 
signal transduction, sugar transport, flagellum biosynthesis, homeostasis or chemotactic 
response are part of its regulon [317]. To investigate this further, transcriptomics using 
whole-genome sequencing will be necessary. 
By introducing the recombinant adeRSABC constructs into A. baumannii NIPH 60, we 
demonstrated that the amino acid change Asp20→Asn in the response regulator AdeR led to 
increased expression of adeB. The fold-difference in the relative number of adeB transcripts 
between the NIPH 60 adeRSABC variants was similar to that previously observed for the 
clinical isolates F and G [89]. The accompanying decrease in susceptibility to a multitude of 
structurally diverse antimicrobials was due to enhanced efflux activity, as determined by the 
ethidium accumulation assay. Reversing this increased efflux activity upon CCCP addition, 
the results provide evidence that the proton-motive force-dependent active efflux mediated 
by AdeABC is responsible for decreased susceptibility in the adeRSABC transformants. The 
impact of the NIPH 60 adeRSABC transformant harbouring the adeR(Asn20) variant on the 
decrease in antimicrobial susceptibility was markedly higher compared to the unmutated 
adeR(Asp20)SABC transformant. Thereby, bacterial fitness was not reduced in the adeRSABC 
transformants although efflux pump synthesis and their functioning have been reported to 
cause decreased growth [183, 199, 234]. Furthermore, no impact on the transcription of 
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adeG or adeJ was detected. As adeG and adeJ expression have been reported to be 
regulated by the LysR-type transcriptional regulator AdeL [112] or the TetR-type regulator 
AdeN [133], respectively, cross-regulation can be ruled out.  
Ethidium accumulation in the adeR(Asn20)SABC transformant was not altered by the 
addition of antimicrobials at sub-inhibitory concentrations. In the E. coli AdeB-homolog AcrB, 
two binding portions within the distal binding pocket have been described in the inner 
periplasmic cleft [177]. Minocycline, levofloxacin, erythromycin, rifampicin and tetracycline 
are predicted to bind to the upper ‘groove’ portion, whereas chloramphenicol seems to bind 
to the lower ‘cave portion. Adapting this to our investigations, ethidium is either preferably 
extruded over the other compounds or both ethidium and the antimicrobials are not in 
competition for the same binding site in AdeB. It is also possible, that the concentration of 
the antimicrobials was too low, as we used sub-inhibitory concentrations. In Salmonella 
enteritidis, for example, changes in the ethidium accumulation were only visible when 
tetracycline concentrations of >100 mg/L were added [318]. With regards to the present 
study, sub-inhibitory concentrations were used to avoid any interfering stress responses due 
to antimicrobial challenge and we wanted to remain within pharmacokinetic boundaries.  
Using the efflux pump inhibitor NMP, antimicrobial susceptibilities were not restored to the 
control values completely; six out of nine antimicrobials, to which the MIC was increased 
with the introduction of the adeRSABC constructs, showed reduced MICs in the presence of 
NMP. In particular, the susceptibility to tigecycline and tetracycline were increased by this 
inhibitor. Investigations in E. coli have shown that NMP acts as a substrate of the RND pump 
AcrB binding to the groove portion of the distal binding pocket, thereby inhibiting substrate 
binding [190]. Our results suggest that tetracycline, which is predicted to bind to the same 
portion of the pocket [177], is a good substrate of the AcrB-homolog AdeB and its extrusion 
is inhibited by the addition of NMP. As a consequence, less tetracycline is extruded out of 
the cell and the intracellular accumulation increases so that toxicity to the cell is achieved by 
lower concentrations. The same might apply for tigecycline, however its binding pattern has 
not yet been investigated. The two efflux pump inhibitors showing the highest efficiency 
against A. baumannii RND efflux pumps in vitro are NMP and PAβN [319]. In P. aeruginosa 
PAβN successfully inhibits the four clinically most relevant efflux pumps (MexAB-OprM, 
MexCD-OprJ, MexEF-OprN and MexXY-OprM) [188]. In A. baumannii its activity has been 
shown against AdeFGH potentiating the activity of clindamycin and, to a lesser extent, to 
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trimethoprim and chloramphenicol [320]. Reduced MICs to tigecycline, gentamicin, 
chloramphenicol and nalidixic acid but not ciprofloxacin were demonstrated in other studies 
[264, 321]. NMP restored ciprofloxacin susceptibility in a number of intermediate resistant 
clinical A. baumannii isolates [322]. Comparing both compounds in fluoroquinolone resistant 
and susceptible A. baumannii isolates revealed that PAβN is more active than NMP at low 
concentration (25 mg/L), especially reducing the MIC of clarithromycin and rifampicin. In 
contrast, NMP showed greater efficacy at high concentration (100 mg/L), particularly 
lowering the MICs of tetracycline, chloramphenicol and linezolid [291]. Overall, in A. 
baumannii NMP was more efficient in reducing MICs than PaβN. However, reducing the MIC 
values of antimicrobial agents not targeted by the introduced AdeABC (chloramphenicol and 
minocycline) our results indicate that other efflux pumps are also inhibited by NMP. These 
might include RND-type efflux pumps other than AdeABC (AdeIJK and AdeFGH) which have 
also been reported to extrude chloramphenicol and minocycline [112, 127]. Furthermore, 
chloramphenicol has been shown to be the only substrate of the MFS-type transporter CraA 
and minocycline is extruded by plasmid encoded MFS-type efflux pumps [270, 281]. Further 
investigations could elucidate which other efflux pumps in A. baumannii are targeted by 
NMP. Nevertheless, causing renal toxicity or likely acting as a serotonin agonist, respectively, 
PAβN and NMP were not further developed to be used as clinically useful drugs [323, 324]. 
Although the development of derivatives with reduced toxicity and the search for alternative 
compounds continues, no efflux pump inhibitor has yet been licensed for the treatment of 
bacterial infections.  
As adeB has often been reported to be overexpressed in clinically relevant MDR A. 
baumannii isolates, it is important to understand the source of overexpression as well as the 
individual impact and contribution on increased resistance rates. In this part of the study we 
demonstrated that adeB overexpression can be caused by the Asp20→Asn substitution in 
AdeR and that the accompanying decrease in antimicrobial susceptibility is due to enhanced 
efflux activity. 
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5. Summary & Conclusion 
Over the past three decades A. baumannii has evolved into a clinically important nosocomial 
pathogen causing epidemic outbreaks worldwide. Due to its intrinsic antimicrobial resistance 
and its ability to easily acquire new resistance determinants, A. baumannii can display 
resistance to all of today’s commonly prescribed antimicrobials, leaving limited treatment 
options. Among all reported resistance mechanisms, chromosomally encoded efflux pumps 
contribute most to multidrug resistance owing to their broad substrate specificity. In A. 
baumannii particularly, the overexpression of RND-type efflux pumps, extruding 
antimicrobials from the periplasm to the extracellular environment, plays a significant role in 
the appearance of MDR clones worldwide.  
With this PhD project it was aimed to further investigate and characterize RND-type efflux 
transporters in A. baumannii. Using BLAST analysis five putative RND pumps in addition to 
the three characterized systems AdeABC, AdeIJK and AdeFGH were identified. Testing the 
prevalence of these eight exporter genes within a genotypically and geographically diverse 
pool of clinical A. baumannii isolates using a PCR-based approach, five of eight RND-type 
efflux genes were present in all isolates. Two of them were present in ≥87% of isolates, 
highlighting the great distribution and relevance of these efflux pumps for this nosocomial 
pathogen. 
Further investigating one of the identified putative exporters (A1S_2660 locus tag in A. 
baumannii ATCC 17978), low-level expression of this pump was induced by antimicrobials 
(carbapenems, chloramphenicol), disinfectants (ethanol) and NaCl, substances which are 
frequently used in the healthcare environment. Carbapenems are used as a last resort 
antibiotic against A. baumannii infections. Overexpression of this exporter was toxic in the A. 
baumannii reference strain ATCC 17978, but did not have a fitness cost in the AdeABC-
deficient isolate NIPH 60. Testing a large collection of antimicrobials, bile salts, disinfectants 
and organic dyes, substrates of A1S_2660 could not be identified.  
Substitutions in the two-component regulatory system AdeRS, which regulates the 
expression of the clinically most significant RND-type efflux pump AdeABC, are rarely further 
investigated and remain merely associated to increased adeB expression and decreased 
antimicrobial susceptibility. Within this thesis, we report that the Asp→Asn20 substitution in 
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the response regulator AdeR induced increased adeB expression levels, which was 
accompanied by decreased susceptibility to a multitude of structurally diverse 
antimicrobials. With the application of the ethidium accumulation assay enhanced efflux was 
determined to be the cause of the changed susceptibility phenotype. Furthermore, the 
Asn20 substitution seemed to specifically enhance the interaction between AdeR and its 
cognate sensor kinase AdeS. Further investigations are needed to verify this hypothesis. 
Being aware of the significant contribution of RND-type efflux pumps to antimicrobial 
resistance and understanding their structure, regulation and transport mechanism will help 
to find new treatment options against infections caused by MDR pathogens. 
On the one hand new antibiotic molecules can be designed which are not extruded by 
polyspecific efflux transporters, like tigecycline for example, which was initially developed 
not to be a substrate of the MFS-type efflux pumps Tet(A-E), that are responsible for 
acquired resistance to tetracyclines like tetracycline, minocycline and doxycycline. However, 
it was later investigated that tigecycline is a substrate of polyspecific RND-type efflux pumps 
in various species. It is another strategy to find compounds which inhibit efflux function. 
Thereby, an ideal efflux pump inhibitor would enhance the activity of multiple antibiotics but 
must be relatively stable and nontoxic to eukaryotic cells. Especially, efflux pumps of the 
RND family are a good target for inhibition as no homologues exist in mammals. Inhibitors 
would be most efficient when used in combination therapy, administered together with an 
antibiotic. As antimicrobial adjuvants, efflux pump inhibitors are hoped to restore the 
effectiveness of the agent active against the pathogen. This kind of therapy is already 
applied successfully when administering β-lactam antibiotics together with β-lactamase 
inhibitors in order to prevent β-lactam degrading enzymes of lowering the effectiveness of 
the antimicrobial agent. Deeper insights into the functionality of polyspecific efflux pumps 
may facilitate the development of new, effective compounds that will combat MDR bacteria. 
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Suppl. Table I List of approved antimicrobials active against Acinetobacter spp. 
                           Adapted from Magiorakos et al. [77] with permission from Elsevier. 
Antimicrobial category Antimicrobial agent 
Aminoglycosides 
Gentamicin 
Tobramycin 
Amikacin 
Netilmicin 
Antipseudomonal carbapenems 
Imipenem 
Meropenem 
Doripenem 
Antipseudomonal fluoroquinolones 
Ciprofloxacin 
Levofloxacin 
Antipseudomonal penicillins +   
β-lactanase inhibitors 
Piperacillin-tazobactam 
Ticarcillin-clavulanic acid 
Extended-spectrum cephalosporins 
Cefotaxime 
Ceftriaxone 
Ceftazidime 
Cefepime 
Folate pathway inhibitors Trimethoprim-
sulfamethoxazole 
Penicillins + β-lactamase inhibitors Ampicillin-sulbactam 
Polymyxins 
Colistin 
Polymyxin B 
Tetracyclines 
Tetracycline 
Doxycycline 
Minocycline 
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Suppl. Figure I Plasmid card pIG14/09::rnd1-lacZ 
 
 
 
For the generation of pIG14/09, the β-galactosidase encoding gene lacZ, amplified from 
pMC1871, was cloned into the PstI restriction site of pWH1266 (Section 2.2.3.1). The 
predicted promoter region of A1S_2660 and its first 21 nucleotides were cloned in frame to 
the lacZ gene using the In-fusion enzyme mix (Section 2.2.3.2). β-galactosidase breaks down 
the lactose analogue X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) to galactose 
and 5-bromo-4-chloro-3-hydroxyindole. The latter forms dimers and is oxidised to 5,5’-
dibromo-4,4’-dichloro-indigo, which appears blue and can therefore be used for a reporter 
assay. 
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Suppl. Figure II Plasmid card pBA03/05::rnd1_oe 
 
 
 
For the generation of pBA03/05, the origin of replication amplified from pWH1266 was 
cloned into the HindIII restricted and blunted pQE80L (Section 2.2.3.4). The rnd1 (A1S_2660) 
gene was cloned into the polylinker in frame with the T5 promoter using the In-fusion 
enzyme mix (Section 2.2.3.5). 
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Suppl. Figure III Plasmid card pJN17/04::adeRS 
 
 
 
For the generation of pJN17/04, the origin of replication amplified from pWH1266 was 
cloned into the multiple cloning site of pBHR1 (Section 2.2.4.1). adeRS genes were blunt 
ligated with pJN17/04 which was linearized by the endonuclease ScaI (Section 2.2.4.2). 
